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Abstract 
Many exciting topics exist at the interface between biology and 
micro/nanotechnology.  This dissertation will discuss interdisciplinary researches that 
leveraging the engineering advances in biomaterials, microfluidics and advanced 
manufacturing for new and better solutions for emerging problems in cancer biology, 
systems immunology, and stem cell-based regenerative medicine.  First, this dissertation 
will discuss the potential of integrated microfluidic immunophenotyping assay device to 
perform rapid, accurate, and sensitive functional cellular immunophenotyping assays for 
target subpopulations of immune cells isolated directly from patient blood.  This 
dissertation will also explore the possible technique using nanotopographic substrates for 
efficient capture of circulating tumor cells regardless of surface protein expression and 
cancer type, critical for early cancer diagnosis and for fundamental understanding of 
cancer metastasis.  This dissertation will also provide a comprehensively profiling of the 
biophysical characteristics of inflammatory breast cancer stem cells at the single-cell 
level using multiple microengineered tools to delineate the live cell phenotypic 
characteristics of the model of the most metastatic breast cancer subtype.  Last, this 
dissertation will further explore synthetic micro/nanoscale ex vivo cellular 
microenvironment for study and regulating human embryonic stem cell behaviors that are 
desirable for functional tissue engineering and regenerative medicine.  These novel 
micro/nanoengineered functional biomaterials and biosystems will not only permit 
advances in engineering but also greatly contribute to improving human health.
 
 
Chapter 1 
Introduction 
1.1 Micro/nanoengineered Biomaterials an Biosystems for 
Medicine 
Micro/nanotechnologies including advanced nanofabrication and functional 
nanomaterials have provided new opportunities for many biological and medical 
applications.  Biological sample processing and analysis are of great importance for both 
medical and science applications, and hold a central role in the diagnosis of many 
physiologic and pathologic conditions, such as immune system dysfunction and cancer. 
However, tapping into the wealth of biological information, for clinical and scientific 
applications, requires not only the understanding of the biology involved but also 
adequate technologies.  Therefore, this dissertation will discuss interdisciplinary 
researches that leveraging the engineering advances in biomaterials, microfluidics and 
advanced manufacturing for new and better solutions for emerging problems in cancer 
biology, systems immunology, and stem cell-based regenerative medicine.  This 
dissertation will particularly discuss the potential of integrated microfluidics to perform 
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rapid, accurate, and sensitive functional cellular immunophenotyping assays for target 
subpopulations of immune cells isolated directly from patient blood, and their potential to 
provide an unprecedented level of information depth on the distribution of immune cell 
functionalities on a patient-by-patient basis.  This dissertation will also explore the 
possible techniques for efficient isolation and informative analysis of circulating tumor 
cells (CTCs) and cancer stem cells (CSCs) from animal models and cancer patients, 
critical for accurate diagnosis and prognosis of cancer and for fundamental understanding 
of cancer metastasis.  In addition to the applications for systems biology and cancer 
biology, this dissertation will further explore synthetic micro/nanoscale ex vivo cellular 
microenvironment for study and regulating human embryonic stem cell behaviors that are 
desirable for functional tissue engineering and regenerative medicine.  These novel 
micro/nanoengineered functional biomaterials and biosystems will not only permit 
advances in engineering but also greatly contribute to improving human health.  
 
Figure 1-1  Micro/nanoengineered Biomaterials and Biosystems for Medicine. 
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1.2 Research Topics and Dissertation Outline 
1.2.1 Integrated Microfluidic Immunophenotyping Platform for 
Functional Cellular Immunophenotyping 
The immune status of patients with infectious diseases and immune dysfunctions 
are dynamic and patient-specific, and such complex heterogeneity has made effective 
immunomodulatory therapies challenging in the clinic [1, 2].  An accurate and real-time 
measurement of the immune status of patients is critical in disease diagnosis and 
prognosis, evaluating efficacy of immunotherapeutics, and tailoring drug treatments [2].  
As such, there is an urgent need for new immunomonitoring technologies that can 
perform rapid and accurate cellular functional assays on patient immune cells in order to 
define and characterize the “immune phenotype” of patients.   
Quantitative characterization of functional signature and diversity of immune 
cells from patient blood is currently challenging, owing to the intrinsic limitations of 
conventional methods, despite its promise to drastically improve clinical knowledge and 
 
Figure 1-1  Isolation, enrichment, enumeration and functional immunophenotyping of immune cells using 
integrated microfluidics.  Using functionalized microbeads with a microfiltration membrane, PBMCs and 
monocytes can be isolated for downstream functional immunosensing using the AlphaLISA assay. 
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practice for many immune and infectious diseases.  Several approaches currently exist for 
assessment of immune status of patients; however, all these approaches have significant 
limitations that prevent their broad applications in the clinical setting.  Enzyme-linked 
immunosorbent assay/spot (ELISA/ELISpot), for example, is a gold standard for 
quantifying cellular cytokine production while enabling multiplexed, highly sensitive 
analyses [3-5].  However, the ELISA/ELISpot technique usually requires numerous 
reagent manipulation processes that involve multiple staining, washing, blocking, and 
sample transfer steps, which are laborious and time-consuming, prohibitive for 
standardization and practical utility in real-time clinical decision making.  In addition, the 
ELISpot method requires isolation and purification of desired subpopulations of immune 
cells prior to analysis, necessitating extensive sample preparation of blood specimens.  
Functional cellular immunoassays can also be performed using intracellular cytokine 
staining (ICS) flow cytometry [6].  However, ICS flow cytometry has so far only enabled 
detection of up to five cytokines, providing only a partial picture of the functional 
immune system.  ICS flow cytometry also requires a large number of cells in suspension 
(> 1 × 107 cells in 1 mL solution) and is sample destructive, thus precluding downstream 
functional assays that require live cells.  ICS flow cytometry has so far remained highly 
variable with regard to sample handling, reagents, instrument setup, and data analysis, 
thus standardization of ICS flow cytometry has proved difficult if not impossible.  The 
limitations associated with the conventional approaches to define the functional immune 
status of patients need to be fully addressed to realize rapid and accurate analysis of the 
immune phenotype of patients, a key step that provides crucial information relating to 
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staging, treatment choice, monitoring of efficacy, safety and dose adjustment of 
immunomodulation, as well as biological assessment of remission.   
In Chapter 2, I will discuss a promising application of microfluidics for immune 
monitoring of patients with minimum sample requirement and rapid functional 
immunophenotyping capability.  Here using a surface micromachining technique, I 
developed a integrated microfluidics-based immunophenotyping assay (MIPA) device  
capable of integrating all the immunophenotyping assay operations on a single chip, 
including cell isolation / enrichment / enumeration, cell stimulation, and cytokine 
secretion detection [7-9].  This integrated microfluidic platfom permits rapid, accurate, 
and sensitive cellular functional immunophenotyping assays on subpopulations of 
immune cells, potentially can provide an unprecedented level of information depth on the 
distribution of immune cell functionalities.     
1.2.2 Micrengineered Nanorough Surfaces for Efficient Capture of 
Circulating Tumor Cells 
Circulating tumor cells (CTCs) detached from both primary and metastatic lesions 
represent a potential alternative to invasive biopsies as a source of tumor tissue for the 
detection, characterization and monitoring of cancers.  Over the last decade, there has 
been a great interest in utilizing the peripheral blood CTCs to predict response to therapy 
and overall survival of patients with overt or incipient metastatic cancers [10, 11].  It has 
been demonstrated that an elevated CTC level is negatively correlated with prognosis in 
patients with metastases of the breast [12-17], prostate [18-23], lung [24, 25], and colon 
[26].  Clinical evidence further suggests that cancer cells disseminate at a much earlier 
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stage in tumorigenesis than previously recognized and that the presence of CTCsmay be a 
marker of successful tumor vascular invasion, having occurred a considerable period of 
time before the establishment of viable distant metastases [27].  The concept of CTCs as 
a marker of very early metastases is a radical departure from current approaches for 
cancer detection, which are based on either radiographic screening or at the development 
stage on serum proteomics [28].  Neither of these approaches captures a living cell in the 
process of metastatic progression and thus, testing for the presence of bona fide CTCs 
constitutes a potentially very powerful tool for cancer diagnosis and prognosis, and by 
studying the alterations of these captured live cancer cells, for tailoring cancer treatments 
on a single patient basis.  
Despite the clinical and pathophysiologicalimportance of CTCs, the current 
molecular and cellular understanding of CTCs is extremely poor, largely owing to the 
 
Figure 1-2  Intrinsic nanotopological sensing for capture of cancer cells.  Inserts show a SEM (left) and a 
zoom-in (right) images of cancer cells captured on nanorough glass surfaces. 
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fact that the current techniques to isolate and characterize these rare cells are limited by 
low yield and purity, complex techniques, and expensive proprietary equipments, 
compounded by yielding little phenotypic and molecular information about the CTCs 
themselves. As such, there is still little knowledge about timing of CTC release 
fromprimary tumors, their heterogeneity and molecular and cellular properties, and the 
degree to which they are representative of either primary or metastatic tumor deposits. 
Nanotechnologies including advanced nanofabrication and functional 
nanomaterials have provided new opportunities for many biological and medical 
applications.  My doctoral study has leveraged novel nanofabrication techniques to 
develop synthetic nanotopographical biomaterial to address specifically these broad 
challenges in understanding the CTC biology.  I introduced a simple yet effective 
microfabrication strategy for precise control and patterning of the local nanoroughness on 
glass surfaces using photolithography and reactive ion etching (RIE) which are well-
established processes used in semiconductor microfabrication. Incorporating this 
nanotopographic surface into a microfluidic platform, I have proven a new approach that 
can efficiently isolate, enrich, realse and potentially informative molecular and cellular 
analysis of live CTCs at the single-cell level.  This novel CTC capture strategy uniquely 
utilized the intrinsic differential adhesion preference of cancer cells to nanorough 
surfaces when compared to normal blood cells and thus did not depend on their physical 
size or surface protein expression, which is a significant advantage as compared to other 
existing CTC capture techniques (Figure 1-2) [29].  I envision that this CTC capture and 
analysis platform which can provide a superior performance for efficient isolation of rare 
and viable CTCs, permit potentional informative analysis of live CTCs for accurate 
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diagnosis and prognosis of cancer and help understand the crucial early metastatic 
process of cancer and hopefully discover new targets or phenotypes in the CTCs that can 
aid in the design of more effective molecular treatments.   
 
1.2.3 Biophysical Phenotyping of Cancer Stem Cells 
 
Cancer stem cells (CSCs), as defined through specific marker expression 
methods, have been shown to initiate tumorigenesis, have the capacity to self-renew, and 
initiate cancer metastasis in many cancer types.  Although identification of CSCs through 
marker expression helps separate and define the CSC compartment, it does not directly 
provide information on how or why this cancer cell subpopulation is more metastatic or 
tumorigenic.  In this Chapter 4, I will provide a comprehensively profiling of the 
functional as well as biophysical characteristics of inflammatory breast cancer (IBC) 
CSCs at the single-cell level using multiple microengineered tools and traditional in vitro 
studies to delineate the live cell phenotypic characteristics of the model of the most 
metastatic breast cancer subtype.  IBC is the most aggressive and lethal form of breast 
cancer with two-thirds of patients presenting with axillary lymph node involvement and 
up to one-third of patients having distant metastases at initial diagnosis [30, 31].  Why  
 
Figure 1-3  Concept of cancer stem cells. 
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IBC is so much more aggressive and metastatic than other breast cancers though is not 
definitively known.  Previous studies have identified ALDH+ IBCs as key mediators of 
tumorigenesis and metastasis, and they are negatively correlated with survival [32]; 
however, the how and why have been left unstudied.  Characterizing the functional 
behaviors of IBC CSCs such as cell migration, growth, adhesion, invasion, self-renewal, 
and differentiation is a direct approach to describe and understand IBC CSCs based upon 
their intrinsic properties, thus paving the way to determine therapeutic approaches to this 
most lethal subpopulation within IBC.  Distinct biophysical properties of IBC CSCs such 
as cell deformability, adhesion strength, and traction force provide physical insights into 
why IBC has an enhanced propensity to metastasize compared to other breast cancers.  
The multiparametric cellular phenotyping of functional and biophysical characteristics of 
IBC CSCs yields a new understanding of IBC’s metastatic properties and how they might 
develop and be targeted for therapeutic interventions. 
 
1.2.4 Nanotopography-mediated Mechanoseing of Human Embryonic 
Stem Cells 
During developmental processes within an embryo and the tissue maintenance 
and repair occurring in an adult organism, a myriad of stem cells are regulated by their 
extracellular matrix (ECM) enriched with tissue/organ-specific nanoscale topographical 
cues, and thus adopt different fates and functions specifically tuned by the 
microenvironment they reside in.  Attributed to their capability of either self-renewal or 
differentiation into most types of somatic cells, stem cells are promising cell sources for 
future regenerative medicine.  However, a major challenge still remains as to achieve 
stem cell fate control in vitro with high specificity as well as high yield.   
10 
 
 
Figure 1-4  Nanotopography regulates stem cell behaviors. 
In Chapter 5, I will demonstrate regulation of stem cell fates and functions via 
ECM nanotopography that enables versatile, robust and large-scale stem cell engineering 
in vitro through the development of synthetic nanotopographical biomaterials mimicking 
stem cell niches.  In this study, I demonstrated that nanoscale topolographic features can 
provide a potent regulatory signal over a diverse array of hESC behaviors, including cell 
morphology, adhesion, proliferation, clonal expansion, self-renewal and fate.  In addition, 
I explored underlying mechanism by which hESCs sense the biophysical cues and 
transduce them into intracellular biochemical signals and behavioral responses 
(‘mechanotransduction’).  Indeed, understanding these fundamental questions of 
mechanobiology in hESCs is of great current interest, as the results generated from such 
research will provide important insights and practical design guidelines for the synthetic 
stem cell microenvironment to direct hESC behaviors that are desirable for functional 
tissue engineering and regenerative medicine.   
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Chapter 2 
Integrateded Microfluidics for Functional 
Immunophenotyping 
2.1 Introduction 
The immune system plays a critical role in protecting a living organism against 
invasions of viruses, bacteria, and parasitic worms, and distinguishes diseased tissue from 
healthy one [33-36]. Leukocytes (white blood cells) are important blood constituents that 
play a major role in innate and adaptive immune responses against pathogenic infections, 
allergic conditions, and malignancies.  Leukocytes are a heterogeneous mixture of 
multiple cell subsets (granulocytes, lymphocytes, and monocytes) defined by their 
morphology, surface antigen expression, and production of cytokines - small proteins for 
intercellular communications between leukocytes of the same type (homotypic) or 
different types (heterotypic) [37-40].  The numbers, proportions and functional responses 
of leukocyte subsets change drastically in the presence of infections, malignancies, and 
autoimmune disorders, making analysis of leukocyte subpopulations particularly valuable 
in the diagnosis and monitoring of diseases [36, 41].  For example, human 
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immunodeficiency virus (HIV) infection causes depletion of CD4+ T cells in peripheral 
blood and other lymphoid tissues [33, 42-44].  As a result, the absolute counts of CD4+ 
T-cells and the ratio of CD4+ / CD8+ T-cells are commonly used as indicators of the 
onset of the acquired immunodeficiency syndrome (AIDS) and as benchmarks for the 
initiation of antiviral therapy to treat AIDS.   
Leukocytes orchestrate immune responses by releasing cytokines [3, 34, 41, 45-
48].  Given the heterogeneity of leukocytes and different roles played by different 
subpopulations of leukocytes in the immune response, measurements of capacity to 
produce cytokines from different subpopulations of leukocytes become critically 
important in clinical diagnosis.  Production of interferon gamma (IFN-γ) by T-cells, for 
example, correlates with the body’s ability to mount a vigorous immune response and is 
used to identify antigen-specific T cells in diseases such as HIV and tuberculosis.[34, 48, 
49]  Sepsis is another serious clinical condition that results from dysregulation of the 
immune response to infection [1, 3, 50-52].  One hallmark of sepsis commonly reported 
is the decreased capacity of monocytes to release pro-inflammatory cytokines such as 
tumor necrosis factor-alpha (TNF-α) in response to ex vivo lipopolysaccharide (LPS) 
challenge [3].   
The immune status of patients with infectious diseases and immune dysfunctions 
are dynamic and patient-specific, and such complex heterogeneity has made effective 
immunomodulatory therapies challenging in the clinic [1, 2].  An accurate measurement 
of the immune status in patients with immune system disorders is critical in evaluating 
the stage of diseases and tailoring drug treatments.  As such, there is an urgent need for 
new technologies that can perform rapid and accurate functional cellular 
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immunophenotyping for quantitative analysis of the cytokine secretion profiles on patient 
immune cells in order to define and characterize the “immune phenotype” of patients.   
A significant challenge in profiling cytokine secretion in a heterogeneous cell 
suspension such as blood is the fact that the same cytokines can be produced by several 
different subpopulations of leukocytes.  For example, IFN-γ is commonly secreted by 
CD4+ T-cells.  However, IFN-γ can also be produced by CD8+ T-cells, macrophages and 
neutrophils.  In addition, the numbers and proportions of subpopulations of immune cells 
may vary in individuals and at different stages of diseases.  The conventional whole 
blood stimulation assay routinely used in the clinical setting involve measurements of the 
capacity of the whole population of leukocytes to produce pro-inflammatory cytokines 
when stimulated ex vivo.  However, this ‘bulk’ assay may not be informative enough 
pinpoint the phenotype or real identity of the reactive immune cells involved, and is 
insufficient to accurately define and characterize the immune status of patients.   
To address this need, an integrated microfluidic immunophenotyping device was 
developed to achieve rapid and efficient isolation, enrichment, stimulation and functional 
immunophenotyping of subpopulations of immune cells directly from blood specimens.  
This microfluidics-based innovative technology can serve as a comprehensive and 
standardized immune monitoring platform to define and characterize the “immunotype” 
of healthy individuals and patients with immune dysfunctions before, during, and after 
targeted immunomodulation, thus leading to interventions that can significantly reduce or 
eliminate symptoms, side effects, disease progression, recurrence, and ultimately immune 
dysfunction-associated mortality.    
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2.2 Overview of the Current Techniques 
2.2.1 Conventional Functional Cellular Immunophenotyping Assays   
Several approaches currently exist for assessment of immune status of patients.  
Enzyme-linked immunosorbent assay/spot (ELISA/ELISpot), for example, is a gold 
standard for quantifying cellular cytokine production while enabling multiplexed, highly 
sensitive analyses (Figure 2-1) [53].  ELISA/ELISpot has been commonly adapted for 
identifying immune status of patients infected by malaria [54], HIV [55, 56] and 
mycobacterium tuberculosis [57] patients and monitoring immune response of cancer 
patients undergoing immuno-therapeutic treatment [58, 59].  However, the 
ELISA/ELISpot technique usually requires numerous reagent manipulation processes that 
involve multiple staining, washing, blocking, and sample transfer steps, which are 
laborious and time-consuming.  The complexity in implementing ELISA/ELISpot has 
been prohibitive for their standardization and has significantly reduced their practical 
utility in real-time clinical decision making.  In addition, the ELISpot method requires 
isolation and purification of desired subpopulations of immune cells prior to analysis, 
necessitating extensive sample preparation of blood specimens. 
Functional cellular immunophenotyping assays can also be performed using 
intracellular cytokine staining (ICS) flow cytometry - a flow cytometry based assay that 
detects the production and accumulation of cytokines (Figure 2-1) [6].  For example, the 
multiple parameter ICS flow cytometry can be used for understanding the functional 
capacity of effector and memory T-cells response, which can provide detailed 
information for vaccine development [6].  ICS flow cytometry has also been widely used 
15 
 
for study of sepsis [3], HIV [60, 61] and tuberculosis [62, 63] cancer immunotherapy [5].  
Although ICS flow cytometry can perform the high-throughput (>10,000 cells/sec) 
single-cell based cytokine production measurement,  it has so far only enabled detection 
of up to five cytokines, providing only a partial picture of the functional immune system.  
ICS flow cytometry also requires a large number of cells in suspension (> 1 × 107 cells in 
1 mL solution) and is sample destructive, thus precluding downstream functional assays 
that require live cells.  ICS flow cytometry has so far remained highly variable with 
regard to sample handling, reagents, instrument setup, and data analysis, thus 
standardization of ICS flow cytometry has been proved difficult if not impossible.  The 
limitations associated with the conventional approaches to define the functional immune 
status of patients need to be fully addressed to realize rapid and accurate analysis of the 
immune phenotype of patients, a key step that provides crucial information relating to 
staging, treatment choice, monitoring of efficacy, safety and dose adjustment of 
immunomodulation, as well as biological assessment of remission. 
 
Figure 2-1 Schematics of ELISA (A) and flow cytometry (B). 
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2.2.2 Microfluidic Cellular Immunophenotyping of Whole Blood  
Recent advances in integrated microfluidics have made possible miniaturization 
and integration of biosample preparative and analytical techniques on a single chip to 
enable rapid, sensitive, and multiplexed high-throughput cell-based assays.  Some of 
these microfluidic tools have been demonstrated as promising immune monitoring 
technologies with cell trapping and analysis functionalities and a minimum sample 
requirement to achieve rapid functional immunophenotyping analysis (Figure 2-2).  
Whole blood immunoassay is one of the most commonly used methods to 
determine patient immune status, which provides useful information for diagnosis [3, 4], 
prognosis [64], and deepening biological understanding of immune and infectious 
diseases [65, 66].  Conventional whole-blood immune tests are based on proteomic 
identification of biomarkers in blood, relying on antibody-based heterogeneous or 
homogeneous immunoassays (e.g., ELISA) to capture soluble biomarkers in blood 
specimens.  Recently, to achieve rapid on-chip immunoassays with a minimum amount of 
blood, several microfluidics-based whole blood immunoassay devices have been 
successfully developed and implemented for disease biomarker detection using patient 
blood.  A notable example is the integrated blood barcode chip recently reported by Fan 
et al. [67] that can achieve on-chip plasma separation from microliter quantities of whole 
blood and rapid in-situ multiplexed protein biomarker measurements (Figure 2-2A).  The 
blood barcode chip consists of two components: (1) a plasma separation structure as the 
plasma-skimming channel based on the Zweifach-Fung effect; (2) a protein detection 
region using a patterned DNA-encoded antibody library (DEAL) barcode immobilized on 
the surface of the plasma-skimming channel.  The blood barcode chip has been reported 
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to be capable of detecting picomolar concentrations of human chorionic gonadotropin 
(hCG), cancer biomarkers such as prostate-specific antigen (PSA), and more than ten 
cytokines in blood samples simultaneously from cancer patients.  
A key enabling technology used in the blood barcode chip for multiplexed bio-
sensing and -detection is the DEAL technology involving DNA-directed immobilization 
of antibodies to convert a prepatterned ssDNA barcode microarray into an antibody array, 
thus providing a powerful means for spatial encoding.  Specifically, in the DEAL assay, 
each capture antibody is tagged with multiple copies of an ssDNA oligomer that is 
complementary to ssDNA oligomers that have been surface-patterned into a microscopic 
barcode within the immunoassay region of the blood barcode chip.  Flow-through of the 
DNA-antibody conjugates transforms the DNA microarray into an antibody microarray 
for subsequent surface-bound immunoassays.  Because DNA patterns are robust to 
dehydration and can survive elevated temperatures, the DEAL approach circumvents 
denaturation of antibodies often associated with typical microfluidics fabrication.  
Compared with conventional whole blood immunoassays such as those using ELISA, 
which require a large blood volume and extensive sample preparations, the microfluidics-
based blood barcode chip enables rapid on-chip blood separation and multiparametric 
measurements of a panel of plasma proteins from a finger prick of whole blood.   
More recently, the same research group has further extended the antibody barcode 
technique to establish an automated, self-powered microfluidic chip for rapid and 
multiplexed protein detection from whole blood [68].  The blood plasma separation and 
subsequent immunoassays are sequentially driven by the capillarity of a filter paper 
coupled with the hydrophilic nature of microfluidic channel surfaces.  This inexpensive 
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Figure 2-2  Intgrated microfluidic devices for functional immunophenotyping of immune cells in whole 
blood (A-B), subpopulations of immune cells (C-D) and single immune cells (E-F).  (A) Design of the 
integrated blood barcode chip (IBBC).  Adapted from reference [67], Copyright © 2008, with permission 
from Nature Publishing Group.  (B) Schematic of a multi-layered MIPA device consisting of a cell culture 
chamber, a PDMS microfiltration membrane (PMM), and an immunoassay chamber.  Reproduced from 
reference [8].  (C) Conceptual design of an antibody-coated microarray for detection of cytokines secreted 
by CD4+ or CD8+ T-cells.  Reproduced from reference [69], by permission of The Royal Society of 
Chemistry.  (D) Schematic of isolation and immunophenotyping of subpopulations of immune cells from 
blood specimens by a combined use of both PMM and functionalized microbeads.  Reproduced from 
reference [9].  (E) Working principle of the microengraving array for capture and immunomonitoring of 
single immune cells.  Adapted from reference [70], Copyright © 2006, with permission from Nature 
Publishing Group.  (F) Photograph and working principle of the single-cell barcode chip for polycytokine 
analysis of single immune cells.  Adapted from reference [71], Copyright © 2011, with permission from 
Nature Publishing Group 
subsequent immunoassays are sequentially driven by the capillarity of a filter paper 
coupled with the hydrophilic nature of microfluidic channel surfaces.  This inexpensive 
and self-powered whole blood immunoassay chip can provide a cost effective platform 
for point-of-care diagnosis in a resource limited environment.  
Several microfluidics-based label-free, real-time detection techniques have also 
been developed recently for immunosensing.  Development of real-time immunosensing 
techniques allows detailed examination of temporal dynamics of cytokine secretion from 
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immune cells, which may provide informative and unique signature about the functional 
status of patient immune system [36].  The ability to assess dynamic cytokine secretion 
from immune cells, for example, can allow detection of onset of the signaling process and 
study of intercellular communications via cytokine-mediated paracrine / autocrine 
signaling.  Monitoring both the location and timing of cytokine secretion events among a 
heterogeneous population of individual immune cells can also potentially allow 
identification of which individual cells initiate the immune response and which cells are 
then activated by such initial immune response.  In clinical diagnosis such as tuberculosis 
detection, pathogen biomarkers (e.g., pathogen-specific antibodies) are not yet available.  
As a result, cytokine production by T-cells is commonly used as a diagnostic marker for 
tuberculosis.  If detection of dynamic response of antigen-specific T cells becomes 
available, it will enable early pathogen detection before pathogen biomarkers are 
produced or the pathogen proliferates in the host.  
A noteworthy microfluidic label-free immunodetection method has been recently 
reported by Stern et al. [72], who have developed CMOS-compatible semiconducting 
nanowires for real-time measurements of antibodies and early signals responsible for T-
cell activation that involve clustering of CD3 receptors.  Another label-free biosensing 
technique reported by Endo et al. [73] has applied immobilized antibodies and localized 
surface plasmon resonance (LSPR) to continuously monitor concentration levels of IL-2 
secreted by concanavalin-A (Con-A) stimulated mouse thymus cells.  The LSPR-based 
biosensor provides a promising platform with attractive advantages for real-time 
detection of cellular responses in a simplified experimental set-up with a low sample 
volume requirement.  Overall, label-free cellular immunophenotyping techniques permit 
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real-time quantifications of dynamic cytokine secretion processes, providing unique 
functional signature of immune cells such as how fast and strong immune cells secrete 
cytokines in response to antigen stimulations. 
2.2.3 Microfluidic Cellular Immunophenotyping of Subpopulations of 
Immune Cells  
Microfluidic whole-blood immunoassays measure the overall capacity of the 
whole population of leukocytes in blood to produce cytokines.  The numbers, proportions 
and capacity to produce cytokines of leukocyte subsets actively respond to the presence 
and status of infections, malignancies, and autoimmune disorders, making analysis of 
leukocyte subpopulations critically important in clinical diagnosis [36, 41].  Thus, 
microfluidic whole-blood immunoassays may not be informative enough to accurately 
reveal the immune status of patients, as in these ‘bulk’ assays it is difficult to pinpoint the 
phenotype or real identity of the reactive immune cells involved.  Recently, there are 
concerted efforts from different research groups to integrate immune cell separation 
procedures into microfluidic immunoassay devices and systems to achieve accurate and 
rapid cellular functional analysis on specific subpopulations of immune cells isolated 
from blood specimens.  Zhu et al., for example, have recently developed a microarray 
device uniformly coated with both T-cell capture antibodies (anti-CD4 and anti-CD8) and 
cytokine capture antibodies (anti-IFN-γ and anti-IL-2) on top of a poly(ethylene glycol) 
(PEG) hydrogel layer (Figure 2-2C) [69].  To enable capture and positioning of single 
CD4+ and CD8+ T-cells, the antibody-coated microarray was covered with 
photolithographically patterned PEG hydrogel microwells on top of the antibody 
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containing hydrogel layer.  The antibody-coated microarray can directly process red 
blood cell (RBC) depleted human whole blood samples for capture of individual CD4+ 
and CD8+ T-cells and subsequent functional examination of IFN-γ and IL-2 secretion 
from single CD4+ T-cells.  To capture CD4+ and CD8+ T-cells, RBC- depleted whole 
human blood was simply introduced into the microfluidic device and the target T-cells 
were immobilized on their respective Antibody spots while the unwanted cells were 
washed away at a pre-defined shear stress.  As the cytokine capture antibody (anti-IFN-γ 
and anti-IL-2) spots were designed to localize next to the isolated T-cells, following 
mitogenic activation and immunofluorescent staining of the captured T-cells revealed 
concentration gradients of surface-bound cytokine molecules.  
The antibody-based microarray platform reported by Zhu et al. has simplified 
sample preparation process and also reduced the required sample volume.  Although 
immobilized antibodies offer a heightened cell isolation purity and cytokine measurement 
sensitivity, it still suffers from several limitations, including the need of multiple washing 
and blocking steps and the difficulty to achieve real-time dynamic cytokine secretion 
measurement.  To address these limitations, the same research group have recently 
applied DNA and RNA-based aptamers as an alternative to antibodies and immobilized 
aptamers on an array of micropatterned gold electrodes [74, 75].  The aptamers have been 
thiolated for assembly on gold and functionalized with methylene blue redox reporter for 
electrochemical signal transduction and detection with gold electrodes.  Instead of using 
fluorescence-based biosensing methods, the authors have demonstrated electrochemical 
measurements to access the dynamic nature of cytokine secretion from activated human 
monocytic cell and T-cell lines with a detection sensitivity of ~ ng/mL [74, 75].   
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2.2.4 Microfluidics to Study Functional Heterogeneity of Single 
Immune Cells 
Functional and phenotypic variation among individual single cells, or single-cell 
functional heterogeneity, is a common feature for hematopoietic cells including immune 
cells.  Thus, quantitative analysis of cytokine secretion profiles of individual immune 
cells is required for precise assessment of subtle variations in the functional immune 
status across different subsets of immune cells.  The most commonly used methods for 
single-cell cytokine secretion analysis are ICS flow cytometry and ELISpot [53, 76].  As 
discussed earlier, quantitative functional assessment of individual leukocytes by ICS flow 
cytometry requires detection of cytokines accumulated inside fixed and permeabilized 
cells.  The need for such cell fixation in ICS flow cytometry prohibits assessments of 
dynamic cytokine secretion from the same single immune cell or post-detection 
functional characterization requiring live cells.  ELISpot assay allows enumeration of 
single immune cells secreting cytokines in response to antigen stimulation.  However, 
ELISpot cannot quantify the amount of cytokine secretion.  Further, ELISpot requires 
removal of immune cells from the substrate coated with capture antibodies upon 
completion of the assay and only allows for tracing cytokine spots left behind on the 
substrate surface, which prevents identification of which individual single cells secrete 
what cytokines on the antibody-coated substrate.  In addition, ELISpot requires isolation 
of desired cell subsets prior to analysis by extensive preprocessing of blood samples.   
Over the last decade, significant research efforts have been directed toward 
applying microfluidics for manipulation of single immune cells and massively parallel, 
high-throughput analysis of cell-secreted soluble molecules, such as antibodies, cytokines 
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and metabolites, at the single-cell level.  One of the most notable example entails plating 
and stimulating single immune cells in an array of microfabricated wells, transferring 
soluble molecules secreted from immune cells onto a secondary solid surface coated with 
capture antibodies, and labeling captured molecules with fluorescently tagged proteins 
(e.g., antigens for antibody detection and secondary antibodies for antigen detection) 
prior to subsequent optical detection.  For example, Love et al. [70] have pioneered the 
development of engraved microarrays made in PDMS using soft lithography to monitor 
cytokines secreted from single immune cells (Figure 2-2E).  The engraved microarray 
can consist of 25,000 microwells (50-100 µm in diameter), each of which can confine 
single immune cells in a nanoliter volume (~ 0.1-1 nL).  After individual immune cells 
trapped and stimulated in the microwell array, the engraved microarray can be flipped 
against an antigen- or secondary antibody-immobilized glass slide to capture primary 
antibodies secreted from cells.  Compared to ELISpot, the engraved microarray enables a 
rapid (< 12 hr) and high-throughput (> 10,000 individual cells) system for identification, 
recovery and clonal expansion of single immune cells producing antigen-specific 
antibodies.  More recently, follow-up studies from the same research group have 
demonstrated the capability of the engraved microarray for characterization of dynamic 
cytokine secretion from individual primary human T-cells after activation ex vivo [77, 
78].   
In addition to the microengraving method developed by Love et al., Jin et al. have 
independently developed a similar functional immunosensing technique called 
‘immunospot array assay on a chip’ (or ISAAC) to detect production of monoclonal 
antibodies by blood lymphocytes [79].  The ISAAC method offers a rapid and high-
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throughput system for screening and analysis of antigen-specific antibody-secreting cells 
(ASCs) on a single-cell basis.  Similar to the microengraving assay, the ISAAC also 
includes an array of microwells for trapping of single live immune cells.  The top surface 
of ISAAC is functionalized with antibodies against immunoglobulin, and antibodies 
secreted by individual ASCs trapped in the wells are captured and bound to the device 
surface around the well.  The ISAAC method is useful for detecting ASCs in response to 
different antigens as well as for selection of ASCs secreting high-affinity antibodies.  
Although both the microengraving and ISAAC methods have used a high-density array of 
microwells to trap and isolate single immune cells, the two methods utilize quite different 
detection techniques.  Fundamentally, the microengraving method pioneered by Love, at 
al. is based on ELISA [70], whereas the ISAAC is based on ELISPOT [79].   
Ma et al. [71] have recently implemented a novel integrated microfluidic 
approach called the "single-cell barcode chip" for high-content assessment of functional 
heterogeneity of antigen-specific T-cells at the single-cell level (Figure 2-2F).  The 
single-cell barcode chip consists of 1,040 microchambers with a nanoliter volume, and 
each microchamber can trap single or a small number of immune cells.  On the bottom 
surface of each microchamber, a spatially encoded antibody barcode array is pre-printed 
to capture cytokine molecules secreted from immune cells trapped in the microchamber.  
Protein concentrations are measured with immunosandwich assays from the spatially 
encoded antibody barcode.  A full barcode from each microchamber represents a com-
plete panel of multiple cytokine species produced by a single immune cell (or a few 
cells).  The single-cell barcode chip permits highly multiplexed (more than ten proteins) 
on-chip detection of a few thousand proteins or less from thousands of immune cells 
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simultaneously.  The single-cell barcode chip reported by Ma et al. represents an exciting 
and very informative microfluidic single-cell immunophenotyping tool for analyzing 
functional signatures of immune cells with high sensitivity, throughput, multiplicity and 
small sample size, which can be used in a wide range of fundamental and clinical 
applications. 
All of the microfluidic devices and systems discussed in this section can clearly 
provide a promising potential for high-throughput study of functional heterogeneity of 
single immune cells.  However, one critical issue common with these approaches is that 
they require off-chip isolation and purification of target cells from whole blood prior to 
on-chip analysis.  As such, there is still an unmet need for highly integrated microfluidic 
technology platform for efficient isolation and informative systems-level cellular 
characterization of immune cells down to the single-cell level and using unprocessed or 
minimally processed blood samples. 
2.3 Methods and Materials 
2.3.1 Surface Micromachining of Polydimethylsiloxane (PDMS)  
Polydimethylsiloxane (PDMS) is one of the most frequently used structural 
materials in microfluidics, due to its great biocompatibility, optical transparency, gas 
permeability, mechanical elasticity, and electrical insulation [80].  The complexity of 
PDMS-based microfluidic systems is also increasing rapidly as sophisticated functions 
have being integrated into single microfluidic devices [81].  Just as the surface patterning 
techniques using lithography and etching processes have been the major drivers for the 
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successful development of micro-electro-mechanical systems (MEMS), there is an 
increasing demand in the field of microfluidics for highly reliable, repeatable and precise 
surface micromachining techniques to pattern PDMS for different practical microfluidic 
and bioengineering applications. 
However, till now, PDMS has been largely considered incompatible with 
conventional lithography, due to its low surface energy resulting in dewetting of 
photoresist on the PDMS surface [82].  Soft lithography is a popular micromachining 
technique for rapid fabrication of PDMS structures [80].  Yet, soft lithography is a bulk 
micromachining technique, and it largely relies on replica molding, which often leaves 
behind a thin residual PDMS layer on top of the mold features.  Through holes in bulk 
PDMS are typically achieved by punching through the PDMS structures, which can only 
generate macroscopic openings in PDMS and is far from a precise patterning method.  
High fidelity PDMS surface micromachining so far remains a major technical hurdle for 
the microfluidics research.  
Several approaches for surface patterning of PDMS have been reported recently, 
even though each of these methods has its intrinsic constraints that have limited the 
scopes of their applications in microfluidics.  Ryu et al. have reported a simple PDMS 
patterning method by mechanically removing excessive PDMS prepolymer from a pre-
patterned mold using a traversing blade [82].  However, this mechanical scrapping 
method could limit the achievable minimum PDMS film thickness and its pattern 
resolution and uniformity.  Another example is the photo-patternable silicone introduced 
by Dow Corning [83, 84].  This photosensitive silicone can be conveniently patterned as 
traditional negative photoresists.  However, it also suffers with the drawbacks associated 
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with negative photoresists in terms of their high cost and limited resolution.  Bhagat et al. 
and some others have proposed another photo-patterning approach by addition of 
photoinitiators such as benzophenone or 2,2-dimethoxy-2-phenyl acetophenone (DMAP) 
into PDMS prepolymer to make it photosensitive and thus directly photo-patternable [85, 
86].  Yet, during UV exposure, the photomasks need to be kept at a minimum distance 
(~80 µm) from the PDMS prepolymer to avoid their direct contact.  Thus, pattern 
resolution achieved using these photosensitive PDMS was significantly limited as 
compared to conventional photolithography operated in the contact mode.  The cytotoxic 
effects of benzophenone or DMAP have not been well characterized yet and thus could 
present potential problems for biological applications.  More recently, a rapid prototyping 
technique using direct UV-lithography followed by chemical development for pre-cured 
PDMS was introduced [87].  Although this technique does not introduce undesirable 
chemical components into PDMS, its pattern resolution is still limited by the required 
chemical development.  Researchers have also recently attempted using intermediary 
adhesion layers, such as metal or polydimethyl-glutarimide (PMGI), to permit high-
resolution lithography on PDMS [88, 89].  Still, these methods unavoidably require 
complex processing steps, and introduce undesirable alterations of the surface and 
mechanical properties of PDMS.  For example, the spontaneous buckling of the metal 
film could result in a permanent deformation of PDMS during thermal curing [90]. 
To address the unguent need for surface patterning of PDMS, I have developed an 
easily-implementable wafer-level surface micromachining method to generate different 
planar PDMS microstructures using direct photolithography followed by reactive-ion 
etching (RIE).  This new PDMS fabrication technique does not induce undesired 
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chemical components into PDMS and can be conveniently integrated with conventional 
silicon (Si)-based surface and bulk micromachining techniques and other PDMS-based 
soft lithography methods.  The PDMS surface micromachining technique permits high 
fidelity lithographic patterning of PDMS structures with a resolution comparable to 
conventional photolithography (~2 µm).  As a proof of its general applicability, this 
PDMS surface micromachining technique has been applied to generate different planar 
microstructures, such as patterned PDMS microfiltration membranes and free-standing 
beam structures, with their thickness ranging from sub-microns to tens of microns. 
The fabrication process for surface micromachining of PDMS is illustrated in 
Figure 2-3 (details see Appendix A).  A Si wafer was first silanized with (tridecafluoro-
1,1,2,2,-tetrahydrooctyl)-1-trichlorosilane (United Chemical Technologies, Bristol, PA) 
for 1 hr under vacuum to facilitate subsequent release of patterned PDMS layers.  PDMS 
prepolymer (Sylgard-184, Dow Corning, Midland, MI) was prepared by thoroughly 
mixing the PDMS curing agent with the PDMS base monomer (wt : wt = 1 : 10).  PDMS 
prepolymer was then spin coated on the silanized Si wafer and completely cured at 110°C 
for 4 hrs.  The thickness of the PDMS layer, ranging from hundreds of microns down to 
~2 μm, could be controlled easily by the spin speed.  To achieve ultra-thin PDMS layers 
with a sub-micron thickness, the PDMS prepolymer could be further diluted with hexane 
(Fisher Scientific, Pittsburgh, PA) to reduce its viscosity [91].  It has been reported that 
this strategy could generate PDMS layers with a thickness as thin as ~70 nm [91].  
Similarly, with a weight ratio of PDMS curing agent:base:hexane as 1:10:20, PDMS thin 
films with a thickness of 500 nm were achieved by spin coating the diluted PDMS 
prepolymer at 5,000 rpm for 2 min. A surface profilometer (Dektak 6M surface profiler,  
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Figure 2-3  Schematic of photolithographic surface micromachining of PDMS. 
Veeco Instruments, Plainview, NY) was then used to measure thickness of the PDMS. 
The PDMS surface was then activated using a gentle treatment of O2 plasma 
(Plasma Cleaner PDC-001, Harrick Plasma, Ithaca, NY) for 5 min to change the PDMS 
surface from hydrophobic to hydrophilic, in order to allow uniform coating of photoresist 
in the following step.  Immediately following the O2 plasma activation, photoresist such 
as AZ 9260 (AZ Electronic Materials, Branchburg, NJ) or SPR 220 (Rohm and Haas, 
Philadelphia, PA) was spin-coated uniformly on PDMS, soft baked at 80ºC for 10 min in 
oven, and then patterned using conventional contact or projection photolithography.  It 
should be noted that sudden temperature changes should be avoided after soft bake of 
photoresist, as cracks in the photoresist layer might develop owning to the known issue of 
a mismatch of the coefficient of thermal expansion (CTE) between PDMS and 
photoresist.  The Si wafer was then processed with RIE (LAM 9400, Lam Research, 
Fremont, CA) using SF6 and O2 gas mixtures to transfer patterns from the photoresist to 
the underlying PDMS layer.  During the RIE process, the reactive gas ions would etch 
anisotropically the exposed PDMS regions where the photoresist had been previously 
developed and dissolved. (Details of the RIE process are discussed in the following 
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paragraphs.)  Photoresist was then striped using solvents or O2 plasma, leaving patterned 
PDMS thin films attaching on the Si wafer (Figure 2-4). 
Our photolithographic method for surface micromachining of PDMS could be 
easily integrated with other conventional microfabrication techniques to generate 
functional microfluidic devices for different biomedical applications.  As shown in Figure 
2-4A & Figure 2-5A-E, large PDMS microfiltration membranes with arrays of through 
holes of different diameters were generated using our photolithographic PDMS surface 
micromachining method.  These PDMS microfiltration membranes had a thickness of 2-
20 µm, and they contained hexagonally spaced or square arrays of through holes with the 
hole diameter and center-to-center (c.t.c.) distance precisely defined by photolithography 
(the hole diameter of 4-20 µm and c.t.c. distance of 6-200 µm).  Using the O2 plasma-
assisted PDMS bonding process, the PDMS microfiltration membrane was further 
transferred onto a secondary bulk PDMS, whose surface contained square-shaped support 
microstructures fabricated using soft lithography, to provide a superior mechanical 
strength for the large microfiltration membrane.  As another example, free-standing thin 
PDMS beam structures (with a thickness of 500 nm) were successfully fabricated using 
XeF2-based bulk Si dry etching (Xetch X4 series, XACTIX, Pittsburgh, PA) after surface 
pattering of PDMS on the Si wafer (Figure 2-4B and Figure 2-5F-I).  Using contact 
photolithography, the minimum beam width along these free-standing PDMS beam 
structures was as small as 2 µm. 
In this new fabrication method, a simple O2 plasma treatment is introduced to 
address the major technical hurdle for wafer-level surface machining of PDMS: 
dewetting of photoresist on the intrinsically hydrophobic PDMS surface.  The difficulty  
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Figure 2-4  Bright-field images of patterned PDMS layers on Si wafers. (A) Arrays of through holes with 
the hole diameters of 20 µm (left and middle) and 8 µm (right). (B) PDMS strips of different line widths. 
 
Figure 2-5  Photolithographic surface micromachining of free-standing PDMS microfiltration membranes 
and beam structures. (A-E) Bright-field (A) and SEM (B-E) images of a PDMS microfiltration membrane, 
bonded to a PDMS support structure (D).  The microfiltration membrane had a thickness of 10 µm and it 
contained an array of hexagonally spaced through holes (with a hole diameter of 4 µm). (F-I) Free-standing 
PDMS beam structures on Si wafers, with the beam thickness of 500 nm and total beam length of 800 µm.  
The minimum beam widths were 2 µm (F), 10 µm (G), 5 µm (H & I), respectively. 
in spin coating photoresist directly onto the untreated PDMS surface is because of its low 
surface energy (~23 mN m-1), which is originated from the shielding effect of the 
nonpolar methyl groups (carbon and hydrogen containing groups) on the polar siloxane 
backbone, resulting in a tendency for photoresist to dewet on PDMS [89, 92].  It is 
showed that a brief treatment of O2 plasma for the PDMS surface could create super-
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hydrophilicity on the PDMS surface, by stripping methyl groups from the PDMS surface 
which could then form silanols [80, 89, 93] (Figure 2-6A).  As evidence of this super-
hydrophilicity on the PDMS surface after the O2 plasma treatment, the contact angle of a 
water droplet was dramatically reduced from about 100º (on untreated PDMS; Figure 
2-6B, left ) to <5º (on plasma-treated PDMS; Figure 2-6B, right).  After the O2 plasma 
activation of PDMS, a uniform photoresist layer could be successfully spin-coated onto 
the PDMS surface (Figure 2-6C, right), which could be difficult to achieve for the 
untreated PDMS surface (Figure 2-6C, left).  It should be noted that the effect of O2 
plasma treatment was not permanent and would decay within a few hours as the low 
molecular weight siloxane chain in the bulk PDMS could migrate to its surface [89, 94].  
Hence, the O2 plasma treatment of the PDMS surface could temporarily establish a 
hydrophilic surface suitable for spin coating photoresist uniformly, and this O2 plasma 
treatment will not introduce permanent alterations of the PDMS surface property. 
 
Figure 2-6  Effect of O2 plasma treatment on coating photoresist on Si wafer. (A) Surface hydrophilization 
of PDMS using O2 plasma treatment. (B) Contact angles of water drops on PDMS before (100º, left) and 
after (<5º, right) 5 min treatment of O2 plasma. (C) Images of photoresist layer spin-coated on PDMS 
surface with (right) and without (left) treatment O2 plasma. Photoresist could not be spread out uniformly 
on the PDMS surface without O2 plasma treatment (left), while after O2 plasma treatment, the photoresist 
could be uniformly spin-coated on PDMS.  
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The RIE process was further optimized for anisotropic dry etching of PDMS 
using SF6 and O2 gas mixtures and achieved a maximum PDMS etch rate of ~0.8 μm/min 
with a vertical etch profile and a smooth etched surface.  After 15-min etching of PDMS, 
the root-mean-square (RMS) surface roughness of the etched PDMS surface measured by 
atomic force microscopy (AFM, Digital Instruments, Tonawanda, NY) was about 1 nm, 
comparable to the intrinsic surface roughness of unprocessed PDMS (data not shown).  It 
has been reported that reactive plasma generated using CF4 and O2 gases could also etch 
PDMS, yet I observed that RIE process using such gases could result in a large surface 
roughness (~μm) for the etched PDMS surface (data not shown) [95].  To further 
examine the anisotropic etch profile for PDMS after the RIE process using SF6 and O2 
gas mixtures, cross-sectional scanning electron microscopy (SEM) images of the PDMS 
microfiltration membrane were taken, and indeed vertical sidewalls of the through holes 
in the PDMS microfiltration membrane were observed (Figure 2-5C), indicating our RIE 
process using SF6 and O2 gas mixtures achieved anisotropic dry etching of thick PDMS 
layers. 
For RIE process using SF6 and O2, the etch rate of PDMS increased with the 
plasma power and the bias voltage but decreased with increasing chamber pressure, 
consistent with previous reports [93].  A sufficiently low chamber pressure was required 
to ensure a short resident time for the reactive ions on the PDMS surface and rapid 
renewal of the reactive species inside the plasma, both contributing to rapid etching of 
PDMS.  SF6 is the main resource for reactive fluorine (F) ions to etch PDMS and these 
fluorine ions could break the Si-O bond and thus etch PDMS.  In addition, the partial 
pressure of O2 in the plasma also affected the PDMS etch rate, which decreased with 
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increasing the partial pressure of O2.  Adding a small fraction of O2 could facilitate this 
fluorine-assisted PDMS etching process, even though the detailed mechanism is not well 
understood yet [92].  The RIE process conditions used in our fabrication were: gas (SF6 
(90 sccm) and O2 (6 sccm)), chamber pressure (0.67 Pa), bias voltage (100 V) and RF 
power (500 W).  Under this RIE condition, the etch rate for photoresist such as SPR220 
was about 0.41-0.46 μm/min, leading to an etch selectivity between PDMS and 
photoresist of about 2:1.  It is also worth noting that the RIE RF power and etching time 
could affect the anisotropic etching profile of PDMS, as excessive RF power or etching 
time often leaded to a slanted sidewall of the PDMS structures.   
This new photolithographic surface micromachining technique can achieve wafer-
level fabrication of different planar PDMS structures with their thickness covering a very 
broad size range from submicron to tens of micrometers.  Similar to surface 
micromachining for processing microelectronics and MEMS devices, our PDMS surface 
micromachining technique involved deposition or spin coating and dry etching of PDMS 
layers on top of the Si substrate.  Further, our PDMS surface micromachining technique 
was compatible with Si-based surface and bulk micromachining techniques, enabling the 
possibility of realizing different monolithic microscale devices and systems in which 
PDMS structures and other electronic and MEMS components could be integrated on the 
same substrate.   
Using the PDMS surface micromachining technique, wafer-level fabrication of 
different planar PDMS microstructures was performed to elucidate its simplicity and 
versatile applications.  The PDMS microfiltration membranes contained a large array of 
closely packed through holes with the hole diameter of 4-20 µm and the hole c.t.c. 
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distance of 8-200 µm (Figure 2-4A & Figure 2-5A-E).  These PDMS microfiltration 
membranes could potentially be utilized for size-based separation of blood cells.  For 
instance, there is a great current interest in devising efficient techniques to isolate and 
enrich the rare live circulating tumour cells (CTCs) from cancer patient blood as 
surrogates to understand the crucial early cancer metastatic process and discover new 
targets or new phenotypes in the CTCs that need to be targeted [10, 11].  The surface 
micromachined PDMS microfiltration membranes could be easily integrated onto PDMS 
support structures to improve its mechanical strength, which would be important for 
PDMS microfiltration membranes with a large surface area.  Our PDMS microfiltration 
device could potentially be applied as a low-cost innovative technology for achieving 
isolation of live CTCs without the requirement for large and expensive apparatus.  
Our PDMS surface micromachining technique could be further combined with Si 
surface or bulk micromachining to generate submicron-scale free-standing planar PDMS 
structures (Figure 2-5F-I).   Free-standing thin PDMS structures could potentially be 
utilized as sensitive mechanical biosensors based on mass- or force-based methods [96].  
These PDMS mechanical biosensors could open new exciting opportunities to seamlessly 
integrate such biosensors with upstream or downstream PDMS-based microfluidic 
sample preparation and bioanalytical components. In addition, the low density and 
mechanical flexibility of PDMS provided additional desirable advantages for mass- or 
force-based sensing. 
In summary, a PDMS surface micromachining strategy was demonstrated using a 
combination of photolithography, RIE, and convenient thin film releasing techniques (O2 
plasma assisted PDMS bonding or XeF2 Si etching).  By using a gentle treatment of O2 
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plasma for the PDMS surface prior to spin coating the photoresist, the long-standing 
challenge of photolithography on the PDMS surface was successfully addressed.  Our 
PDMS surface micromachining technique was compatible with existing Si-based surface 
and bulk micromachining techniques, thus opening promising opportunities for 
generating different novel hybrid devices for highly integrated bio-sensing and -analytical 
applications.  Our PDMS surface micromachining method could provide an efficient tool 
for fabricating well-defined PDMS microstructures, fulfilling the current technical 
demands of PDMS surface micromachining in microfluidic and bioengineering 
applications. 
2.3.2 Integrated Microfluidic Immunophenotyping Device 
Using the above-mentioned surface micromachining technique for soft materials, 
we have developed a highly integrated microfluidic immunophenotyping assay (MIPA) 
device that can perform efficient isolation and rapid and accurate functional 
immunophenotyping of subpopulations of immune cells from patients with 
immunodysfunctions [7-9].  The new immunophenotyping platform employed a 
combined use of a surface micromachined PDMS microfiltration membrane (PMM) in 
the MIPA device and antibody-conjugated polystyrene microbeads for isolation, 
purification, and functional immunophenotyping of different subpopulations of immune 
cells directly from blood specimens (Figure 2-7).  Immobilized on the microbead surface 
were monoclonal antibodies against cell surface antigens specific to the desired 
subpopulation of immune cells.  When mixed with a blood specimen, the microbeads 
could selectively capture the desired subpopulation of immune cells by recognizing and 
37 
 
binding covalently to the specific surface proteins of the cells.  The diameter of the 
through holes in the PMM, which solely defined the effective size cutoff for 
microfiltration, was designed to be smaller than the size of the microbeads but larger than 
normal blood leukocytes.  Thus when the blood specimen was introduced into the 
microfiltration device and forced to pass through the PMM, the cell/microbead 
conjugates were readily trapped and isolated on the PMM, whereas other untargeted 
leukocytes and erythrocytes (red blood cells) unbound to microbeads could freely pass 
through the PMM.  Owing to its large surface area and high porosity, the PMM permitted 
a heightened volume throughput (> 5 mL min-1) for processing blood specimens without 
causing clogging of the PMM, a common problem in microfiltration membrane filters. 
 
Figure 2-7   Microfluidic device for isolation and immunophenotyping of subpopulations of immune cells. 
(A) Schematic of isolation and immunophenotyping of subpopulations of immune cells from blood 
specimens.  Subpopulations of immune cells were recognized and captured by microbeads conjugated with 
monoclonal antibodies against specific cell surface antigens.  Owing to the increased size of cell-microbead 
conjugates, the desired subpopulation of immune cells was retained on the PDMS microfiltration 
membrane (PMM) upon loading of the blood sample, while the other blood cells including undesired 
immune cells could pass freely through the PMM.  On-chip functional immunophenotyping was then 
performed to examine the capacity of this subpopulation of immune cells to produce pro-inflammatory 
cytokines following stimulation.   (B) Schematic of a multi-layered MIPA device consisting of a cell 
culture chamber, a PMM, and an immunoassay chamber. 
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The MIPA device further allowed in situ quantitative immunosensing of cell-
secreted cytokines by detecting optical signals resulted from a no-wash homogeneous 
sandwich chemiluminescence assay.  In this homogeneous immunoassay, so called 
“AlphaLISA” [97-99], the analyte of interest (i.e., cytokine) binds simultaneously to 
primary antibody-coated donor and acceptor beads, which brings the beads into a close 
proximity to each other.  In this bead proximal state, singlet oxygen generated by laser 
excitation ( = 680 nm) from the donor bead will transfer to the acceptor bead, eliciting a 
shorter wavelength emission ( = 615 nm) from the acceptor bead.  The AlphaLISA 
assay provides an efficient way for quantitative detection of cytokine production, without 
involving complex reagent loading and washing steps as in the conventional 
fluorescence-based immunoassays (e.g., enzyme-linked immunosorbent assay (ELISA)) 
[53, 100].   
In addition, the miniaturized size of the PMM-integrated microfiltration device 
required only a sample volume as small as 5 µL for each assay.  The MIPA device, 
permitting the homogenous AlphaLISA immunoassay in a microfluidic chamber, could 
reduce the entire assay time comprising the time for pretreatment, process, and detection 
down to a few hrs, a nearly 10-fold reduction in total assay time as compared to the 
conventional whole blood stimulation assay using ELISA or the enzyme-linked 
immunosorbent spot (ELISpot) assay [53, 100].  Given the shortened assay time, 
enhanced sample efficiency, and the ability to determine the functional status of different 
subpopulations of immune cells, our microfluidic immunophenotyping technology 
promises to provide a new approach to diagnosing infectious and inflammatory diseases 
across a broad patient spectrum. 
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Figure 2-8 Schematic of fabrication process of the PMM-integrated microflitration device. 
The structure of the MIPA device consists of three different PDMS layers (Figure 
2-7). The top and bottom PDMS chambers are the cell culture and immunoassay 
chambers, respectively.  Embedded between the top and bottom layers is the PMM, 
which serves (1) for isolation, enrichment, and enumeration of immune cells, and (2) for 
allowing cytokines secreted by immune cells to diffuse rapidly into the bottom 
immunoassay chamber for quantitative immunosensing.   
In last section, a wafer-scale surface micromachining method have been 
demonstrated to generate different PDMS thin film microstructures, with their critical 
dimensions ranging from sub-microns to tens of microns, using a combination of  
photolithography, RIE and convenient thin film releasing techniques [7].  This method to 
achieve surface patterning of PDMS applies an O2 plasma treatment to PDMS to activate 
its surface to overcome the challenge of poor photoresist adhesion on PDMS for 
photolithography.  Utilizing this newly developed PDMS surface micromachining 
technique, we have achieved wafer-scale batch fabrication of large PMMs containing a 
regular array of micron-scale through holes with high porosity (Figure 2-8 and Appendix 
A for the detailed fabrication procedure).  Specifically, using our PDMS surface 
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micromachining technique, We successfully fabricated PMMs with an effective 
membrane area of 3 cm × 3 cm and porosity up to 30%; both factors could contribute to a 
heightened volume throughput for processing unprocessed blood specimens without 
causing clogging of the PMM, a common problem in microfiltration membrane filters.  
For comparison, conventional track-etched polycarbonate filters, which have been used 
for isolation of blood cells and circulating tumor cells, has porosity of less than 2%, and 
the other more recently developed parylene-based micropore membrane has porosity of 
7% - 15% [101-103].  Since the through holes in the PMM were defined by 
photolithography, the size and pattern of the through holes in the PMM could be 
precisely controlled.  The PMMs used in this work had a thickness of about 10 µm and 
contained a regular array of hexagonally arranged through holes with a hole diameter of  
6 - 60 µm and a center-to-center distance of 10 - 100 µm (Figure 2-9A-C).  By 
 
Figure 2-9   SEM images showing free-standing PMMs with high porosity.  (A-C) Top (A&B) and tilted 
(C) view SEM images showing PMMs containing a regular array of hexagonally arranged through holes 
with the hole diameter of either 6 µm (A), 30 µm (B), or 60 µm (C).  The PMMs had a thickness of 10 µm.  
(D) Top view SEM image showing PDMS supporting pillars with a height of 100 µm and a diameter of 60 
µm.  (E) SEM image showing a cross-section view of a free-standing PMM bound to PDMS supporting 
posts.  In E, the diameter of the PMM through hole was 30 µm. 
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controlling anisotropic etching of PDMS using RIE, the through holes of the PMM had a 
near vertical sidewall profile (Figure 2-9C).  The transparent nature of PDMS permitted 
imaging and enumeration of cells captured on the PMM using standard clinical 
histopathological stains, in addition to immunofluorescence-conjugated antibodies. 
Our PDMS surface micromachining technique is compatible with soft lithography 
techniques and other silicon-based microfabrication methods.  Thus, the PMM can be 
easily integrated with PDMS supporting structures and other PDMS-based molecular and 
cellular analysis components while maintaining a large surface area and high porosity.  In 
this study, using O2 plasma-assisted PDMS-PDMS bonding, the PMM was assembled 
with two structured PDMS layers serving as the top cell culture chamber and the bottom 
immunoassay chamber to form a completely sealed PMM-integrated microfiltration 
device (Figure 2-8).  The cell culture and immunoassay chambers in the microfiltration 
devices contained supporting pillar structures to provide the aforementioned mechanical 
strength for the PMM during cell filtration process (Figure 2-9E). 
2.4 Results and Discussions 
2.4.1 Capture of Subpopulation of Immune Cells Using Microbeads 
Conjugated with Antibodies 
Surface functionalized micro/nano scale beads and particles are widely used for 
isolations of cells and proteins (see Appendix B for details).  Leukocytes are known to 
produce specific antigens on their surfaces.  By using the biotin-streptavidin conjugation 
chemistry to coat polystyrene microbeads with antibodies directed against specific cell 
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surface antigens, these microbeads could recognize and capture desired subpopulations of 
immune cells expressing specific surface proteins.   
The cell capture efficiency of on microbeads was first characterized using 
functionalized microbeads with a diameter of 32 µm and conjugated with monoclonal 
antibodies directed against CD14, a unique surface protein marker of monocytes.  Well-
controlled quantities of the microbeads were mixed with known quantities of 
fluorescence-tagged CD14+ THP-1 cells, a human acute monocytic leukemia cell line as 
a model for human monocytes.  THP-1 cells were suspended in either blank culture 
media,  culture media spiked with known quantities of peripheral blood mononuclear 
cells (PBMCs) mimicking blood leukocytes, or lysed blood that was pre-stained with DiI 
to label blood leukocytes (the concentrations of THP-1 cells and microbeads were 2 × 106 
mL-1 and 4 × 105 mL-1, respectively).  Well-controlled quantities of the microbeads were 
also mixed directly with lysed blood that was pre-stained with Calcein AM to label blood 
leukocytes at a concentration of 10 × 106 mL-1.  The mixture of the microbeads and 
immune cells were incubated for 1 hr on a roller mixer before they were examined under 
florescence microscopy (Figure 2-10A-C).   
The results in Figure 2-10D&E showed that for THP-1 cells spiked in growth 
media or lysed blood, on average, there were about 4 THP-1 cells bound to a single 
microbead following cell-bead mixing and incubation.  Similar to results for THP-1 cells,  
on average, there were about 4 CD14+ monocytes from lysed blood bound to a single 
microbead following cell-bead mixing and incubation (Figure 2-10F).  The overall 
capture efficiency of the microbeads for THP-1 cells (defined as the ratio between the 
total number of THP-1 cells captured by microbeads and the total number of THP-1 cells 
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in the sample) was further quantified to validate the capture performance.  The results in 
Figure 2-10G showed that for THP-1 cells spiked in culture media or lysed blood, the 
capture efficiency of the microbeads conjugated with anti-CD14 antibodies was all 
greater than 70%.  Together, our data in Figure 2-10 strongly supported the utility of 
functionalized microbeads for efficient recognition and capture of desired subpopulations 
of immune cells from a complex mixture of background cells, such as blood leukocytes.   
 
Figure 2-10   Capture of immune cells using microbeads conjugated with anti-CD14 antibodies.  (A-C) 
Representative merged brightfield and fluorescence images showing THP-1 cells (green; A&B) and CD14+ 
monocytes (green; C) captured by microbeads in either culture media (A) or lysed blood (B&C).  The 
microbeads with a diameter of 32 µm were conjugated with anti-CD14 monoclonal antibodies.  THP-1 
cells were pre-stained with CellTracker Green.  Blood leukocytes in B&C were pre-stained with DiI (B) or 
CellTracker Green (C).  (D-F) Distributions of the number of cells captured per bead for THP-1 cells 
(D&E) and CD14+ monocytes (F) in either culture media (D) or lysed blood (E&F).  For D&E, 2 × 106 
THP-1 cells were mixed with 4 × 105 microbeads in 1 mL cell culture media (D) or lysed blood (E).  For F, 
2 mL lysed blood containing about 2 × 107 leukocytes was mixed with 3 × 105 microbeads.  Gaussian 
functions (red curves) were used for fitting in D-F.  (G) Capture rate of functionalized microbeads for THP-
1 cells spiked in growth media, in growth media with PBMCs, and in lysed blood as indicated.  Error bars 
represent ± standard error of the mean (s.e.m; n = 4). 
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2.4.2 Capture Efficiency Characterization 
After capturing the taget immune cells on the microbeads, the bead-lable cells can 
be further filted and isolated on PMM in the MIPA device.  Owing to the significant 
physical size difference between the microbeads and leukocytes, when the blood sample 
was passing through the PMM, the desired subpopulation of immune cells that were 
bound to functionalized microbeads could be efficiently isolated by the PMM, while the 
other blood cells including undesired immune cells would pass freely through the PMM. 
To validate the isolation performance of the PMM, the capture efficiency of the 
PMM was first characterized using well-controlled quantities of fluorescence-tagged 
polystyrene microbeads spiked in PBS (Figure 2-11).  The PMM used in these assays 
contained a regular array of through holes with a hole diameter of 13 µm and a center-to-
center distance of 20 µm.  The porosity of the PMM was about 25%.  Two different sized 
polystyrene microbeads were assayed with the means of their diameters of 6 µm and 15 
µm.  The microbeads at a concentration of 2 × 104 mL-1 in the PBS were injected into the 
PMM-integrated microfiltration device using a syringe infusion pump under a constant 
flow rate of 100 µL min-1.  The fluorescence-tagged microbeads trapped on the PMM 
could be visually examined and enumerated under bright-field and fluorescence 
microscopy (Figure 2-11A).  Since the diameter of the through holes in the PMM was 13 
µm, smaller than the 15 µm microbeads but larger than the 6 µm ones, the PMM would 
capture virtually all the 15 µm microbeads while letting all the 6 µm ones passing 
through.  The quantitative results in Figure 2-11B-D demonstrated an extremely high 
efficiency of the PMM to separate the two different sized microbeads, as evidenced by a 
capture yield (defined as the ratio of the number of beads captured on the PMM to the 
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total number of beads injected) and purity of 97.2% and 98%, respectively, for the 15 µm 
microbeads.     
 
Figure 2-11  Characterization of capture efficiency of the PMM using florescence-tagged microbeads.  (A) 
Temporal sequence of merged brightfield and fluorescence images showing isolation of 6 µm (top), 15 µm 
(middle), and a mixture of 6 µm and 15 µm (1:1 ratio; bottom) florescence-tagged microbeads on a PMM 
with the through hole diameter of 13 µm.  The microbead concentration was 2 × 104 mL-1, and they were 
injected through the PMM with a volume flow rate of 100 µL min-1.  Virtually all 15 µm beads were 
trapped on the PMM while all 6 µm beads passed through the PMM.  (B&C) Captured yield of 6 µm (B) 
and 15 µm (C) microbeads as a function of the total number of microbeads injected through the PMM.  
Data was calutlated from the top and middle panels of images shown in A.  (D) Captured yield of 6 µm and 
15 µm microbeads from a mixture of 6 µm and 15 µm microbeads, as a function of the total number of 
microbeads injected through the PMM.  Data was calculated from the bottom panel of images shown in A.  
(E) Capture yield of 15 µm microbeads as a function of the volume flow rate.  The microbead 
concentration was 2 × 104 mL-1, and they were injected through the PMM with a varied volume flow rate.  
Error bars in B-E represent ± s.e.m. (n = 4). 
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Figure 2-12  Characterization of capture efficiency of the PMM using samples spiked with THP-1 cells.  
(A&B) Representative brightfield, fluorescence, and merged microscopic images showing fluorescence-
tagged THP-1 cells bound to microbeads isolated on the PMM.  THP-1 cells labeled with CellTracker 
Green were spiked in either cell culture media (A) or lysed blood pre-stained with DiI to label blood 
leukocytes (B).  The microbeads with a diameter of 32 µm were conjugated with anti-CD14 antibodies.  
The PMM had a through hole diameter of 30 µm.  (C) Regression analysis of capture efficiency of the 
PMM for the functionalized microbeads used for capturing THP-1 cells.  The plot represents the number of 
microbeads (bound with or without cells) captured on the PMM against the total number of microbeads 
(bound with or without cells) injected through the PMM.  (D) Capture yield of microbeads (bound with or 
without cells) as a function of the total number of microbeads (bound with or without cells) injected 
through the PMM.  (E&F) Capture yield (E) and purity (F) of THP-1 cells on the PMM.  For C-F, known 
quantities of THP-1 cells (2 × 106) were mixed with microbeads (4 × 105) in 1 mL cell culture media (red 
symbols or bars), 1 mL cell culture media containing 5 × 106 mL-1 PBMCs (green symbols or bars), or 1 mL 
lysed blood containing about 6 × 106 mL-1 leukocytes (blue symbols or bars), as indicated.  The volume 
flow rate was 1 mL min-1.  Solid lines in C&D represent linear fitting.  Error bars represent ± s.e.m (n = 4). 
The effect of flow rate on the capture efficiency of the PMM was further 
examined, by comparing the capture efficiency of the PMM for microbeads under 
different flow rate conditions (from 1 - 20 mL min-1; Figure 2-11E).  The results in 
Figure 2-11E suggested that the PMM was able to achieve extremely high capture 
efficiency for the microbeads even under a flow rate as high as 20 mL min-1, without 
evidence showing plastic deformation or fracture of the PMM under the microscopy, 
which might be attributable to the PDMS supporting pillars integrated in the 
microfiltration device.  
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Then, the isolation performance of the PMM was characterized for the bead-
labled THP-1 cells. In this study, the diameter of the through hole in PMM was 30 µm 
and THP-1 cells were bound to 32 µm microbeads functionalized with anti-CD14 
antibodies as described before (Figure 2-12).  Here known quantities of THP-1 cells (2 × 
106) labeled with CellTracker Green were mixed and incubated with the functionalized 
microbeads (4 × 105) for 1 hrs in either 1 mL cell culture medium containing 5 × 106 mL-1 
PBMCs or 1 mL lysed blood containing about 6 × 106 mL-1 leukocytes and 5 × 105 mL-1 
CD14+ monocytes.  Different volumes of the culture medium and lysed blood samples 
were injected into the PMM-integrated microfiltration device at a flow rate of 1 mL min-1.  
The cells bound to the microbeads trapped on the PMM were examined under 
fluorescence microscopy to determine the capture efficiencies for the microbeads and 
THP-1 cells (Figure 2-12A&B).  As expected, virtually all the 32 µm microbeads (> 
99%), regardless whether bound with or without cells, were captured on the PMM 
(Figure 2-12C&D).  The capture yield of THP-1 cells, defined here as the ratio between 
the number of THP-1 cells bound to microbeads captured on the PMM to the total 
number of THP-1 cells injected into the microfiltration device, was all greater than 70%, 
regardless whether THP-1 cells were spiked in culture media, culture media containing 
PBMCs, or lysed blood.  In addition, capture purities of THP-1 cells, defined as the ratio 
between the number of THP-1 cells bound to microbeads captured on the PMM to the 
total number of cells captured on the PMM, was on average as high as 97%, regardless 
whether THP-1 cells were spiked in culture media, culture media containing PBMCs, or 
lysed blood.  Together, our data in Figure 2-12 convincingly supported our approach of 
using functionalized microbeads and the PMM for efficient capture and isolation of 
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subpopulations of immune cells with a high purity.  From our data in Figure 2-12, the 
overall capture yield of our method to isolate subpopulations of immune cells was largely 
determined by the yield of the cell capture process using the functionalized microbeads, 
not by the microbead isolation process using the PMM. 
2.4.3 Isolation of Subpopulation of Immune Cells from Blood 
Using the PMM coupled with functionalized microbeads, direct isolation, 
enrichment, and enumeration of CD14+ monocytes was demonstrated from both lysed as 
well as whole blood specimens (Figure 2-13A-C; see Appendix C for blood processing 
details).  As a control, PMMs with the through hole diameter of 6 µm were used to isolate 
the whole population of leukocytes from lysed blood (Figure 2-13A).  Leukocytes in the 
lysed blood were stained with Calcein AM for visualization.  Lysed blood with the 
leukocyte concentration of 5 × 106 mL-1 or diluted lysed blood with the leukocyte 
concentration of 1 × 106 mL-1 was filtered by the PMM with the through hole diameter of 
6 µm in the microfiltration device at a flow rate of 1 mL min-1.  The number of 
leukocytes trapped on the PMM increased lineally with the sample injection volume, and 
our regression analysis of capture efficiency of the PMM for leukocytes in Figure 2-13D 
revealed that about 93% of leukocytes in the lysed blood were captured on the PMM 
under a flow rate of 1 mL min-1.   
To isolate CD14+ monocytes from human blood, known quantities of 
functionalized 32 µm microbeads conjugated with anti-CD14 antibodies were added into 
blood samples.  Prior to this, leukocytes in the blood sample were pre-labeled with 
Calcein AM.  After 1-hr mixing and incubation, the blood specimens were injected  
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Figure 2-13   Isolation of CD14+ monocytes from blood specimens using the PMM.  (A-C) Representative 
merged brightfield and fluorescence images showing flurescence-tagged leukocytes (A) and CD14+ 
monocytes (B&C) from lysed blood (A&B) or whole blood (C) isolated on the PMM.  The PMM had a 
through hole diameter of 6 µm (A) or 30 µm (B&C).  CD14+ monocytes were first captured by 30 µm 
microbeads conjugated with anti-CD14 antibodies before the cell-microbead conjugates were isolated on 
the PMM.  Leukocytes in the blood samples were stained with Calcein AM for visualization.  (D) 
Regression analysis of capture efficiency of the PMM with the through hole diameter of 6 µm for blood 
leukocytes, under a flow rate of 1 mL min-1.  The plot represents the number of leukocytes captured on the 
PMM against the number of leukocytes injected through the PMM, using undiluted (5 × 106 mL-1) as well 
as diluted (1 × 106 mL-1) lysed blood samples as indicated.  Solid lines represent linear fitting.  (E&F) 
Percentage (E) and purity (F) of CD14+ monocytes captured using functionalized microbeads and the 
PMM from lysed and whole blood.  For E&F, known quantities of microbeads (3 × 105) were mixed with 2 
mL lysed and whole blood (containing about 2 × 107 leucocytes).  The shaded area in E indicates the 
normal percentage range of CD14+ monocytes in blood from healthy adults.  Error bars represent ± s.e.m. 
(n = 4). 
through a PMM with the through hole diameter of 30 µm.  The results in Figure 2-13E 
showed that about 6.0% and 3.5% leukocytes from the lysed and whole blood samples, 
respectively, were bound to the 32 µm microbeads and subsequently captured by the 
PMM with the through hole diameter of 30 µm as CD14+ monocytes.  These results are 
consistent with the fact that the normal percentage range of CD14+ monocytes in blood 
from healthy adults is from 2% - 8% [104, 105].  Compared to the results for lysed blood, 
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the capture yield of CD14+ monocytes from whole blood was slightly lower, likely due 
to the large number of erythrocytes (red blood cells) and other undesired leukocytes in 
whole blood blocking effective interactions between CD14+ monocytes and 
functionalized microbeads. Using microbeads conjugated with different antibodies, 
various subpopulations of the immune cells including CD4+ and CD8+ T-cells have also 
been successfully isolated on PMMs in the MIPA devices with high yield and purity. 
2.4.4 Functional Cellular Immunophenotyping of Subpopulations of 
Immune Cells  
After cell isolation, a rapid, no-wash, quantitative immunosensing method, the 
AlphaLISA [97-99], was further demonstrated to achieve on-chip functional 
immunophenotyping of subpopulations of immune cells using minute quantities of blood.  
The overall immunophenotyping assay protocol using the microfiltration device was 
shown in Figure 2-14A (see Appendix D for details).  After the desired subpopulation of 
immune cells (e.g., CD14+ monocytes) was captured and enriched by functionalized 
microbeads and the PMM from blood specimens (Step 1 in Figure 2-14A), the cells 
trapped on the PMM were stimulated and incubated with LPS loaded from the inlet of the 
top cell culture chamber of the microfiltration device (Step 2 in Figure 2-14A).  LPS is a 
canonical endotoxin that can cause septic shock in the human body due to severely 
pronounced immune response.  Pro-inflammatory cytokines secreted from LPS-
stimulated immune cells would diffuse rapidly through the PMM to the bottom 
immunoassay chamber, where the AlphaLISA donor and acceptor beads were loaded and 
optically detected in situ for quantitative immunosening (Step 3 in Figure 2-14A).  The 
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AlphaLISA signal detected could be converted to the cytokine concentration using 
standard curves generated using AlphaLISA with samples spiked with known 
concentrations of cytokines (Figure 2-15).   
 
Figure 2-14  Immunophenotyping of subpopulations of immune cells isolated from human blood.  (A) 
Schematic showing the immunophenotyping assay protocol using the PMM-integrated microfiltration 
device and the AlphaLISA: (1) isolation and enrichment of CD14+ monocytes on the PMM from blood 
samples;  (2) LPS stimulation of CD14+ monocytes trapped on the PMM to release pro-inflammatory 
cytokines;  (3) Loading and incubation of AlphaLISA beads in the immunoassay chamber;  (4) Detection of 
TNF-α using the AlphaLISA, in which the streptavidin-coated donor (blue) and acceptor beads (orange) 
were both conjugated with TNF-α antibodies.  The beads were brought into a close proximity (< 200 nm) 
through binding simultaneously to TNF-α.  Using a 680 nm laser for excitation, the singlet oxygen released 
by the donor bead would diffuse to the nearby acceptor bead and trigger it to emit the 615 nm fluorescent 
light.  Measurement of this emission light from the acceptor beads using our custom optical setup (Fig. S3) 
would allow a quantitative detection of TNF-α secretion.  (B) Comparison of TNF-α secretions from LPS-
stimulated free THP-1 cells and THP-1 cells bound to microbeads.  (C&D) Comparative study of TNF-α 
secretion from LPS-stimulated THP-1 cells, leukocytes isolated directly from lysed blood, and CD14+ 
monocytes isolated from lysed blood.  For C&D, about 2 × 104 THP-1 cells, leukocytes, and CD14+ 
monocytes were trapped on the PMM before quantitative immunosensing.  C&D plot the bulk TNF-α 
concentration and TNF-α molecules secreted per cell, respectively, as a function of LPS concentration.  
Solid lines in D represent linear fitting.  Error bars represent ± s.e.m. (n = 4).  P-values were calculated 
using the paired student’s t-test.  ns (P > 0.05; not significant), * (P < 0.05). 
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Figure 2-15  Optical setup for AlphaLISA detection.  (A) Schematic of a custom optical setup for the on-
chip AlphaLISA signal detection using the PMM-integrated microflitration device.  (B) Photo of a MIPA 
device. (C) Standard curve for TNF-α detection using AlphaLISA.  To generate the standard curve, cell 
growth media spiked with known concentrations of TNF-α (0-5,000 pg/mL) was assayed using 
AlphaLISA. 
In this research, MIPA device and the AlphaLISA were applied to detect secretion 
of TNF-α from LPS-stimulated CD14+ monocytes isolated from blood specimens.  TNF-
α is a pro-inflammatory cytokine and a key biomarker associated with host defense and 
immunosurveillance.  Secretion of TNF-α from LPS-stimulated monocytes has been 
shown to reflect the functional status of the innate immune response.  The data in Figure 
2-15B showed that TNF-α secretion from LPS-stimulated free THP-1 cells and THP-1 
cells bound to microbeads were very similar, leading us to conclude that binding to anti-
CD14 antibodies on microbeads would not significantly affect TNF-α secretion from 
CD14+ monocytes. 
Next, MIPA device was applid for quantitative immunosensing of cytokines 
secreted from LPS-stimulated CD14+ monocytes isolated directly from lysed blood.  The 
results were compared with cytokine secretions from LPS-stimulated leukocytes isolated 
directly from lysed blood and from LPS-stimulated THP-1 cells.  In these assays, equal 
numbers of THP-1 cells, leukocytes and CD14+ monocytes (about 2 × 104) were trapped 
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on the PMM before quantitative immunosensing.  The result in Figure 2-15C 
demonstrated that similar to THP-1 cells, TNF-α secreted by CD14+ monocytes isolated 
directly from lysed blood would increase with LPS concentration.  Further, the amount of 
TNF-α secreted by CD14+ monocytes was very comparable to that from THP-1 cells but 
significantly higher as compared to TNF-α secretions from leukocytes isolated directly 
from lysed blood, confirming the functional heterogeneity between different types of 
immune cells. 
2.4.5 Application of the MIPA Device for Patient Samples 
After validating the system, MIPA device was futher applied for functional 
cellular immunophenotyping of pediatric patients with congenital heart defects (CHD) 
undergoing cardiopulmonary bypass (CPB) to prospectively validate the use of the MIPA 
device in predicting post-operative infections in pediatric patients following CPB.  CHD 
are among the most common birth defects and are the leading causes of birth defect-
related deaths [106].  Mortality associated with CHD accounts for up to 50% of pediatric 
deaths and nearly 6000 deaths each year [106].  Over 48% of these deaths occur in 
children less than 1 year of age [106].  Thus, mortality associated with CHD remains a 
serious public health problem necessitating the identification of risk factors and novel 
therapeutic strategies to decrease mortality, especially in high-risk populations.  
Nearly all children with CHD require surgical correction of their lesions 
necessitating the use of CPB.  However, post-operative infections contribute significantly 
to the mortality associated with pediatric patients undergoing cardiac surgery with CPB 
[107-110].  Pediatric studies have suggested an average incidence of post-operative 
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infections in pediatric patients following CPB around 20% and a mortality rate of nearly 
25% associated with post-operative infections and infectious complications [109].  
Pediatric patients who develop post-operative infections are significantly younger, have 
longer surgeries, extended intubations and longer lengths of stay - all attributes associated 
with complex cardiac repairs [109-111].   
A pervading theory as to the reason for the development of the post-operative 
infections following cardiac surgery with CPB is that the hyper-inflammatory state 
created by CPB results in a compensatory anti-inflammatory immune response in the 
body leading to a hypo-inflammatory state rendering the patient immunosuppressed and 
susceptible to invading pathogens [1, 112].  This acquired immunosuppression has been 
termed immunoparalysis [113].  Recent study has shown that immunoparalysis in 
children following CPB increases the likelihood of developing a post-operative infection 
by nearly 6 times that of non-immunoparalyzed patients [4].  Allen and colleagues have 
also demonstrated that immunoparalysis following CPB can increase the risk for 
development of post-operative sepsis [114].  These clinical studies demonstrate a 
heightened risk for the development of post-operative infections for immunoparalyzed 
patients following CPB, hence it requires an accurate immunomonitoring and instant 
immunomodulatory therapy for these immunoparalyzed patients following CPB.  Hall et 
al. have shown that immunoparalysis can be reversed in critically ill children by treating 
them with granulocyte macrophage colony-stimulating factor (GM-CSF), and thus reduce 
the risk of developing infections in children with multiple organ dysfunction syndrome 
[115].  However, current post-operative practices for pediatric patients following CPB do 
not address monitoring the function of the immune system, even though the clinical 
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presentations and consequences of post-operative infections that may develop are the 
result of the dysregulation of the immune response [1, 116].  This omission is a direct 
consequence of the current lack of standardized immunophenotyping tools in the clinical 
setting that can easily and rapidly determine the functional status of different 
subpopulations of immune cells involved in the immune response.  Taken together, there 
is a critical need for accurate measurement of the immune status of children following 
exposure to CPB in order to identify those children who are immunoparalyzed and may 
benefit from the GM-CSF therapy.  To address this need, we have applied our highly 
integrated microfluidics-based immunomonitoring platform for efficient isolation and 
rapid, accurate, and multiplexed functional immunophenotyping of subpopulations of 
immune cells from pediatric patients undergoing cardiac surgery with CPB, rapidly 
identify immunoparalysised pediatric patients and accordingly introduce effective and 
personalized immunomodulatory interventions and therapy.  
The incidence of immunoparalysis as well as data on development of infections 
from any patient along with the functional status of the immune cells (PBMCs and 
CD14+ monocytes) have be collected and analyzed in relationship to the individual 
patient’s immunophenotype (dichotomized as immunoparalyzed or non-
immunoparalyzed).  To immunophenotype the enrolled patients, 600-800 μL of patient 
blood (200 μL for each standard whole blood assay and 20 μL for each assay with the 
MIPA device; each assay was run in triplicate) were obtained as allowed by our currently 
approved IRB protocols right before and one day after (day 1) the CPB.  TNF-α 
concentrations were measured and compared using the MIPA device for the whole blood 
leukocytes (PBMCs) as control as well as the CD14+ monocytes. 
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Figure 2-16  Feasibility of the MIPA device for immunophenotyping in pediatric patients following CPB. 
(A&B) TNF-α secretion from LPS-stimulated PBMCs (cell number: 20,000) and CD14+ monocytes (cell 
number: 20,000) isolated directly from whole blood samples of pediatric patients before and 1 day after 
CPB. (C) Bland-Altman plot of agreement between TNF-α values obtained with the MIPA device and 
values obtained using standard ELISA.  Flow cytometry comparison of the number of cells expressing 
CD14 (D) and the density of CD14 (e) before and 1 day after CPB (n=7 patients).  All Pre values were 
collected within one hour of initiation of CPB, while Day1 values were collected on the morning of the first 
post-operative day. 
Our preliminary research investigating post-operative infections following CPB at 
the University of Michigan C.S. Mott Children's Hospital is consistent with published 
data reporting a 17% overall rate of infection with most occurring in younger patients 
undergoing longer surgeries [4].  Additionally, all of the children in our cohort who died 
(n = 3) had developed a post-operative infection.  The whole blood stimulation assay 
determined that 42% of patients who developed a post-operative infection were 
immunoparalyzed whereas only 7% of the patients who did not develop any infection 
were classified as immunoparalyzed.  These clinical data strongly argue for the need to 
identify pediatric patients following CPB as immunoparalyzed in order to 
performindividualized, immunomodulatory therapies to reverse the immunoparalysis.  
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More importantly, the highly predictable immunoparalysis characteristics of this cohort 
(time of initial insult [i.e. CPB], % incidence [~20%], and nearly universal depression at 
day 1 post-CPB) make this an ideal cohort to validate the MIPA platform as compared to 
less well characterized, though no less important cohorts, such as pediatric subjects with 
sepsis. 
Preliminary data from patients support the feasibility of using the MIPA device on 
patient blood samples before and after CPB (Figure 2-16).  A reduction of TNF-α 
production was detected using the MIPA device for LPS-stimulated PBMCs as well as 
CD14+ monocytes isolated directly from patient whole blood samples before and 1 day 
after CPB (Figure 2-16A&B).  Our data further indicate a strong agreement between 
results generated from the MIPA and standard ELISA following whole blood stimulation 
(Figure 2-16C).  We also observed no change in the number of immune cells expressing 
CD14 (Figure 2-16D) or in the density of the CD14 receptor (Figure 2-16E) on post-
operative day 1 compared to pre-CPB values in this cohort.  These preliminary data 
strongly support the feasibility of using the MIPA device to detect immunoparalysis in 
patients following CPB as well as using CD14 as a monocyte marker to isolate a 
subpopulation of leukocytes using the MIPA device.   
2.5 Conclusion 
Functional immunophenotyping of immune cells is a promising method for 
diagnosis of immune dysfunctions.  The conventional functional immunophenotyping 
assay involves measurements of the capacity of peripheral blood mononuclear cells to 
produce cytokines when stimulated ex vivo.  However, this ‘bulk’ assay measures the 
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overall reactivity of a population of immune cells, making it difficult to pinpoint the 
phenotype or real identity of reactive immune cells involved.  In this work, an integrated 
microfluidic immunophenotyping device was developed for rapid and efficient isolation, 
enrichment, stimulation and functional immunophenotyping of subpopulations of 
immune cells directly from blood specimens.  Owing to the high porosity and large 
surface area of the PMM, the PMM-integrated MIPA device could process lysed and 
whole blood samples with a high volume throughput (up to 20 mL min-1).  The MIPA 
device could achieve high capture yield (> 90%) and excellent capture purity (> 97%) for 
subpopulations of immune cells from blood samples.  Further, the MIPA device could be 
directly integrated with the AlphaLISA biosensing technique and used for rapid, efficient 
on-chip immunophenotyping assays for subpopulations of immune cells isolated directly 
from minute quantities of blood samples.  The total assay time including cell isolation, 
stimulation and cytokine detection only need 4 hours, 6 faster than the conventional 
ELISA method.  The MIPA device can provide a very high sensitivity for cytokine 
measurement, about 75 pg mL-1, which is comparable to ELISA. Because of the 
microfluidic environment, the MIPA device requires very small amount of sample (< 5 
µL mL-1) for the measurement. All together, the new integrated microfluidic functional 
immunophenotyping technology could perform rapid, accurate, and sensitive cellular 
functional assays on different types or subpopulations of immune cells, which could 
provide an unprecedented level of information depth on the distribution of immune cell 
functionalities.  Such an innovative tool will potentially allow comprehensive and 
systems-level immunomonitoring to define and characterize the “immunotype” of healthy 
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individuals and patients, critical for clinical interventions and managements of patients 
with immune system disorders.  
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Chapter 3 
Nanoroughened Surfaces for Capture of Circulating 
Tumor Cells 
3.1 Introduction 
Over the last decade, there has been great interest in utilizing peripheral blood 
circulating tumor cells (CTCs) to predict response to therapy and overall survival of 
patients with overt or incipient metastatic cancers [12, 117].  CTCs are shed by both 
primary and metastatic lesions and they are thought to contribute to hematogenous spread 
of cancer to distant sites [27, 118].  It has been demonstrated that the presence of elevated 
CTC levels is negatively correlated with prognosis in patients with metastases of the 
breast, prostate, lung, and colon [11, 119].  Despite the clinical and pathophysiological 
importance of CTCs, the current molecular and cellular understanding of CTCs is 
extremely poor, largely due to the fact that the current techniques to isolate and 
characterize these rare cells are limited by low yield and purity, complex techniques, and 
expensive proprietary equipments, compounded by the currently employed techniques 
yielding little phenotypic and molecular information about the CTCs themselves [10, 
120].   
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So far, different approaches have been used to isolate CTCs, which can be divided 
into two groups: cell size-based isolation using membrane filters or microfluidic sieves 
[102, 103, 121] and immunoaffinity purification using immunomagnetic beads [12, 122] 
or microfluidic chips [117, 123-128] conjugated with antibodies against surface markers 
of cancer cells.  Even though these approaches have been used to demonstrate the 
presence of CTCs in patients with metastatic cancer, each of these approaches has 
intrinsic major limitations.  Briefly, size-based separation of CTCs is hampered by the 
fact that CTCs are not universally larger than all leukocytes and leukocytes clot filter 
pores or are collected along with CTCs thereby contaminating the isolate.  For 
immunoaffinity purification, a monoclonal antibody against the epithelial cell adhesion 
molecule (EpCAM) is most commonly used because of its nearly universal expression on 
cells of epithelial origin and its absence from blood cells.  However, surface expression 
of EpCAM on CTCs might be more heterogeneous than initially anticipated (e.g., due to 
the epithelial-mesenchymal transition) and even absent altogether in some tumor types 
(such as melanoma) [129, 130].  Thus, positive isolation and enrichment of CTCs based 
on their EpCAM expression can potentially result in a substantial loss of informative 
CTCs [131, 132].  To avoid the biases of selecting cells based on their EpCAM 
expression alone, immunoaffinity-based negative depletion methods to remove CD45+ 
leukocytes and thereby enrich residual CTCs have also been employed [133, 134].  
Although this strategy has the potential to purify CTCs regardless of cancer cell surface 
markers, the extremely low prevalence of CTCs can significantly limit the yields of 
purified CTC fractions achieved by negative selection [133, 134].   
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Herein, by taking advantage of the differential adhesion preference of cancer cells 
to nanorough surfaces when compared to normal blood cells, we demonstrated a simple, 
yet effective strategy for capturing CTCs regardless of their physical size and without 
using any capture antibody [29].  To this end, we have recently developed a simple yet 
precisely-controlled method to generate random nanoroughness on glass surfaces using 
reactive ion etching (RIE) [135, 136].  RIE-based nanoscale roughening of glass surfaces 
is consistent with a process of ion-enhanced chemical reaction and physical sputtering 
[137].  We had shown that bare glass surfaces treated with RIE for different periods of 
time could acquire different levels of roughness (as characterized by the root-mean-
square roughness Rq; Rq = 1 - 150 nm) with a nanoscale resolution [135].  Integrating RIE 
with photolithography, spatially patterned nanorough islands could be generated on glass 
surfaces.  Thus, by precisely controlling both techniques, photolithography and RIE, 
wecould specify the location, shape, area, and nanoroughness levels of different 
nanorough regions on glass surfaces.  In this work, we successfully demonstrated that the 
RIE-generated nanorough surfaces could efficiently capture different kinds of cancer 
cells (i.e., MCF-7, MDA-MB-231, Hela, PC3, SUM-149) without using any capture 
antibody.  My cancer cell capture strategy with the nanorough glass surface uniquely 
utilized the differential adhesion preference of cancer cells to nanorough surfaces when 
compared to normal blood cells, and thus it did not depend on the cancer cells' physical 
size or surface protein expression, a significant advantage as compared to other existing 
CTC capture techniques. 
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3.2 Microfabrication of Nanorough Glass Surfaces 
In this work, the surface nanoroughness on the silica-based glass wafers 
(Borofloat 33 glass) was generated with RIE, a well-established process used in 
semiconductor microfabrication (Figure 3-1A) [29, 135, 136].  The etching of the silica-
based glass wafer was consistent with a process of the ion-enhanced chemical reaction 
and physical sputtering as reported by others [137, 138].  Specifically, during the RIE 
process, bombardment by the reactive ion species generated using the SF6 and C4F8 gases 
disrupted the unreactive glass substrate and caused damage such as dangling bonds and 
dislocations, resulting in the glass surface reactive towards the etchant species.  
Interestingly, since small concentrations of impurities such as Al, K and Na (about 6% 
w/w in total) existed in the silica glass, these impurities resulted in accumulations of less 
volatile species (such as AlF3, KF, NaF, etc.) on the glass surface during the RIE process 
[137, 138].  Thus, when the reactive plasma species approached the glass surface, these 
less-volatile compounds inevitably underwent numerous collisions with the plasma 
species.  Some of these compounds were then backscattered onto the glass surface and 
formed randomly distributed small clusters that could shield the glass surface from 
bombardment and reaction with reactive ions.  These compound clusters effectively 
generated the so-called “micro masking” effect that could randomly shadow the glass 
surface and thus result in nanoscale roughening of the glass surface during the RIE 
process [137].  Therefore, under the same RIE process conditions, the surface 
nanoroughness of the glass wafer could be precisely controlled in nanoscale by solely 
adjusting the RIE process duration (Figure 3-1B).   
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Figure 3-1  Microfabrication of nanotopographical glass surfaces.  (A) Schematic of the fabrication process 
for patterned nanorough glass substrates using photolithography followed by RIE.  (B) Nanoscale surface 
roughness generated on glass substrates using RIE as a function of the RIE process time, with a red fitting 
curve plotted for guidance.  (C) SEM images of glass surfaces patterned with nanorough letters (NANO; 
top) and different shaped islands (bottom) using photolithography followed by RIE.  (D) High-resolution 
SEM images of glass surfaces without (top) or with (middle and bottom) treatments of RIE-based surface 
roughening processes, with their RMS nanoroughness indicated. 
The initial surface roughness of the unprocessed silica-based glass wafers, 
characterized by atomic force microscope (AFM) using the root mean square (RMS) 
roughness Rq (see Appendix F for details of fabrication and surface characterization of 
nanorough glass samples), was about 1 nm.  The glass wafers were processed with RIE 
(LAM 9400, Lam Research, Fremont, CA) for different periods of time to generate 
nanorough surfaces with Rq ranging from 1 nm to 150 nm  (Figure 3-1B), using SF6, 
C4F8, He and Ar gas mixtures.  To spatially pattern nanoroughness on the glass wafers, 
the glass wafers were first spin-coated with photoresist, and the photoresist layer was 
then patterned with photolithography to physically expose different glass regions of 
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various sizes and shapes for subsequent RIE etching.  After the RIE process, photoresist 
was striped using solvents, and the glass wafers were cleaned using distilled water and a 
Piranha solution (4:1 H2SO4:H2O2) to remove organic residues from the glass substrates 
[139].  Thus, by precisely controlling photolithography and RIE, we could specify the 
location, shape, area, and nanoroughness level of different nanorough regions on glass 
substrates (Figure 3-1B&C). 
3.3 Results and Discussion 
CTCs detached from both primary and metastatic lesions represent a potential 
alternative to invasive biopsies as a source of tumor tissue for the detection, 
characterization and monitoring of cancers.  Based on our nanotopograchic surfaces, we 
demonstrated a simple yet effective strategy for capturing CTCs without using capture 
antibodies [29].  This new capture method uniquely utilized the differential adhesion 
preference of cancer cells to nanorough surfaces when compared to normal blood cells 
and thus did not depend on their physical size or surface protein expression, a significant 
advantage as compared to other existing CTC capture techniques. 
3.3.1 Nanotopographic Sensing of Cancer Cells 
Using RIE-generated nanorough glass surfaces, we first examined the differential 
adherence preference of cancer cells to nanorough glass surfaces.  Two breast cancer cell 
lines, MCF-7 (EpCAM-positive, or EpCAM+) and MDA-MB-231 (EpCAM-negative, or 
EpCAM-) were seeded as single cells on a glass surface patterned with nanorough islands 
or letters (Rq = 70 nm).  Phase-contrast images of cancer cells taken 24 hrs after cell 
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seeding showed both cell types adhering selectively to patterned nanorough regions 
(Figure 3-2A).  Quantitative analysis revealed that adhesion selectivity, defined as the 
ratio of the number of cells adhered to nanorough regions and the total number of cells 
attached to the whole glass surface, was 96.1% and 95.2% for MCF-7 and MDA-MB-
231, respectively (Figure 3-2B), suggesting strong segregation of cancer cells for 
adherance to nanorough surfaces, regardless of their EpCAM expression status.  We 
further performed the EdU proliferation assay for cancer cells, and our data suggested 
that proliferation rate of cancer cells increased with nanoroughness (Figure 3-2C). 
 
Figure 3-2   Adhesion selectivity of cancer cells to nanoroughness.  (A) Phase-contrast microscopic image 
showing MDA-MB-231 cells selectively adhering to patterned nanorough letters (NANO; Rq = 70 nm) on 
the glass surface 24 hr after cell seeding.  (B) Bar graph showing cell adhesion rates of MCF-7 and MDA-
MB-231 cells on the smooth glass surface (Rq = 1 nm) and the patterned nanorough islands (Rq = 70 nm) of 
a glass substrate.  Data was obtained 24 hr after cell seeding.  Error bars represent ± s.e.m. (n = 3).  ** (P < 
0.01; Student’s t-test).  (C) Proliferation rates of MDA-MB-231 cells as a function of nanoroughness.  Error 
bars represent ± s.e.m. (n = 3).   
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3.3.2 Capture of Cancer Cells without Using Capture Antibodies  
To examine specifically whether the RIE-generated nanorough glass surfaces 
could achieve efficient capture of cancer cells without using any capture protein bait, we 
prepared two sets of unpatterned nanorough glass surfaces: one coated with anti-EpCAM 
antibody and the other unprocessed.  MCF-7 and MDA-MB-231 cells spiked in 500 µL 
growth media were seeded at a concentration of 105 cells mL-1 on nanorough glass 
surfaces.  After different periods of incubation (0.5 - 8 hrs), glass samples were rinsed 
gently to remove floating cells, and the remaining adherent cells were stained with DAPI 
for visulization and enumeration (Figure 3-3D & Figure 3-4A).  Cancer cell capture yield, 
defined as the ratio of the number of cancer cells captured on glass surfaces to the total 
number of cells initially seeded, was quantified as a function of both incubation time and 
nanoroughness Rq.   
The results in Figure 3-4 and Figure 3-3D-F revealed significant enhancements of 
cancer cell capture yield and speed by nanorough surfaces, and such improvements 
appeared to increase with nanoroughness Rq but were independent of anti-EpCAM 
antibody coating.  For example, bare uncoated nanorough glass surfaces with Rq = 150 
nm captured 80% MCF-7 and 73% MDA-MB-231 cells within 1 hr of cell incubation.  In 
distinct contrast, only 14% MCF-7 and 10% MDA-MB231 cells were captured on bare 
smooth glass surfaces (Rq = 1 nm) over the same period of time.  Importantly, the 
contribution to additional cancer cell capture using anti-EpCAM antibody coating was 
relatively insignificant, especially when Rq > 50 nm (Figure 3-3E-F).  We further 
performed capture assays using other cancer cell lines, including Hela cervical cancer 
cells, PC3 prostate cancer cells, and SUM-149 inflammatory breast cancer cells, and 
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similar significant enhancements of cancer cell capture yield and speed by nanorough 
surfaces were observed (Figure 3-3G).  Taken together, our results demonstrated that 
RIE-generated nanoroughness on glass surfaces enhances cancer cell capture yield up to 
80% within 1 hr of cell incubation, regardless of EpCAM expression on cancer cell 
surfaces and without using any capture antibody coating.   
 
Figure 3-3  Intrinsic nanotopological sensing for capture of cancer cells.  (A&B) Schematic of 
nanotopography generated by RIE on glass surfaces.  Inserts show a zoom-in (left) and a SEM (right) 
images of cancer cells captured on nanorough glass surfaces.  (C) SEM images of glass surfaces with their 
RMS nanoroughness indicated.  (D-G) Cancer cells spiked in growth media at a concentration of 105 mL-
1captured on glass surfaces 1 hr after cell seeding.  D shows fluorescence images of MCF-7 cells captured 
on glass surfaces coated with (bottom) or without (top) EpCAM antibodies.  MCF-7 cells were stained for 
nuclei (DAPI; green) for visualization and enumeration.  E-G plotted capture yields of MCF-7 (E), MDA-
MB-231 (F), and other cancer cell lines (G) as a function of nanoroughness.  Error bars represent ± 
standard error of the mean (s.e.m; n = 4).  
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Figure 3-4   Temporal study of cancer celll adhesion behavors to the nanoroughness.  (A) Representative 
fluorescence images showing temporal sequences of capture of CellTracker Green-labeled MDA-MB-231 
cells on smooth (Rq = 1 nm; top) and nanorough (Rq = 150 nm; bottom) glass surfaces.  These images were 
used for calculation of cell capture yields as a function of incubation time shown in B & C.  (B&C) Capture 
yields of MCF-7 (B) and MDA-MB-231 (C) cells on smooth (Rq = 1 nm) and nanorough (Rq = 150 nm) 
glass surfaces as a function of incubation time, with fitting curves plotted for guidance using logistic 
functions.  Error bars represent ± s.e.m. (n = 4).  For A-C, cancer cells were spiked in growth media at a 
concentration of 105 mL-1. 
To evaluate the efficiency of our RIE-generated nanorough substrates for 
capturing rare CTCs from blood specimens without using capture antibody, we conducted 
capture assays for known quantities of MCF-7 and MDA-MB-231 cells (n = 10 - 1,000) 
spiked in 500 µL culture media containing peripheral blood mononuclear cells (PBMCs; 
cancer cells mixed with PBMCs at a ratio of 1:1) or 500 µL lysed human blood (Figure 
3-5).  Target cancer cells and background cells (PBMCs or leukocytes in lysed blood) 
were first labeled with CellTracker Green and Δ9-DiI, respectively, before they were 
mixed and used for 1-hr cell capture assays with nanorough glass surfaces (Rq = 150 nm).   
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Figure 3-5  Capture and enumeration of cancer cells.  (A) Representative fluorescence and merged 
microscopic images showing known quantities of MDA-MB-231 cells as indicated spiked in lysed blood 
captured on nanorough glass surfaces (Rq = 150 nm) 1 hr after cell seeding.  Target MDA-MB-231 cells 
were labeled with CellTracker Green before spiked in lysed blood that was pre-stained with DiI.   (B-E) 
Regression analysis of 1-hr capture efficiency for MCF-7 (B&C) and MDA-MB-231 (D&E) cells on 
smooth (Rq = 1 nm) and nanorough (Rq = 150 nm) glass surfaces.  In A-E, known quantities of cancer cells 
(n = 10 - 1,000) were spiked in 500 mL growth media containing PBMCs or 500 mL lysed blood as 
indicated.  For PBMC samples, cancer cells were mixed with PBMCs at a constant ratio of 1:1.  Insets in 
B&D show correlations between captured cell number and loaded cell number for n = 10 - 60, indicating 
efficient capture of low abundant CTCs.  Solid lines represent linear fitting.  Error bars represent ± s.e.m. (n 
= 4). 
As shown in Figure 3-5, high capture yields were achieved with nanorough glass 
surfaces for both EpCAM+ MCF-7 and EpCAM- MDA-MB-231 cells, even at low 
cancer cell concentrations and for both PBMC and lysed blood samples (Figure 3-5B-E).  
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On average, capture yields were 88.7% ± 3.0% and 93.3% ± 1.5% for MCF-7 cells mixed 
with PBMCs and spiked in lysed blood, respectively (Figure 3-5B&C), while for MD-
MB-231 cells, capture yields were 94.9% ± 2.4% and 95.4% ± 2.2% for the PBMC and 
lysed blood samples, respectively (Figure 3-5D&E).  In contrast, control experiments 
using smooth glass substrates (Rq = 1 nm) with cancer cells spiked in culture media 
showed much lower capture yields for both MCF-7 and MDA-MB-231 cells (22.0% ± 
1.0% for MCF-7 and 13.9% ± 0.4% for MDA-MB-231) (Figure 3-5B-E), again 
confirming the efficiency of nanorough substrates for capturing cancer cells. 
We further studied systematically the effect of admixtures of cancer cells with 
other background cells on the efficiency and purity of cancer cell capture on uncoated 
nanorough glass surfaces (Rq = 150 nm) by varying the ratio of MDA-MB-231 and 
PBMCs from 1:1 to 1:200, with the MDA-MB-231 cell number fixed at 1,000 (Figure 
3-6A).  Our 1-hr cell capture assay results in Figure 3-6 showed that capture yields of 
MDA-MB-231 were preserved with admixture and were as high as 93.6%.  Thus, the 
capture yield was not affected strongly by the proportion of background PBMCs (Figure 
3-6B&C).  Interestingly, capture yields of PBMCs by uncoated nanorough glass surfces 
remianed low and were gradually decreased from 16.7% to 4.1% when the ratio of MDA-
MB-231 and PBMCs decreased from 1:1 to 1:200 (Figure 3-6C).  Not surprisingly, as the 
absolute numbers of PBMCs captured on nanorough glass surfaces increased when the 
ratio of MDA-MB-231 and PBMCs decreased from 1:1 to 1:200, capture purity of MDA-
MB-231 cells was significantly decreased from 84% to 14% (Figure 3-6D). 
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Figure 3-6   Effect of cellular background on capture yield and purity of cancer cells.  (A) Fluorescence and 
merged microscopic images showing CellTracker Green-labeled MDA-MB-231 cells and DiI-stained 
PBMCs captured on nanorough glass surfaces (Rq = 150 nm) 1 hr after cell seeding.  The ratio of cancer 
cells and PBMCs was varied as indicated.  (B-D) Captured cell number (B), capture yield (C) and purity 
(D) of MDA-MB-231 cells on nanorough glass surfaces (Rq = 150 nm) as a function of the ratio of MDA-
MB-231 cells to PBMCs.  Results were obtained 1 hr after cell seeding.  In A-D, a fixed number of cancer 
cells (1,000) were mixed with PBMCs in growth media to achieve cell ratios from 1:1 to 1:200.  Error bars 
represent ± s.e.m. (n = 4). 
The current concept of metastasis proposes that the process of epithelial-
mesenchymal transition (EMT) occurs in the primary tumors [140, 141].  EMT could 
contribute to the generation of CTCs in the bloodstream, where phenotypic changes are 
very likely to occur.  Tumor cells leave the primary site of cancer and enter the 
circulation after undergoing EMT.  During the EMT process, tumor cells lose the 
epithelial features such as EpCAM, and acquire mesenchymal characteristics, which 
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include enhanced migratory capacity, invasiveness, elevated resistance to apoptosis, and 
greatly increased production of ECM components [142].   There have been many studies 
on their predictive, diagnostic or prognostic significance, including a recent study in 
breast cancer patients that demonstrated dynamic changes in the epithelial and 
mesenchymal composition of CTCs with disease progression [143].  However, the most 
current commenly used CTC isolation techniques based on EpCAM expression can 
potentially result in a substantial loss of these CTCs of mesenchymal phenotype after 
undergoing EMT [131, 132].  Expression of EpCam is very heterogeneous and it is 
significantly down regulated during EMT.  Therefore, relying on EpCAM failed to 
capture mesenchymal-like CTCs as a result of EMT [143]. 
Our nanorough surface based method which can capture CTCs regardless of 
cancer cell surface markers, can efficiently capture both epithelial (non-EMT) and 
mesenchymal like (EMT) cells with equal high efficiency, a significant advantage as 
compared to other existing CTC capture techniques.  To induce the EMT process, A549 
lung caner cells (ATCC, Manassas, VA) were treated for 3 days with transforming 
growth factor-beta (TGF-beta), a cytokine that is rich in tumor microenvironments and a 
potent inducer of EMT.  To evaluate the efficiency of our RIE-generated nanorough 
substrates for capturing EMT and non-EMT cells from blood specimens, capture assays 
were conducted for known quantities of EMT and non-EMT cells cells (n = 40 - 10,000) 
spiked in 500 µL lysed human blood (Figure 3-7).  Target A549 cancer cells and 
background cells (leukocytes in lysed blood) were first labeled with CellTracker Green 
and Δ9-DiI, respectively, before they were mixed and used for 1-hr cell capture assays 
with nanorough glass surfaces (Rq = 150 nm).   
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Figure 3-7  Capture of EMT and non-EMT lung cancer cells from lysed blood. (A) Representative 
fluorescence and merged microscopic images showing known quantities (10,000) of EMT and non-EMT 
lung cancer cells (A549) as indicated spiked in lysed blood captured on nanorough glass surfaces (Rq = 150 
nm) 1 hr after cell seeding.  Target lung cancer cells were labeled with CellTracker Green before spiked in 
lysed blood that was pre-stained with DiI.  (B-C) Regression analysis of 1-hr capture efficiency for EMT 
and non-EMT cancer cells on nanorough (Rq = 150 nm) glass surfaces.  In B-C, known quantities of cancer 
cells (n = 40 - 900) were spiked in 500 µL lysed blood as indicated.  (D) Ratio of captured cell number of 
non-EMT and EMT cells on nanorough glass surfaces (Rq = 150 nm) as a function of the loading ratio.  
Results were obtained 1 hr after cell seeding.  In D, a fixed number of EMT cancer cells (1,000) were 
mixed with non-EMT cells in lysed blood to achieve cell ratios from 1:0.5 to 1:4.  Solid lines represent 
linear fitting.  Error bars represent ± s.e.m. (n > 4). 
As shown in Figure 3-7, high capture yields were achieved with nanorough glass 
surfaces for both EMT and non-EMT cells, even at low cancer cell concentrations.  On 
average, capture yields were 89.4% ± 5.3% and 89.2% ± 2.2% for EMT and non-EMT 
cells spiked in lysed blood, respectively (Figure 3-7B&C).  We further studied 
systematically the effect of admixtures of EMT cells with non-EMT cells on the 
efficiency of cancer cell capture on nanorough glass surfaces (Rq = 150 nm) by varying 
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the ratio of EMT and non-EMT cells from 1:0.5 to 1:4, with the EMT cell number fixed 
at 1,000 (Figure 3-7D).  The 1-hr cell capture assay result showed that the capture yield 
was not affected strongly by the proportion of EMT or non-EMT cells (Figure 3-7D).  
Taken together, our results demonstrated that the nanorough glass surfaces permited 
cancer cell capture yield >89% within 1 hr of cell incubation, for both EMT and non-
EMT cells. 
3.3.3 Cell Adhesion Strength Measurements 
Our results in Figure 3-5 & Figure 3-6 showed a significantly different levels of 
preference between cancer cells and PBMCs to adhere to nanorough glass surfces, which 
suggested an interesting possibility that adhesion strength of cancer cells might be 
affected by nanotopographic sensing, while adhesion of PBMCs might not be sensitive to 
nanotopographic cues.  To examine this possibility, we developed a microfluidic channel 
using polydimethylsiloxane (PDMS) integrated with smooth (Rq = 1 nm) or nanorough 
(Rq = 100 nm) glass substrates for direct measurements of adhesion strength of cancer 
cells and PBMCs (see Appendix G for details; Figure 3-8A & Figure 3-9) [144].  A low 
density of cancer cells (MCF-7, MBA-MB-231 and PC3 cells) or PBMCs was seeded 
uniformly inside the microfluidic channel for 12 hrs before they were exposed to constant 
directional fluid shear (0.1 - 120 dyne cm-2) for 5 min.  The fractions of cancer cells and 
PBMCs remained adherent on smooth and nanorough substrates were quantified after 
their treatments with this sustained 5-min directional fluid shear [145].  Our data 
demonstrated that indeed, cancer cells attached on nanorough surfaces could withstand 
much greater fluidic shear stress than on the smooth surface, regardless of EpCAM  
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Figure 3-8   Effect of nanotopological sensing on cell adhesion strength.  (A) Schematic of a microfluidic 
channel integrated with smooth or nanorough glass substrates for quantifications of cell adhesion strength.  
Insert shows adherent cancer cells in the channel under sustained directional fluid shear.  (B-E) Fraction of 
MCF-7 (B), MBA-MB-231 (C), PC3 (D) and PBMCs (E) remained adherent on smooth (Rq = 1 nm) or 
nanorough (Rq = 100 nm) substrates after 5-min exposures to sustained directional fluid shear.  Low 
densities of cancer cells or PBMCs were seeded into microfluidic channels and cultured for 12 hrs before 
PBS was flowed continuously along the channel to exert fluid shear stress on cells.  (F) Adhesion strength 
of MCF-7, MBA-MB-231 and PC3 cells on smooth (Rq = 1 nm) or nanorough (Rq = 100 nm) substrates.  
Solid lines in B-E represent logistic (B-D) or exponential (E) fitting to guide eyes.  Error bars represent ± 
s.e.m. (n = 4).  Statistical analysis was performed by employing the Student's t-test.  ** indicates p < 0.01.   
expression on cancer cell surfaces (Figure 3-8B-D & Figure 3-9).  Adhesion strength of 
cancer cells, defined as the fluidic shear stress at which 50% of cancer cells initially 
attached on glass surfaces would detach after exposed to fluid shear for 5 min [146], was 
significantly greater for cancer cells adhering on the nanorough surface than the smooth 
one (Figure 3-8F).  As expected, adhesion strength of PBMCs to both smooth and 
nanorough glass surfaces was low, and they could easily be washed away even under a 
shear stress < 1 dyne cm-2, consistent with our observation that most PBMCs were still 
77 
 
floating on both smooth and nanorough glass surfaces even after 12 hrs of incubation.  
Measurements of adhesion strength of cancer cells and PBMCs after 1 hr of incubation 
had been difficult, as most cells were still floating and not attach to glass surfaces, likely 
attributable to the confined microfluidic environment.  Together, our results in Figure 3-8 
demonstrated that nanotopographic surfaces could significantly enhance adhesion 
strength of cancer cells, regardless of their EpCAM expression.  Adhesion of PBMCs to 
uncoated glass surfaces appeared to be not sensitive to nanotopographic cues. 
 
Figure 3-9  Microfluidic device for study of cell adhesion strength. (A) Schematic of fabrication process for 
the microfluidic channel for quantifications of cell adhesion strength.  The microfluidic channel was 
fabricated in PDMS using soft lithography and was bound to smooth and nanorough glass substrates using 
the oxygen plasma-assisted PDMS bonding process.  (B) Representative phase images showing temporal 
sequences of adherent MCF-7 cells detaching from the smooth (Rq = 1 nm; top)  and nanorough (Rq = 100 
nm; bottom)  glass surfaces under a constant fluid shear stress of 12.5 dyne cm-2.  
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3.3.4 Nanotopological Sensing through Focal Adhesions 
To investigate the possible mechanotransductive mechanism for nanotopographic 
sensing of cancer cells, we examined focal adhesions (FAs) of EpCAM+ MCF-7 and 
EpCAM- MDA-MB-231 cells plated as single cells on both smooth and nanorough glass 
surfaces.  Published data indicate that integrin-mediated FA signaling, critical for many 
cellular functions and strongly dependent on their nanoscale molecular arrangement and 
dynamic organization, may play an important role in regulating cellular 
mechanosensitivity to nanotopography [147].  After 24 hrs in culture, both MDA-MB-
231 (Figure 3-10) and MCF-7 (Figure 3-11) cells exhibited distinct FA formation and 
organization on the smooth and nanorough glass surfaces, as characterized by 
immunofluorescence staining of vinculin, a FA protein.   
On smooth glass surfaces where Rq = 1 nm, mature and prominent vinculin-
containing FAs formed primarily on the periphery of both cancer cells.  By comparison, 
on nanorough surfaces with Rq = 150 nm, both MDA-MB-231 and MCF-7 cells exhibited 
randomly distributed, punctate FAs of small cross-sections throughout the entire cell 
spread area.  Morphometric analysis of cell populations showed that on nanorough glass 
surfaces, both MDA-MB-231 and MCF-7 cells had smaller mean cell spread area and 
single FA area and less total number of FAs and total FA area per cell than on the smooth 
surface (Figure 3-10B-E & Figure 3-11B-E).  The molecular arrangement and dynamic 
organization of integrin-mediated FAs of both cancer cells appeared sensitive and 
responsive to local presentation of nanotopographical cue and hence might result in their 
distinct adhesion behaviors on nanorough surfaces as demonstrated in this work. 
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Figure 3-10  Effect of nanotopological sensing on FA formation of MDA-MB-231 cells.  (A) 
Representative immunofluorescence images of MDA-MB-231 cells adherent on smooth (Rq = 1 nm) and 
nanorough (Rq = 100 nm) glass surfaces after 24 hr of culture.  Cells were co-stained for nuclei (DAPI; 
blue), actin (red), and vinculin (green).  (B-E) Cell area (B), total FA area per cell (C), average single FA 
area (D) and number of FAs per cell area (FA density; E) of MDA-MB-231 cells adherent on smooth (Rq = 
1 nm) and nanorough (Rq = 100 nm) glass surfaces after 24 hr of culture.  Error bars represent ± s.e.m. (n > 
30).  Statistical analysis was performed by employing the Student's t-test.  ** indicates p < 0.01. 
 
Figure 3-11  Effect of nanotopological sensing on FA formation of MCF-7 cells.  (A) Representative 
immunofluorescence images of MCF-7 cells adherent on smooth (Rq = 1 nm) and nanorough (Rq = 100 nm) 
glass surfaces after 24 hr of culture.  Cells were co-stained for nuclei (DAPI; blue), actin (red), and vinculin 
(green).  (B-E) Cell area (B), total FA area per cell (C), average single FA area (D) and number of FAs per 
cell area (FA density; E) of MCF-7 cells adherent on smooth (Rq = 1 nm) and nanorough (Rq = 100 nm) 
glass surfaces after 24 hr of culture.  Error bars represent ± s.e.m. (n > 20).  Statistical analysis was 
performed by using the Student's t-test.  ** indicates p < 0.01. 
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3.3.5 Microfluidics-based CTC Capture Chip for in vivo Study 
In the last section, a simple yet effective strategy has demonstrated for highly 
sensitive and specific capture of different types of cancer cells using RIE-generated 
nanorough glass surfaces.  Based on the nanorough glass surface, a CTC capture chip 
combining nanorough glass substrate with a microfluidic chamber was futher developed 
for capture of CTCs with improved capture performance (Figure 3-12).   
The microfluidic CTC capture platform includes three components: a nanorough 
glass substrate, a PDMS microfluidic chamber, and a polyacrylate holder sandwiching 
the PDMS chamber and the glass substrate.  The glass substrate has dimensions of 50 mm 
× 76 mm and an effective nanoroughed region of 44 mm × 56 mm.  The PDMS 
microfluidic chamber with a height of 400 µm, width of 44 mm and width of 56 mm was 
produced by soft-lithography using a replicate on a silicon mold.  A holder composed of 
two pieces of polyacrylate plates was home-machined to sandwich the PDMS 
microfluidic chamber and the glass substrate. The PDMS microfluidic chamber was 
aligned onto the patterned glass substrate. Then the holder can sandwich these two parts 
by screws at the sides of plastic plates.  Two through-holes were drilled on the top plastic 
plate with a good alignment to the inlet and outlet holes of the PDMS microfluidic 
chamber, thus allowing convenience connection of tubings to the microfluidic channel of 
the chip.  The complete assembly is capable of enduring back pressure of about 10 psi on 
the tested fluid samples without leaking.  Such a microfluidic setting can lead to a 
significant enhancement in cell–substrate contact frequency compared to a simple 
nanorough glass substrate, hence improve the CTC capture yield and throughout.   
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Figure 3-12   Microfluidic chip for capture of CTCs.  (A) The left image shows a photo of a representative 
microfluidic CTC capture chip. The right images shows SEM images of the nanotough surface (top, Rq = 
150 nm) and cancer cells captured on the nanotough surface. (B) Cell capture yield of MCF-7, MBA-MB-
231 and SUM-149 cells on smooth (Rq = 1 nm) or nanorough (Rq = 150 nm) substrates.  Error bars 
represent ± standard error of the mean (s.e.m; n = 4). 
The microfluidic CTC capture chip including a nanorough substrate (Rq = 150 nm) 
and a microfluidic chamber achieved high capture yields for MBA-MB-231 (83.3% ± 
9.8%), SUM-149 cells (80.9% ± 5.7%) and MCF-7 (85.7% ± 3.2%) within 30 min of 
capture time for 1 mL sample.  In distinct contrast, only 6.7% MDA-MB-231, 8.0% 
SUM-149 and 8.6% MCF-7cells were captured in microfluidic chip with a bare smooth 
glass surfaces (Rq = 1 nm) over the same period of time.   
Since the discovery of CTCs, most of the investigative efforts have been focused 
on their clinical application in terms of prognosis and monitoring response to therapy.  To 
date, very few studies assessed the functional significance of CTCs in terms of their role 
in the clinical manifestation of tumor metastasis.  CTCs have been found in patients both 
with and without metastatic disease [118, 148].  A recent survey by ASCO concluded that 
only a proportion of patients with detectable CTCs will go on to develop overt metastasis 
with a 5-10 year follow up [149].  This clearly indicates that qualitative assessment of 
CTCs and understanding their functional relevance to EMT and clinical manifestation of 
metastasis is essential for improving their clinical potential.   Using well-defined cell 
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lines in xenogeneic as well as syngeneic mouse models, we have examed the functional 
relevance of CTCs with respect to the tumor progression and metastasis capability using 
our newly developed CTC capture chip. 
First, we identified CTCs that spontaneously intravasated into the circulation from 
orthotopic tumor xenografts of human breast cancer cells.  To generate tumor xenografts, 
1 × 106 MDA-MB-231 or SUM-149 breast cancer cells were injected orthotopically into 
left inguinal mammary fat pad of each female Ncr nude mouse (Taconic; 5–6 week old) 
[150].   
 
Figure 3-13  Capture of CTCs from mice with breast cancer xenografts. (A) Reprenstitive photos of MDA-
MB-231tumor xenografts. (B)  Representative immunofluorescence images of captured CTCs from mice 
with MDA-MB-231tumor xenografts. Cells were co-stained for nuclei (DAPI; blue), cytokeratin (green), 
and CD45 (red). (C-E) Serial analysis of temporal changes in CTC during tumor progression. Tumor 
volume (C) and recovered CTC quantity (D) from mice with MDA-MB-231 and SUM-149 tumor 
xenografts increase over time. The recovered CTC quantity coralated with the tumor weight (E). Mice were 
implanted with orthotopic tumor xenografts of MDA-MB-231 or SUM-149 human breast cancer cells. 
Approximately, 0.5-1 mL blood samples were obtained via cardiac puncture from mice anesthetized with 
1.5% isoflurane.  
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At each time point, small volume (0.5–1 mL) blood samples were collected from 
each mouse by puncture of the left ventricle for CTC capture experiments when animals 
were euthanized for tumor burden.  In the experiments, CTCs were successfully 
identified from all the mice with tumor xenografts (n = 16).  Numbers of CTCs ranged 
from 10 to 10,000 cells/100 µL blood increased significantly over a 9-week period during 
tumor progression, corresponding with an increase in tumor weight/volume of the 
primary tumor (Figure 3-13). 
To determine the functional relevance of CTCs with respect to the metastasis 
capability, we further applied the CTC capture chip to a syngeneic lung cancer mouse 
model.  Two well-defined mouse lung cancer cell lines (344SQ and 393P) with different 
metastasis capability were used sub-cutaneously implanted in C57BL6 mice to generate 
tumor allografts (Taconic).  The mouse 344SQ lung cancer cells have high metastatic 
potential, while the mouse 393P cells are metastasis-incompetent [151].  The 344SQ cells 
undergo metastasis when implanted sub-cutaneously (spontaneous metastasis) or through 
tail vein (experimental metastasis), but 393P does not metastasize at all by both routes 
[151]. Using our CTC capture platform, CTCs were detected in all 6 mice using 
metastatic 344SQ cell line, but only idenfied CTCs from 2 out of 4 mice uing the 
metastasis-incompetent 393P cell line (Figure 3-14).  Similar to the result from the 
xenograft mouse model, the number of CTCs strongly corelated to the tumor volume of 
the primary tumor (Figure 3-14).  More CTCs were identified from mice with large 
tumors and no CTCs were captured from blood samples collected from mice without 
tumor xenografts (Figure 3-14B & C).  More interestingly, the number of captured CTCs 
is also corresponding to the metastasis capability.  Overall, significantly higher number of 
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CTCs was identified from mice implanted with tumor allografts of lung cancer cells with 
high metastasis capability (344SQ) than that from the mice using a metastasis-
incompetent cell line (393P).  This distinct CTC kinetics between the two compartments 
indicated a strong relationship between CTCs and metastasis. 
 
 
Figure 3-14 Capture of CTCs from mice with lung cancer allografts. (A) Representative 
immunofluorescence images of captured CTCs from mice with 344SQ lung tumor allografts. Cells were 
co-stained for nuclei (DAPI; blue), cytokeratin (green), and CD45 (red). (B-F) Serial analysis of CTC in 
mice with 344SQ and 393P lung tumor allografts. (B) Tumor volume and (C) recovered CTC quantity from 
individual mouse with 344SQ and 393P lung tumor allografts. (D) Average tumor volume and (E) average 
recovered CTC quantity from mice with 344SQ and 393P lung tumor allografts. (F) The recovered CTC 
quantity coralated with the tumor weight. Mice were implanted with tumor allografts of 344SQ or 393P 
lung tumor cells. Approximately, 0.4-1 mL blood samples were obtained via cardiac puncture from mice 
anesthetized with 1.5% isoflurane. The mouse 344SQ lung cancer cells have high metastatic potential, 
while the mouse 393P lung cancer cells are metastasis-incompetent. Error bars represent ± standard error of 
the mean (s.e.m; n > 4). Statistical analysis was performed by using the Student's t-test.  * indicates p < 
0.05. 
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3.4 Conclusion 
In summary, a simple yet effective strategy was demonstrated for highly sensitive 
and specific capture of different types of cancer cells using nanorough glass surfaces.  
Our cancer cell capture strategy uniquely utilized the differential adhesion preference of 
cancer cells to nanorough surfaces when compared to normal blood cells and thus did not 
depend on their physical size or surface protein expression, a significant advantage as 
compared to other existing CTC capture techniques.  Our cancer cell capture strategy is 
applicable to many different cancer cell types regardless of EpCAM expression and EMT 
process, can potentially provide a promising solution to study intratumor phenotypic 
heterogeneity at the single-cell level using patient CTCs for diagnostics and therapy [152, 
153].  Exploiting the differential adhesion preference of cancer cells for nanorough 
surfaces when compared to normal blood cells is a promising strategy to achieve their 
efficient capture at very low costs and is expected to lead to better isolation and 
enrichment strategies for live CTCs from cancer patient’s blood specimens, critical for 
informative analysis of CTCs and for accurate diagnosis, therapeutic choices, and 
prognosis and for fundamental understanding of cancer metastasis.  
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Chapter 4 
Biophysical Phenotyping of Inflammatory Breast 
Cancer Stem Cells 
4.1 Introduction 
Increasing evidence indicates that cancer cells with stem cell-like properties, 
termed ‘cancer stem cells’ (CSCs), have the potential for self-renewal, differentiation, 
and tumorigenicity and play a major role in cancer recurrence and metastasis [154-156].  
CSCs have been shown to initiate tumorigenesis in numerous cancer types [157-159], and 
recent studies have begun to define a role for CSCs in cancer metastasis as well [32, 160-
162].  CSCs have been characterized on the basis of their expression of particular surface 
markers [163, 164] - such as CD133 and CD44 - and also on the basis of cell adhesion 
molecules [165], cytoprotective enzymes (e.g. aldehyde dehydrogenase, ALDH) [166], 
and drug-efflux pumps (e.g. ABC transporters) [167].  CSCs, defined as the high ALDH-
expressing subpopulation, have been shown to play a role in inflammatory and aggressive 
breast cancers [32].  Inflammatory breast cancer (IBC) is the most lethal form of breast 
cancer with 20 - 30% of patients presenting with metastasis at initial diagnosis [30, 31].  
Although RhoC GTPase and anaplastic lymphoma kinase (ALK) are implicated in the 
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IBC phenotype, the underlying detailed mechanisms that allow IBC to be so aggressively 
metastatic from its inception are still under study.  In order to advance the field, an 
understanding of the physical attributes of CSCs that underlie their ability to execute the 
multiple events of metastases is important and has not been previously undertaken.  
Here we analyzed both the intrinsic functional capabilities of IBC’s CSC 
compartment as well as these cells’ inherent biophysical properties that make them 
capable of early metastasis, essentially from the tumor’s inception. During metastatic 
progression, cancer cells encounter complex biophysical environments consisting of 
different degrees of extracellular matrix (ECM) cross-linking [168], a differing ECM 
topology [169-171], mechanical heterogeneity within the ECM [170, 172, 173], as well 
as being exposed to shear flow and interstitial pressure [174-176].  In response, 
metastatic cancer cells must acquire unique biophysical characteristics in order to 
navigate through this dynamic microenvironment to reach and proliferate in distant sites.  
As CSCs are believed to play critical roles in metastasis, it is highly possible that CSCs 
too will develop biophysical properties - such as increased deformability and decreased 
adhesion strength - necessary to traverse this environment and be capable, for example, 
of repopulating tumor masses following treatment. 
Cell deformability (i.e. compliance under an applied load) has been postulated to 
play key roles in cancer cell invasiveness [174, 177-180].  Cytoskeletal changes have 
been suggested to underlie mechanical differences observed in invasive cancer cells, 
consistent with a process of selection for cells that are able to squeeze into vessels by 
traversing walls (intravasate) [174, 181, 182].  Many studies have demonstrated a 
significantly higher degree of cell deformability for both cancer cell lines and primary 
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tumors when compared to normal epithelial cells [177-179].  In the case of breast and 
ovarian cancers, the subpopulation of cancer cells with increased cell deformability has 
been shown to have a more malignant phenotype compared to stiffer cells [177, 183].  
Cell traction force is another key mechanical factor that has previously been shown to 
mediate cell functions (e.g. migration, adhesion, and proliferation) as well as 
mechanotransduction [136, 184-186].  Therefore, cell traction forces may also be 
involved in cancer progression.  
Previous studies have convincingly established the usefulness of biophysical 
characteristics for identifying more aggressive cancer cells in a label-free manner that is 
independent of current immunohistological methods [174, 177, 181, 182, 187, 188].  
Given that IBC is the most aggressive and metastatic breast cancer, we sought to utilize 
quantitative techniques to characterize the IBC CSC compartment using a panel of assays 
to specifically profile the functional as well as biophysical characteristics of CSCs at the 
single-cell level.  Such comprehensive, multiparametric phenotypic profiling of CSCs can 
provide useful insights into the qualities of IBC CSCs that increase their aggressiveness 
and propensity for tumorigenesis and metastasis as well as allow for studies of novel 
therapeutic interventions targeting CSCs functions. 
4.2 Results and Discussion 
4.2.1 Functional Phenotyping of IBC CSCs. 
High activity of ALDH within tumors has been associated with a poor prognosis 
in many cancers including breast [32, 164, 189, 190], lung [191, 192], liver [193], colon 
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[166, 194], pancreatic [195], ovarian [196], head and neck [197], and prostate [198] 
cancer.  ALDH is a superfamily of detoxifying enzymes responsible for metabolizing a 
wide variety of intracellular aldehydes and plays an important role in multiple biological 
activities, including drug resistance, cell differentiation, and oxidative metabolism [199-
201].  ALDH expression has been used as a predictive marker of CSCs for breast cancer 
[164, 189, 190, 202] – including IBC [32] – and ALDH expression has proven to be more 
predictive than other established markers such as CD44+ / CD24- for identification of 
breast CSCs, as it has been shown that ALDH can identify cells with a greater resistance 
to chemotherapy [203, 204].   
In this study, breast CSCs with high ALDH enzymatic activity were isolated from 
an IBC cell line, SUM149, using an ALDEFLOUR assay (Figure 4-1B; See Appendix I8 
for details) [189].  SUM149 cells were stained for ALDH using the ALDEFLOUR 
reagent and sorted by flow cytometry. ALDEFLUOR treated cells quenched with the 
ALDH inhibitor diethylaminobenzaldehyde (DEAB) were used to set the ALDEFLUOR-
positive FACS gate, containing less than 0.1% of DEAB-treated cells (Figure 4-1B).  
SUM149 cells above this 0.1% fluorescence threshold were sorted as ALDH-positive 
(ALDH+).  ALDH negative (ALDH-) cells were sorted as the bottom percentage of cells 
that corresponded to the ALDH+ percentage (i.e. if 3.5% of cells were ALDH+, then the 
bottom 3.5% of cells were gated for the ALDH- population). 
We performed comprehensive profiling to study functional phenotypes of 
ALDH+ IBC CSCs.  First, the ratio of ALDH+ CSCs in the SUM149 cell line was 
quantified across multiple sortings to establish reliability (>20).  The proportion of 
ALDH+ cells in the SUM149 cell line was between 1 - 7%, with an average of 3.93% ± 
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1.84%, similar to what has been reported previously [32].  Interestingly, the ALDH+ 
CSC population maintained a dynamic equilibrium in the SUM149 cell line.  In a purified 
ALDH+ population, the percentage of ALDH+ cells gradually decreased from 100% to 
the normal level (3 - 5%) for SUM149 cells over 3-5 days, presumably by cell 
differentiation.  Thus, the ALDH+ compartment was able to recapitulate the 
heterogeneity of the parent cell population by maintaining an almost constant percentage 
of ALDH+ CSCs, consistent with previously reported results [32, 205, 206]. 
 
Figure 4-1  Functional phenotyping of IBC CSCs.  (A) Concept of cancer stem cells.  (B) Representative 
ALDEFLUOR analysis for SUM149 cells by FACS.  Negative control samples (left) pre-treated with 
DEAB inhibitor were used to ensure identification of ALDH+ and ALDH- cells (right).  (C&D) 
Representative images (C) and quantitative data (D) from in vitro invasion assays performed for ALDH+ 
and ALDH- SUM149 cells using the Biocoat Matrigel Invasion Chambers.  In C, invading cells were fixed 
with formaldehyde before stained with 1% crystal violet.  (E&F) Distribution (E) and average (F) migration 
track area for single ALDH+ and ALDH- SUM149 cells measured by the Cellomics Cell Motility kit.  
(G&H) Cell population doubling time (G) and normalized cell population as a function of culture time (H) 
determined using the MTT Cell Proliferation Assay Kit.  For D, F, G, and H, error bars represent ± 
standard error of the mean (s.e.m.; n = 4).  p-values were calculated using the student's t-test;  ns (p > 0.05), 
* (p < 0.05), and ** (p < 0.01). 
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To study the tumorigenic and metastatic potential of ALDH+ IBC CSCs, in vitro 
invasion, migration, and proliferation assays were conducted.   In vitro invasion assays 
were performed using the Biocoat Matrigel Invasion Chamber (See Appendix I9 for 
details) to examine the ability of cancer cells to invade through a Matrigel membrane 
under a serum gradient, mimicking the basement membrane invasion process in cancer 
metastasis.  As shown in Figure 4-1C&D, ALDH+ IBC CSCs were more invasive 
compared to the ALDH- population and the unsorted SUM149 control.   
To examine cell motility, the Cellomics Cell Motility kit was utilized to measure 
the migration area of ALDH+ and ALDH- cells (See Appendix I7 for details).  Each 
sorted cell type (ALDH+ and ALDH-) was plated in equal densities in 3 -5 wells of a 96-
well plate that had previously been coated with blue fluorescent microbeads.  After 24 hr 
of incubation, the area a cell migrated is represented by the negative space in the 
microbead carpet that has been pushed away or phagocytosed by the cell.  This cell 
motility assay demonstrated a significantly higher motility for ALDH+ than ALDH- cells 
(Figure 4-1E&F), suggesting a more aggressive and motile phenotype for ALDH+ IBC 
CSCs.   
To evaluate the growth rates of ALDH+ and ALDH- cells, these populations were 
quantified and compared with unsorted SUM149 controls using MTT assays (See 
Appendix I10 for details).  Cell populations of flow-sorted ALDH+ and ALDH- cells and 
unsorted SUM149 controls were measured at 24 hr, 36 hr, 72 hr, and 96 hr post sorting.  
As shown in Figure 4-1G&H, ALDH+ cells had a slower growth rate and significantly 
longer cell doubling time compared to ALDH- cells and unsorted control cells.  This 
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slower growth rate for ALDH+ cells suggests that the IBC CSCs can maintain a semi-
quiescent or slowly-cycling state, similar to the behavior of many adult stem cell types. 
4.2.2 Cell Deformability Measurements 
Our invasion assays demonstrated that ALDH+ cells had a greater capability to 
migrate through confined physical spaces, a process that necessitates significant cell 
shape and cytoskeleton changes.  Thus, we hypothesized that there would be a 
concomitant difference in cell deformability between ALDH+ and ALDH- cells.  
Furthermore, at a key step in the metastatic cascade, cell deformability has been 
postulated to play a key role in invasion through the basement membrane [181, 182].  To 
explore potential differences in cell deformability between the ALDH+ IBC CSCs and 
ALDH- subpopulations, we utilized a microfluidics-based deformability microcytometer 
especially designed for highly-sensitive, high-throughput and label-free quantification of 
cell deformability at the single-cell level. 
The microfluidic deformability microcytometer was made of PDMS and 
contained an array of identical funnel-shaped, long confining microchannels that served 
to automatically direct and trap individual live cancer cells within each channel (Figure 
4-2A; See Appendix I11 for details).  The microchannel walls were pre-coated with 
Pluronic-127, a hydrophilic non-ionic surfactant, so that friction between the cell and the 
channel wall would be negligible.  Within the deformability microcytometer, differential 
hydrodynamic pressure acting on individual cancer cells gradually pushes the cell down 
the funnel and, ultimately, the motion of the cell stops and the cell is trapped due to 
confining space of the funnel-shaped channel.  For inert microfluidic channels where cell 
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trapping is dictated by steric interactions between cancer cells and the channel wall, the 
penetration length (L) of an individual cancer cell into the channel is completely 
determined by its cell volume and cell deformability (Figure 4-2A&B).  Thus, the cell 
deformability of each cancer cell can be calculated (See Appendix I11 for details) based 
upon known or measured parameters including pressure, cell volume, and the penetration 
length L (or the distance d between the position where the cell started to deform and the 
final trapped position in the channel).   
We quantified the cell deformability of both ALDH+ and ALDH- SUM149 cells 
using the deformability microcytometer, with results showing that under the same 
differential hydrodynamic pressure across the confining microchannels, the average 
penetration length L of ALDH+ IBC CSCs was significantly greater than that of ALDH- 
cells, while the cell diameters of both populations were comparable (Figure 4-2C&D).  
This suggested a greater deformability of ALDH+ IBC CSCs than ALDH- cells.  We 
further performed correlative studies using single cell data for cell deformability and cell 
diameter.  Our analysis in Figure 4-2E showed no strong correlation between cell 
deformability and cell diameter for either ALDH+ or ALDH- cells, suggesting that cell 
deformability is an intrinsic biophysical property regardless of cell size.  Interestingly, 
deformability of ALDH+ cells was distributed across a relatively higher range than 
ALDH- cells  (Figure 4-2E&F), pointing to a potential inherent propensity and ability of 
ALDH+ IBC CSCs to more readily undergo the necessary cytoskeletal rearrangement to 
intravasate across the basement membrane during invasion.  Together, our data show that 
the small population of IBC CSCs possesses a greater degree of cell deformability than 
normal breast cancer cells. 
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Figure 4-2  Cell deformability measurements for IBC CSCs.  (A) Schematic of microfluidic deformability 
microcytometer for single cell deformability measurements.  (B&C) Representative images (B) and 
quantitative data (C) showing differential penetrating distances for ALDH+ and ALDH- SUM149 cells in 
the deformability microcytometer under different pressures as indicated.  (D) Average cell diameter of 
ALDH+ and ALDH- SUM149 cells.  (E) Cell deformability plotted as a function of cell diameter.  Each 
data point represents an individual cell.  (F) Average cell deformability of ALDH+ and ALDH- SUM149 
cells.  For C, D, and F, error bars represent ± s.e.m (n > 100).  p-values were calculated using the student t-
test;  ns (p > 0.05) and ** (p < 0.01). 
4.2.3 Cell Adhesion Strength Characterization 
We conducted adhesion assays for SUM149 breast cancer cells to evaluate their 
ability to make stable physical contact with surfaces (Figure 4-3A&B).  Three groups of 
SUM149 cancer cells - sorted ALDH+ cells, ALDH- cells, and an unsorted control – 
were seeded at the same density as single cells in polystyrene 48-well cell culture plates.  
Three hours after cell seeding, floating cells were removed, and adherent cancer cells 
were stained with Calcein AM for visualization.  Fluorescence images of stained cancer 
cells in the entire sample area were taken for quantification of the adhesion rate, defined 
as the ratio of the number of cells adhered to the surface to the total number of cells 
initially seeded per sample.  Quantitative analysis revealed that ALDH+ cells had a much 
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lower adhesion rate compared to both the ALDH- population and unsorted control 
(Figure 4-3B).  On average, the adhesion rate after 3 hr of cell seeding was 25.6% for 
ALDH+ cells, while for ALDH- cells and unsorted control cells the adhesion rates were 
60.6% and 52.0%, respectively. 
Our results in Figure 4-3A&B demonstrating a significant difference in the 
adhesion properties of ALDH+ and ALDH- cancer cells suggested the possibility that 
adhesion strength of cancer cells might similarly be correlated with ALDH expression as 
was cell deformability.  To examine specifically the possibility of the IBC CSC 
compartment consisting of intrinsically less adherent cells, we developed a microfluidic 
cell adhesion assay for direct measurements of the adhesion strength of cancer cells 
(Figure 4-3C; see Appendix G for details).  A low density of ALDH+ or ALDH- IBC 
cells was seeded uniformly inside the microfluidic channel for 12 hr before they were 
exposed to constant directional fluid shear (0.1 - 320 dyne cm-2) for 3 min.  We 
quantified the fraction of cancer cells remaining adherent in the microfluidic channel 
after exposure to this sustained 3-min directional fluid shear.  Our data demonstrated that 
indeed, the ALDH+ IBC CSCs that adhered to the microfluidic channel were only 
capable of withstanding much lower fluidic shear stresses than the ALDH- cells (Figure 
4-3D&E).  The adhesion strength of cancer cells, defined as the fluidic shear stress at 
which 50% of cancer cells initially adherent on the microfluidic channel detach after 
exposed to shear, was significantly lower for ALDH+ IBC CSCs than ALDH- cells 
(Figure 4-3F).  Together, our results in Figure 4-3 demonstrated that adhesive properties 
could be quantitatively delineated and correlated with the ALDH-defined IBC CSC 
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population in the SUM149 cell line.  In summary, ALDH+ IBC cells had a decreased 
ability to adhere to a substrate and overall decreased adhesion strength. 
 
Figure 4-3  Cell adhesion strength characterization.  (A&B) Representative fluorescence images (A) and 
quantified adhesion rate (B) of ALDH+, ALDH-, and unsorted SUM149 cells adhering to polystyrene 48-
well cell culture plates 3 hr after cell seeding.  Cells were stained with Calcein AM for visualization and 
enumeration.  (C) Schematic of a microfluidic channel for quantification of cell adhesion strength.  Insert 
shows adherent cancer cells in the channel under sustained directional fluid shear.  (D) Representative 
brightfield images showing temporal sequences of ALDH+ and ALDH- SUM149 cells detaching from the 
microfluidic channel under increased fluid shear stress.  (E) Fraction of ALDH+ and ALDH- SUM149 cells 
remaining adherent in the microfluidic channel after 3-min exposures to sustained directional fluid shear.  
Low densities of cancer cells were seeded into microfluidic channels and cultured for 12 hr before PBS was 
flowed continuously along the channel to exert fluid shear stress on cells.  Solid lines represent logistic 
curve fitting.  (F) Adhesion strength of ALDH+ and ALDH- SUM149 cells.  For B, E, and F, error bars 
represent ± s.e.m. (n = 4).    p-values were calculated using the student t-test;  ns (p > 0.05) and ** (p < 
0.01).  
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4.2.4 Cell Deformability 
The difference seen in cell adhesion properties between ALDH+ IBC CSCs and 
ALDH- cells implicated an involvement of actin cytoskeleton (CSK) and integrin-
mediated focal adhesions that tether the actin CSK to the extracellular matrix.  To 
investigate this hypothesis, we utilized an array of PDMS microposts as subcellular live-
cell force sensors to quantify intracellular CSK contractile forces (Figure 4-4; see 
Appendix H for details) [207-209].  This PDMS micropost array consists of hexagonally 
spaced, vertical, elastomeric posts fabricated using replica molding with PDMS from 
microfabricated silicon masters (Figure 4-4A).  After adhesive proteins are coated on the 
post tips using microcontact printing, cells are able to adhere, spread out, and exert 
contractile forces that deflect the underlying posts (Figure 4-4A-D).  Each post, therefore, 
functions as a cantilever and force sensor, capable of measuring local cellular traction 
force exerted at the post tip [207-209]. 
We performed quantitative analysis of cell morphology and CSK contractility of 
SUM149 cells with the PDMS micropost array (Figure 4-4E&F).  Our results revealed 
that the total cell traction force was significantly less for ALDH+ cells compared to 
ALDH- ones Figure 4-4G).  Previous studies have demonstrated that cell traction force 
generation can be confounded by a cell’s footprint area [136, 186, 207].  To exclude the 
possibility that the decreased cell traction force for ALDH+ CSCs was simply caused by 
a variance in cellular area, we quantified cell spread area for SUM149 cells.  Our results 
in Figure 4-4H showed no significant difference in cell spread area between ALDH+ and 
ALDH- cells.  To further investigate the role of cell spread area in the generation of 
traction forces, we analyzed the total traction force of each cell normalized by its spread  
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Figure 4-4  Quantification of cell traction force.  (A-D) Representative SEM (A-C) and 
immunofluorescence (D) images showing single SUM149 cells adherent on the PDMS micropost array.  In 
D, the single SUM149 cell was stained with fluorophore-labeled phalloidin for visualization of actin 
filaments (green).  The underlying PDMS posts were labeled with DiI for visualization.  (E&F) Phase (E) 
and colorimetric (F) maps showing subcellular traction forces exerted by single ALDH+ (top) and ALDH- 
(bottom) SUM 149 cells on the PDMS microposts.  (G-J) Quantitative analysis of cell morphology and 
traction force.  G-I plot total traction force per cell (G), total cell spread area (H), and traction force per cell 
area (I) for single ALDH+ and ALDH- cells.  Data represents the means ± s.e.m (n > 15).  p-values were 
calculated using the student t-test;  ns (p > 0.05) and ** (p < 0.01).  (J) Total traction force per cell as a 
function of cell spread area.  Each data point represents an individual cell.  Data trends in J are plotted 
using linear least square fitting (black lines), with slope values ± s.e.m indicated. 
area (traction force per cell area), with results showing that the average traction force per 
cell area was lower for ALDH+ IBC CSCs compared to ALDH- SUM149 cells (Figure 
4-4I).  Hence, these results indicate that the smaller traction forces exerted by ALDH+ 
IBC CSCs vs. ALDH- cells are not linked to differences in cell spread area, but to other 
inherent cellular differences between the two populations.  Consistent with previous 
reports though [136, 186, 207], within the same group of cells (ALDH+ or ALDH-) the 
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correlative plot (Figure 4-4J) of single-cell data of total traction force and cell spread area 
did show a strong linear correlation of increasing traction force with cell spread area.  
However, the slope of the linear correlation between the traction force and cell spread 
area was substantially less for ALDH+ cells than for ALDH- cells (0.13 nN µm-2 vs. 0.07 
nN µm-2), again indicating distinct biophysical properties of ALDH+ and ALDH- cells.  
Our traction force study in conjunction with the adhesion strength results indicate that 
ALDH+ and ALDH- cells have differential biophysical properties with the ALDH+ IBC 
CSCs being less adherent and exerting less contractile force.  This may help explain the 
metastatic potential difference between the ALDH+ and ALDH- populations.  Cells that 
are prone to forming strong connections with their surrounding ECM (ALDH- cells) may 
be less likely to successfully migrate away from the primary tumor [210]. 
4.3 Conclusion 
CSCs as defined through specific marker expression methods, have been shown to 
initiate tumorigenesis, have the capacity to self-renew, and initiate cancer metastasis in 
many cancer types.  Although identification of CSCs through marker expression helps 
separate and define the CSC compartment, it does not directly provide information on 
how or why this cancer cell subpopulation is more metastatic or tumorigenic.  IBC is the 
most aggressive and lethal form of breast cancer with two-thirds of patients presenting 
with axillary lymph node involvement and up to one-third of patients having distant 
metastases at initial diagnosis [30, 31].  Why IBC is so much more aggressive and 
metastatic than other breast cancers though is not definitively known.  Previous studies 
have identified ALDH+ IBCs as key mediators of tumorigenesis and metastasis, and they 
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are negatively correlated with survival [32]; however, the how and why have been left 
unstudied.  In this study, we comprehensively profiled the functional as well as 
biophysical characteristics of IBC CSCs at the single-cell level using multiple 
microengineered tools and traditional in vitro studies to delineate the live cell phenotypic 
characteristics of the model of the most metastatic breast cancer subtype.   
Characterizing the functional behaviors of IBC CSCs such as cell migration, 
growth, adhesion, invasion, self-renewal, and differentiation is a direct approach to 
describe and understand IBC CSCs based upon their intrinsic properties, thus paving the 
way to determine therapeutic approaches to this most lethal subpopulation within IBC.  
Distinct biophysical properties of IBC CSCs such as cell deformability, adhesion strength, 
and traction force provide physical insights into why IBC has an enhanced propensity to 
metastasize compared to other breast cancers.  Such multiparametric cellular phenotypic 
profiling of CSCs can provide critical insight into the characteristics of these cells and 
their biomechanical adaptation for cancer metastasis, opening the door for the 
standardization of studies to potentially prognosticate the probability of metastatic growth 
and/or of therapies that target a tumor’s unique biophysical signature associated with IBC 
CSCs.    
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Chapter 5 
Nanotopography-mediated Mechanoseing of Human 
Embryonic Stem Cells 
 
5.1 Introduction 
Human embryonic stem cells (hESCs) have great potentials for future cell-based 
therapeutics.  However, their mechanosensitivity to biophysical signals from the cellular 
microenvironment is not well characterized.  In their physiological niche, stem cells are 
challenged by both soluble biochemical cues and insoluble physical stimuli from the 
microenvironment [211, 212].  At the frontier of cell-microenvironment interactions, cell-
extracellular matrix (ECM) interfaces are composed of structural units of nanometer 
length scale, which thus enable the regulation of stem cell fates by extracellular 
nanotopographical cues along with other physical factors [213-216].  For example, in 
vivo ECM is enriched with hierarchical fibers/fibrils consisting of filamentous proteins 
such as collagen, elastin, fibronectin, vitronectin, and laminin, which present adhesive 
ligands on a structured landscape with spatially organization of characteristic dimensions 
from a few nanometers to hundreds of nanometers [217]. The helical surface 
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topographical periodicity of individual ECM (e.g., collagen I) fibrils is also an operative 
physical cue that could dictate stem cell differentiation [218].  In direct contact with the 
ECM, the cell membrane is also rich of adhesive molecules and protrusive structures with 
characteristic lengths of nanometers. For instance, integrins, the transmembrane receptors 
directly linking the ECM ligands to the intracellular adaptor proteins and actin 
cytoskeleton (CSK), are on the dimension of 20~50 nm [213, 219], and the nanoscale 
filopodia (“nanopodia”) has also been shown in the cellular probing of extracellular fine 
nanotopographical features [220].  Therefore, the symphony between the extracellular 
nanotopographical cues and the nanoscale architecture of cell-ECM adhesions initiates 
unique mechanotransduction processes, resulting in the regulation of a multitude of cell 
behaviors, such as adhesion, morphology, proliferation, gene expression, self-renewal 
and differentiation [147, 216, 221-226].   
Due to their potential roles as important regulators of stem cell fates in the niche, 
the extracellular nanotopography recently attracts much attention from bioengineers in an 
effort to leverage the stem cell mechanobiology and fate control using synthetic 
nanotopograhical biomaterials for future tissue engineering and regenerative medicine 
[217, 224].  Recent reports have shown that the nanoscale surface topography plays a 
critical role in regulating survival, proliferation and differentiation of various types of 
adult multipotent stem cells [227-231].  For example, human mesenchymal stem cells 
(hMSCs) cultured on nanoscale gratings on PDMS surfaces tend to align and elongate 
their actin cytoskeleton (CSK) and nuclei along the nanogratings [229].  Likewise, gene 
profiling and immunostaining of these hMSCs demonstrate a significant up-regulation of 
neuronal markers when cultured on the nanogratings, as compared to unpatterned flat 
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controls [229].  Recent published reports have also demonstrated that the nanoscale 
disorder in a nanopit array can stimulate osteogenesis of hMSCs in the absence of 
osteogenic supplements [228], while another study from the same group verifies that the 
perfectly ordered arrays of nanopits support long-term maintenance of hMSC phenotype 
and multipotency [231].   
Only in the last few years has experimental evidence begun to emerge showing 
that pluripotent stem cells such as embryonic stem cells (ESCs) are sensitive to the cell-
ECM physical interactions [232-238], including their intrinsic sensitivity to the nanoscale 
surface topography [237, 238].  These early findings have promoted significant interest 
from the developing fields of functional tissue engineering and regenerative medicine, as 
ESCs are able to replicate themselves (self-renewal) while retaining their ability to give 
rise to any type of specialized cell in the adult body (pluripotency) [239-241] and as such, 
hESCs are a promising cell source for disease modeling [242, 243], drug screenings [244-
246] and future cell-based therapeutics to treat degenerative human diseases such as 
diabetes mellitus and trauma such as spinal cord injury [247-250].   
To date, the existing work on regulation of ESC behaviors using nanotopography 
has focused on their neurogenic differentiation with regularly arranged nanoscale surface 
structures.  For example, it has been shown that the electrospun fibrous scaffolds can not 
only enhance differentiation of mouse ESCs (mESCs) into specific neural lineages, but 
also promote and guide the neurite outgrowth [237].  More recently, nanoscale 
ridge/groove pattern arrays generated on polyurethane acrylate (PUA) surfaces are shown 
to induce morphological changes and differentiation of hESCs into a neuronal lineage 
without treatment with differentiation-inducing biochemical agents [238].   
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However, all the aforementioned work on nanotopography for stem cells has 
largely relied on complex and expensive nanofabrication techniques, such as electron 
beam and nanoimprint lithography, to generate nanoscale surface structures to regulate 
cell-ECM interactions.  Further, it is still largely unknown to what extent such synthetic 
regular nanoscale structures can mimic the intrinsic random nanoscale topology 
associated with the in vivo cellular microenvironment.  Using our RIE-generated 
nanorough glass surfaces, we explored the nanoscale surface roughness as a potent 
physical signal in the cellular microenvironment to regulate a diverse array of hESC 
behaviors, including their morphology, cell adhesion, self-renewal, and fate [135].  As an 
example of the regulation effect of the nanotopography cue on hESCs, we demonstrated 
using the nanorough glass surfaces for promoting motor neuron differention.  In order to 
bring current mechanistic understanding of stem cell mechanobiology into the context of 
nanotopography-regulated fate control, a few important mechanosensing and 
mechanotransduction mechanisms are discussed that have been implicated in the cellular 
responsiveness to extracellular nanotopography. Finally, we will also discuss some 
speculations regarding how these mechanotransduction events converge with classical 
signal transduction pathways to control stem cell fates.   
5.2 Nanotopological Sensing of hESCs 
5.2.1 Functional Responses of hESC to the Nanotopographic Cue 
Using the nanorough glass substrates described above, we first examined 
functional responses of hESCs to different levels of nanoroughness, including their 
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morphology, adhesion, proliferation and clonal expansion, and differentiation.  Here, all 
glass substrates were pre-coated with vitronectin (5 µg/mL) by adsorption to support 
long-term self-renewal of hESCs as reported by others [251].  Using AFM, we confirmed 
that the RMS roughness Rq of the smooth and nanorough glass surfaces did not 
significantly change before and after vitronectin coating (Figure 5-1A&B).  To further 
confirm that the density of the adsorbed vitronectin on the glass surfaces was independent 
of the nanoroughness Rq of the glass surface, control assays were performed.  Using 
fluorophore-labeled proteins, no apparent difference in fluorescence intensity was 
observed between glass surfaces of different nanoroughness Rq, indicating constant 
protein densities on the glass surfaces (Figure 5-1C&D).  
 
Figure 5-1  Surface analysis of the nanorough glass.  (A) Top-view SEM image showing a patterned glass 
surface with smooth (top) and nanorough (bottom) regions on the same substrate as indicated.  (B) AFM 
topographs of the smooth and nanorough regions of the glass substrate shown in A with (right) or without 
(left) vitronectin coating.  The values of the RMS roughness Rq were indicated on the topographs.  (C) 
Phase-contrast (top), immunofluorescence (middle), and merged (bottom) images of a glass surface 
patterned with nanorough letters (NANO).  The patterned glass surface was coated uniformed with 
vitronectin (5 µg/mL).  A fluorescence conjugated antibody was used for visualization of vitronectin.  (D) 
Normalized fluorescence intensity along the three dashed lines (a-c) shown in C. 
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First, hESCs demonstrated significant adhesion selectivity between different 
levels of nanoroughness on the glass surfaces.  For example, after 48 hr of culture on a 
glass surface patterned with square-shaped, smooth islands surrounded by nanorough 
surfaces, hESCs selectively adhered to, and aggregated on, the smooth islands where Rq = 
1 nm, but not on the nanorough areas where Rq = 70 nm (Figure 5-2A).  During this 
selective adhesion and aggregation process, hESCs retained their stemness, as evidenced 
by their positive expression of Oct3/4 (Oct3/4+), a transcription factor and a hallmark of 
undifferentiated hESCs (Figure 5-2A).  Interestingly, spontaneously differentiated 
hESCs, which would loose their expression of Oct3/4 (Oct3/4-), did not show any 
adhesion preference to either the smooth or nanorough surfaces, and Oct3/4- hESCs 
would randomly distribute on the patterned glass substrate (Figure 5-2B).   
We quantified the cell adhesion rate, defined as the ratio of number of cells 
adhered to the glass surface to the total number of cells initially seeded, of single Oct3/4+ 
hESCs plated on glass substrates with different values of Rq.  Our results showed that 24 
hr after cell seeding, Oct3/4+ hESCs at the single cell level had a strong tendency to 
adhere to smooth glass surfaces with smaller Rq (Figure 5-2C).  In contrast, Oct3/4+ 
hESCs adhered less to surfaces with an increasing Rq.  Both phenomena were consistent 
regardless of treatment with or without Y27632, a Rho-Associated Coil Kinase (ROCK) 
inhibitor used to enhance survival of single fully-dissociated hESCs (Figure 5-2C).  
The effect of topological sensing of hESCs on their self-renewal and stemness 
maintenance was also investigated.  In the experiments, Oct3/4+ hESCs were seeded at a 
low density (5 × 103 cells/cm2) on both smooth (Rq = 1 nm) and nanorough (Rq = 150 nm) 
glass surfaces and cultured for 7 d.  Subsequently, cells were fixed and stained with 4',6-
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diamidino-2-phenylindole (DAPI) to identify nuclei and fluorescent-labeled antibodies 
for Oct3/4 (Figure 5-2F).  Quantification of Oct3/4+ hESCs as a function of Rq showed a 
higher percentage of Oct3/4+ cells (93.6%) on the smooth glass surface (Rq = 1 nm) as 
compared to cells seeded on nanorough surfaces (41% and 36.6% for Rq = 70 nm and 150 
nm, respectively; Figure 5-2D).  Thus, our results indicated that the smooth glass surface 
was conductive for self-renewal and maintenance of hESC stemness in long-term culture, 
while the nanorough glass surfaces resulted in a large portion of hESCs undergoing 
spontaneous differentiation thus loosing their pluripotency (Figure 5-2D&F).   
To investigate the extent to which nanoscale topological cues could affect 
proliferation of hESCs, small clusters of undifferentiated hESCs were seeded on glass 
substrates with different values of Rq (1, 70 and 150 nm).  Phase-contrast microscopic 
images of hESC colonies were taken 1, 2, and 3 days after cell seeding for these different 
glass substrates.  The colony sizes were analyzed using these colony images with the 
image analysis software ImageJ to calculate the cell population doubling time.  hESCs 
proliferated more rapidly with a shortened cell population doubling time of 41 hr on the 
smooth glass surface (Rq = 1 nm) as compared to cells on the RIE-generated nanorough 
surfaces, on which the cell population doubling time was 71 hr for Rq = 70 nm and 77 hr 
for Rq = 150 nm (Figure 5-2E&G).  Together, these results confirmed that the 
nanotopological cue on the RIE-generated glass surface to which hESCs adhered could 
provide a potent regulatory signal that affects a diverse array of hESC behaviors 
including cell morphology, adhesion, proliferation and self-renewal. 
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Figure 5-2  Functional responses of hESCs to the nanoroughness on glass. (A) Representative phase-
contrast (top) and merged (bottom) microscopic images showing Oct3/4+ hESCs selectively attached and 
aggregated on the smooth region (Rq = 1 nm) of a patterned nanorough glass substrate.  (B) Representative 
merged microscopic image showing Oct3/4- hESCs randomly distributed on a patterned nanorough glass 
surface without showing a preference for either smooth or nanorough areas.  For A & B, the nanorough 
regions of the glass substrate had a RMS Rq of 70 nm.  Cells were cultured 48 hr after initial cell seeding 
and co-stained with DAPI for nuclei (blue) and Oct3/4 (red).  (C) Adhesion rate of single hESCs after 24 hr 
of culture on glass substrates with different levels of nanoroughness.  Cells were treated with or without 
Y27632 (Y27) as indicated.  Error bars represent ± standard error of the mean (s.e.m, n = 3).  (D) 
Percentage of Oct3/4+ hESCs on the glass substrates with different levels of nanoroughness as indicated, 
after culture for 7 days.  Error bars represent ± s.e.m (n = 3).  (E) Doubling time of hESCs on the glass 
substrates with different levels of nanoroughness as indicated.  Error bars represent ± s.e.m (n = 20).  For 
C-E, ns (P > 0.05) and ** (P < 0.01) (Student’s t-test).  (F) Representative immunofluorescence images of 
hESCs cultured for 7 days on both the smooth (Rq = 1 nm; top) and nanorough (Rq = 150 nm; bottom) glass 
substrates.  The cells were co-stained for Oct3/4 (red) and nuclei (DAPI; blue).  (G) Representative phase-
contrast microscopic images of hESC colonies on smooth (Rq = 1 nm; left) and nanorough (Rq = 70 and 150 
nm; middle and right) glass substrates after culture of 1 day (top) and 3 days (bottom).   
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5.2.2 Topological Sensing by FAs, CSK Structure, and Cell-cell 
Contacts 
The molecular mechanism for topological sensing by adherent cells remains 
largely undetermined, yet existing evidence from different cell types has suggested the 
involvement of integrin-mediated focal adhesion (FA) signaling [252].  Integrins mediate 
cell adhesion to the ECM and contribute to cell-matrix signaling by activating 
intracellular tyrosine kinase and phosphatase signaling to elicit downstream biochemical 
signals important for regulation of gene expression and stem cell fate.  Importantly, 
integrin-mediated FA signaling is closely related to its molecular arrangement and 
dynamic organization, which can be affected directly by  local nanotopological cues 
[252].   
 
Figure 5-3  Foacal adheiosn analysis of hESCs to nanoroughness.  (A) Representative immunofluorescence 
images of Oct3/4+ (i & iii) and Oct3/4- (ii & iv) hESCs on smooth (Rq = 1 nm) and nanorough (Rq = 100 
nm) glass substrates after 48 hr of culture.  Cells were co-stained for nuclei (DAPI; blue), Oct3/4 (red), and 
vinculin (green).  (B) Bar graphs showing quantitative results of cell spread area (top left), total FA area 
per cell (top right), average single FA area (bottom left), and number of FAs per cell (bottom right) for 
Oct3/4+ and Oct3/4- hESCs cultured on glass substrates with different levels of nanoroughness as indicated.  
Error bars represent ± s.e.m (n = 50).  ns (P > 0.05), ** (P < 0.01); Student’s t-test. 
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Figure 5-4  Nanotopography reugulates hESC myosin IIA and E-cadherin.  Representative 
immunofluorescence images of Oct3/4+ (i & iii) and Oct3/4- (ii & iv) hESCs on smooth (Rq = 1 nm) or 
nanorough (Rq = 100 nm) glass surfaces after culture of 48 hr.  The cells were co-stained for nuclei (DAPI; 
blue), Oct3/4 (red), and myosin IIA (A; green) or E-cadherin (B; green).   
To investigate the likely involvement of integrin-mediated FA formation in 
regulating topological sensing of hESCs, we examined FA formation of single hESCs 
plated on nanorough glass surfaces.  After 48 hr of culture, single hESCs exhibited 
distinct FA formations and organizations on the smooth and nanorough glass surfaces, as 
characterized by immunofluorescence staining of vinculin, a FA protein.  On smooth 
glass surfaces, where Rq = 1 nm, vinculin-containing FAs formed primarily on the 
periphery of undifferentiated hESCs (Oct3/4+) but distributed randomly throughout the 
whole cell spread area of differentiated cells (Oct3/4-) (Figure 5-3A).  However, on the 
nanorough surface where Rq = 100 nm, both Oct3/4+ and Oct3/4- hESCs exhibited 
randomly distributed, punctate FAs of small areas throughout the entire cell spread area 
(Figure 5-3A).  Morphometric analysis of cell populations suggested that on the smooth 
glass surface, Oct3/4- hESCs had a smaller mean cell spread area than Oct3/4+ hESCs, 
and the nanorough surface resulted in both Oct3/4+ and Oct3/4- hESCs having a small 
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mean cell spread area comparable to Oct3/4- hESCs on the smooth glass surface.  
Furthermore, our results indicated that both Oct3/4+ and Oct3/4- hESCs on the 
nanorough surface formed FAs of smaller areas but with a greater density as compared 
with the cells on the smooth surface (Figure 5-3B).  Collectively, our results indicated 
that the nanotopography significantly affected the molecular arrangement, formation and 
distribution of FAs in hESCs (Figure 5-3).  
Previous studies have suggested that non-muscle myosin IIA (NMMIIA)-
dependent CSK contractility is a key mediator of the mechano-sensing and -transduction 
processes in different types of stem cells [233, 253-255].  For hESCs, recent studies show 
that the NMMIIA-mediated CSK contractility plays a critical role in regulating hESC 
survival and cloning efficiency by controlling E-cadherin-mediated intercellular adhesion 
of hESCs [255-258].  Thus, we hypothesized that a feedback regulation and mechanical-
biochemical integration involving FA, NMMIIA, and E-cadherin might be engaged in 
topological sensing of hESCs by their cross-regulation of intercellular adhesion and cell-
ECM interactions (Figure 5-3 & Figure 5-4).   
To examine this possibility, we examined NMMIIA (Figure 5-4A) and E-cadherin 
(Figure 5-4B) expressions in hESCs plated on both the smooth (Rq = 1 nm) and 
nanorough (Rq = 100 nm) glass substrates after 48 hr of culture, by co-staining the cells 
with Oct3/4 and DAPI.  Subcellular organizations of NMMIIA and E-cadherin were 
distinct between Oct3/4+ and Oct3/4- hESCs on the smooth surface, where Oct3/4+ 
hESCs demonstrated strong expressions of NMMIIA and E-cadherin concentrating and 
co-localizing on the cell-cell contacts, while Oct3/4- cells displayed a random distribution 
of NMMIIA throughout the whole cell spread area and a low expression level for E-
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cadherin.  Interestingly, regardless of the Oct3/4 expression levels, hESCs adhered to the 
nanorough surface demonstrated a random distribution of NMMIIA throughout the entire 
cells and a weak expression of E-cadherin, similar to Oct3/4- hESCs adhered on the 
smooth surface, suggesting that topological sensing and functional regulation by hESCs 
might involve the functional interplay between the mechanosensory components of FA, 
NMMIIA, and E-cadherin.   
We further performed western blot analysis of full-length E-cadherin, vinculin, 
NMMIIA, focal adhesion kinase (FAK; a kinase involved in regulating FA signaling), 
Oct3/4, and β-actin (as a housekeeping control protein) in Oct3/4+ hESCs plated on 
smooth (Rq = 1 nm) and nanorough (Rq = 100 nm) glass substrates after 24 hr and 48 hr 
of culture.  Our result suggested that for both time points, the total amount of vinculin, 
NMMIIA, and FAK did not change between cells plated on smooth and nanorough 
surfaces (Figure 5-5).  However, expression of E-cadherin was clearly down-regulated 
for hESCs plated on the nanorough surfaces as compared to cells on the smooth 
substrates, consistent with the immunostaining results shown in Figure 5-4.  Combining 
together the results in Figure 5-3 and Figure 5-5, it appeared that nanotopography might 
regulate hESC behaviors through its direct effect on the local molecular arrangement and 
formation of FAs that might in turn regulate the spatial organization of NMMIIA-
mediated CSK contractility and thus the E-cadherin-mediated intercellular adhesion of 
hESCs, even though the total expression levels of FA proteins such as vinculin and 
NMMIIA might not be significantly affected by nanotopography.  It was highly likely 
that E-cadherin-mediated cell-cell contacts of hESCs might serve as the downstream 
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mediator to convert the nanotopographic signal through FAs and CSK contractility to 
regulate downstream gene expression and fate decisions of hESCs (Figure 5-6). 
 
Figure 5-5  Western blot analysis of full-length E-cadherin, vinculin, NMMIIA, focal adhesion kinase 
(FAK), Oct3/4, and β-actin in Oct3/4+ hESCs plated on smooth (Rq = 1 nm) and nanorough (Rq = 100 nm) 
glass substrates after 24 hr (left) and 48 hr (right) of culture. 
 
Figure 5-6  Schematic showing a feedback regulation and mechanical-biochemical integration involving 
FA, NMMIIA, and E-cadherin engaged in the topological sensing of hESCs by their cross-regulation of 
intercellular adhesion and cell-ECM interactions.  Focal adhesion kinase (FAK), talin, paxillin (Pax), 
vinculin, zyxin, and vasodilator-stimulated phosphoprotein (VASP) are mechanosensitive proteins 
contained in the FA plague. 
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5.2.3 Nanotopographic Cue for Cell Separation 
As discussed in the last section, hESCs showed higher adheiosn preference to the 
smooth surfaces.  Contrariously, NIH/3T3 fibroblasts attached preferentially to the 
patterned nanorough islands and spread to conform to the different geometries of the 
nanorough islands (Figure 5-7A-C).  The adhesion selectivity of NIH/3T3 fibroblasts to 
the patterned nanorough islands was about 91% (Figure 5-7B), suggesting the patterned 
nanoroughness could serve as an effective means to control the adhesion location and cell 
shape or spread area of NIH/3T3 cells.  In addition, when a high density of single 
NIH/3T3 fibroblasts were seeded on a glass surface patterned with large nanorough 
islands, the cells attached and aggregated to the patterned nanorough islands to form cell 
colonies that conformed to the different geometries of the nanorough islands (Figure 
5-7D).  Thus, the adhesion response of NIH/3T3 fibroblasts to nanotopography was 
completely contrary to that of hESCs (Figure 5-2), indicating cell-type specificities in 
cellular responses to nanotopography.  The cell-type specific preference to adhere to 
either smooth or nanorough surfaces provided an opportunity to spatially separate 
different cell types for cell co-culture applications.  To explore this prospect, a mixture of 
hESCs and NIH/3T3 fibroblasts were cultured on a patterned nanorough glass substrate 
containing an array of nanorough strips separated by smooth regions.  The cell adhesion 
and separation on the patterned surface after co-culturing the cells for 48 hr was 
examined, showing that hESCs and NIH/3T3 fibroblasts selectively attached and 
autonomously segregated to the smooth and nanorough regions, respectively (Figure 
5-7E).  Quantitative analysis suggested a superior cell segregation efficiency for hESCs 
and NIH/3T3 cells using the patterned nanorough surfaces, as 87% of the cells adhered 
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on the smooth regions of the glass surface were hESCs, while on the nanorough regions 
97% of cells were NIH/3T3 fibroblasts (Figure 5-7F). 
 
Figure 5-7  Study of nanotopographic cue for cell separation. (A) Phase-contrast microscopic image of 
single NIH/3T3 fibroblasts adhered on patterned nanorough islands (Rq = 70 nm) on a glass substrate 4 hr 
after initial cell seeding.  (B) Bar graph showing the cell adhesion rate of single NIH/3T3 fibroblasts on the 
smooth surface (Rq = 1 nm) and the patterned nanorough islands (Rq = 70 nm) of a glass substrate.  Error 
bars represent ± s.e.m. (n = 30).  ** (P < 0.01); Student’s t-test.  (C) Immunofluorescence image showing 
single NIH/3T3 fibroblasts attaching and conforming to nanorough islands (Rq = 70 nm) of different 
geometries on the glass surface.  The cells were fixed and stained 4 hr after initial cell seeding.  (D) 
Immunofluorescence (left) and phase-contrast (right) microscopic images of clusters of NIH/3T3 
fibroblasts selectively attaching and conforming to nanorough islands (Rq = 70 nm) of different geometries 
on the glass surface.  The images were taken 24 hr after initial cell seeding.  For C & D, cells were co-
stained with DAPI (blue) and phalloidin (red) for visualization of nuclei and actin microfilaments, 
respectively.  (E) Merged microscopic image showing co-cultured Oct3/4+ hESCs and NIH/3T3 fibroblasts 
spatially self-segregating on a patterned nanorough glass surface after 48 hr of culture.  Cells were fixed 
and stained for nuclei (DAPI, blue) and Oct3/4 (red).  The smooth and nanorough regions on the glass 
surface had RMS Rq of 1 nm and 70 nm, respectively.  (F) Bar graph showing percentages of hESCs and 
NIH/3T3 fibroblasts located on the smooth (Rq = 1 nm) and nanorough (Rq = 70 nm) regions of the 
patterned nanorough glass substrate after culture of 48 hr.  Error bars represent ± s.e.m (n = 3).    
5.3 Nanotopography-mediated Neuron Differention of hESCs 
Human pluripotent stem cells (hPSCs) including hESCs and induced pluripotent 
stem cells (hiPSCs) are a promising source of differentiated cells for developmental 
studies, cell transplantation, disease modeling, and drug testing.  However, their 
widespread use even for intensely studied cell types like spinal motor neurons (MNs) is 
hindered by poorly defined culture conditions, protracted differentiation and low yield 
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and purity of existing protocols for in vitro differentiation.  Current hPSC-based MN 
differentiation protocols also rely extensively on soluble morphogens such as sonic 
hedgehog (SHH) and retinoic acid (RA) acting as ventralization and caudalization factors 
to direct MN differentiation.  Given that during development of human embryonic brain, 
extensive cellular morphogenesis occurs with embryonic cells experiencing dynamic 
modulations of extracellular physical signals, it is likely that insoluble physical signals 
such as nanotopograhy, which has been overlooked in existing stem cell reseearch, may 
be important for differentiation and functional maturation of neural subtypes from 
hESCs.   
In this work, we sought to investigate if the intrinsic mechanosensitive properties 
of hESCs to nanotopography could be leveraged to improve derivation of functional 
spinal MNs.  Using the RIE-generated nanorough glass surfacces, we first examined 
whether substrate nanoroughness could influence neural induction of hESCs.  Single 
undifferentiated hESCs were seeded in growth media at a high density (20,000 cells cm-
2) on glass surfaces with varied surface roughness (Rq = 1, 100 and 200 nm) and being 
pre-coated with vitronectin that is supportive for hESC self-renewal [251].  After 24 hr, 
hESCs were switched from growth media to neural induction media containing dual 
Smad inhibitors, SB 431542 (SB, a TGF-β inhibitor) and LDN 193189 (LDN, a BMP4 
inhibitor), and allowed to differentiate for a total of 8 d (Figure 5-8A).  Combined 
treatments with dual Smad inhibitors can greatly increase efficiency of neural induction 
of hESCs [259].  Neural induction was monitored by expression of Pax6, an early marker 
of neuroectodermal differentiation.  On nanorough surfaces, Pax6+ neuroepithelial cells 
(NEs) appeared as early as day 2, and the percentage of NEs rose quickly and reached 
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94.5% by day 8 (Figure 5-8 & Figure 5-9).  In distinct comparison, on smooth glasses 
Pax6+ NEs started to appear only at day 4 and constituted only 32.2% of total cells at day 
8 (Figure 5-8 & Figure 5-9).  At the same time, we also observed the stem cell 
pluripotency marker Oct3/4 was downregulated significantly more on the nanorough 
surfaces at the early stage of the neural induction than that on the smooth ones (Figure 
5-8D & Figure 5-9A).  We further analyzed temporal expressions of pluripotency (OCT4  
 
Figure 5-8  Nanorough substrates promoted neuroepithelial conversion while inhibiting neural crest 
differentiation of hESCs in a BMP4 dependent manner.  (a) Schematic diagram showing experimental 
design of neural induction of hESCs.  hESCs were cultured for 8 d in neural induction media containing 
dual Smad inhibitors, SB 431542 (SB, 10 µM) and LDN 193189 (LDN, 100 nM).  (b) Representative 
immunofluorescence images showing Pax6+ NEs and NCs (AP2+ or p75+) derived from hESCs after 8 d 
of culture on glass surfaces with different surface roughness (Rq = 1, 100, 200 nm).  (c-d) Bar graphs 
showing percentage of Pax6+ NEs (c) and Oct3/4+ hESCs (d) on smooth (Rq = 1 nm) and nanorough (Rq = 
200 nm) glass surfaces at day 2, 4, 6, and 8.  (e-g) Bar plots showing percentages of Pax6+ NEs (e), AP+ 
NCs (f) and p75+ NCs (g) derived from hESCs at day 8 as a function of surface roughness.  (h) Western 
blotting showing expression levels of Pax6, Sox1, Ap2-α and HNK-1 for hESCs cultured for 8 d on smooth 
(Rq = 1 nm) and nanorough (Rq = 200 nm) glass surfaces. Data represents means ± s.e.m with n = 3.  P-
values were calculated using Student’s t-test.  *, P < 0.05; **, P < 0.01.   
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Figure 5-9  Temporal expressions of pluripotency and neuroectodermal markers during neural induction of 
hESCs. (a) Representative immunofluorescence images showing Pax6+ NE cells derived from hESCs 
cultured in neural induction media at day 2, 4, 6 and 8 on smooth (Rq = 1 nm) and nanorough (Rq = 200 nm) 
glass surfaces.  (b-e) RT-qPCR for temporal expressions of pluripotency (OCT4 and NANOG; b&c) and 
neuroectodermal (PAX6 and SOX1; d&e) markers during neural induction of hESCs.  hESCs were cultured 
in neural induction media on smooth (Rq = 1 nm) and nanorough (Rq = 200 nm) glass surfaces.  NANOG, a 
gene associated with pluripotency, decreased more significantly since day 4 on nanorough as compared to 
smooth ones. Genes associated with neural lineages, including PAX6 and SOX1, both showed greater levels 
of expression on nanorough surfaces since day 2 when compared to those from smooth surfaces.  The 
earliest neural markers expressed in our culture system were SOX1, preceding induction of PAX6, 
consistent with previous studies using dual Smad inhibitors.  Expression level of each gene was normalized 
to data from undifferentiated hESCs.  Data represents means ± s.e.m with at least three biological replicates 
and three technical replicates.  P-values were calculated using two-side unpaired student t-test.  *, P < 0.05;  
**, P < 0.01.   
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and NANOG) and neuroectodermal (PAX6 and SOX1) genes using quantitative real-time 
PCR with results confirming that nanorough surfaces could accelerate disruption of the 
transcriptional circuitry that maintains pluripotency of hESCs while simultaneously 
promoting neuroectodermal gene expressions (Figure 5-9).  Our screening assay using 
glass surfaces with varied surface roughness (Rq = 1, 100, 200 nm) further revealed a 
strong corelation between the surface roughness and neural induction efficiency (Figure 
5-9B&E). A glass surface with surface roughness of 200 nm showed a potent effect on 
neural induction, whereas smooth surfaces (Rq = 1 nm) did not. 
Consistent to results reported previously [259], treatment of hESCs with dual 
Smad inhibitors led to not only Pax6+ NEs but also Pax6- cells co-expressing neural crest 
cell (NC) markers, including AP2, p75 and HNK-1 (Figure 5-8).  At day 8, 18.0% and 
14.4% cells were AP2+ and p75+ on smooth glasses (Rq = 1 nm), respectively.  
Strikingly, only 1.6% and 3.4% cells were AP2+ and p75+ on nanorough surfaces (Rq = 
200 nm) (Figure 5-8D).  Immunoblot analysis confirmed greater expressions of Pax6 and 
Sox1 (a neuroectodermal transcription factor) but low expression of AP2 and HNK-1 for 
hESCs at day 8 on nanorough surfaces (Rq = 200 nm) than cells on smooth glasses (Rq = 
1 nm) (Figure 5-8H).  We further examined whether caudalized NEs derived from 
nanorough surfaces could be specified into spinal MNs in the presence of the 
ventralization factor purmorphamine (Pur), using oligodendrocyte transcription factor 2 
(Olig2) as a MN marker.  When NEs were cultured continuously for another 8 d in the 
presence of Pur and RA, 58.5% cells on nanorough surface (Rq = 200 nm) emerged as 
Olig2+, whereas only 11.2% cells became Olig2+ on smooth glasses (Rq = 1 nm) (Figure 
5-10).   
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Figure 5-10  Nanorough surfaces promoted motor neuron (MN) specification of hESC-derived neural 
epithelial cells (NEs).  (b) Representative immunofluorescence images and (c) bar plots showing 
percentages of Olig2+ MN progenitor cells derived from hESCs at day 16 on smooth (Rq = 1 nm) and 
nanorough (Rq = 200 nm) glass surfaces.  hESCs were cultured on glass surfaces in neural induction media 
containing dual Smad inhibitors SB and LDN for 8 d before switched to MN differentiation media 
containing purmorphamine (Pur), basic fibroblast growth factor (bFGF), and retinoic acid (RA) for another 
8 d.  Olig2 is a transcription factor expressed by motor neuron progenitors at the pMN domain of the 
ventral neural tube.  Data represents means ± s.e.m with n = 3.  P-values were calculated using two-side 
unpaired student t-test.  **: P < 0.01.  
In summary, combining dual Smad inhibition with nanotopographic cue, here we 
achieved accelerated high-yield and -purity generation of NEs and spinal MNs from 
hESCs.  Nanorough glass substrats are fully defined substrates that can be easily mass-
produced for large-scale hESC culture.  Our results further showed that just like many 
other human adult stem cells [254, 260, 261], hPSCs are intrinsic mechanosensitive, and 
surface topography can serve as an in vitro extracellular switch to direct the NE vs. NC 
lineage decisions.  Thus, it is tempting to speculate that physical properties of in vivo 
ECM may serve as a "physical trigger" to work synergistically with soluble morphogens 
to direct neural plate specification during primary neurulation. 
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5.4 Mechanisms of Cellular Responses to Nanotopography: a 
Hypothetical Core Axis of Stem Cell Mechanotransduction 
In the past decade, much effort has been directed to study the behaviors of stem 
cells in the presence of nanotopographic cues and successfully demonstrated the 
significant potential of nanotopographical biomaterials in stem cell-based tissue 
engineering.  However, the underlying molecular mechanisms governing these processes 
remain elusive.  Two most challenging questions are: how do stem cells sense matrix 
nanotopography and how is the topographical signal transduced and integrated into 
intracellular signaling pathways?  Hereby, we discuss some common yet prominent 
mechanosensing machineries possibly involved in nanotopographic sensing with the 
focus on their operational mechanisms as well as functions in the context of cellular 
mechanotransduction.  We will discuss how signaling pathways downstream of these 
mechanosensing machineries might relay the extracellular mechanical signals such as the 
nanotopography through a hypothetical axis composed of potential cytoplasmic 
transducers, cytoskeletal integrators and transcriptional actuators, which might provide a 
route map for future study and understanding of nanotopography-sensitive stem cell 
mechanobiology. 
5.4.1 Plasma Membrane-associated Mechanosensors and Cytoplasmic 
Transducers  
Playing a pivotal role in initiating and organizing cell-ECM adhesions, integrins 
are heterodimeric transmembrane proteins composed of an α and a β subunit.  Currently, 
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Figure 5-11  Potential mechanotransduction mechanisms in cellular responsiveness to nanotopographical 
biomaterials. (left) On smooth surfaces, integrins could undergo free lateral recruitment and ligation with 
ECM proteins, and thus cluster and form mature, stable focal adhesions together with the unhindered 
recruitment of FA adaptor proteins. This process initiates signals from plasma membrane, enhancing RhoA 
activity, which further promoting cell tension (through ROCK-MLCK) as well as stress fiber formation 
(through ROCK and mDia). Cell tension, as an important mediator of mechanotransduction, could provide 
positive feedback to the focal adhesions and cell-cell contacts. In addition, cell tension could also induce 
phosphorylation of emerin, a nuclear envelope-located protein, and thus initiate nuclear 
mechanotransduction through enhanced nuclear actin polymerization and subsequent nuclear translocation 
of MAL, a transcription co-factor of SRF. In the meantime, prominent stress fibers formed in cells on 
smooth surfaces could promote the nuclear translocation of YAP/TAZ, a transcription co-factor of TEAD. 
Nuclear shuttling of SMAD 2/3 (R-SMAD), the transcription factor downstream of TGFβ signaling, is also 
controlled by YAP/TAZ translocation. (right) On nanotopographical surfaces, although integrins could still 
freely diffuse laterally, the nanoscale surface features restrict the ligation of additional integrins to the ECM 
proteins, which further restrict successful recruitment and clustering of integrins and other focal adhesion 
proteins, resulting in smaller, less stable FAs. Such process disrupts the activation of RhoA and therefore 
limits the formation of stress fibers and might induce high cytoplasmic G-actin level, which inhibits the 
nuclear translocation of MAL and thus SRF signaling. In addition, nanotopography was found to induce 
high phosphorylation level of FAK, which could further connect MAPK signaling pathways to stem cell 
fate regulation. Last but not the least, compromised stress fibers and FAs on nanotopographical substrates 
could potentially intersect with Hippo/YAP pathway by enhancing YAP/TAZ phosphorylation via either 
Lats-dependent or –independent mechanisms, resulting in cytoplasmic retention of YAP/TAZ. 
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there are 24 known integrin heterodimers that are constituted by different combinations 
of 18 α and 8 β subunits, hosting a wide range of differential sensing to external chemical 
and mechanical cues [262-265].  For human pluripotent stem cells in particular, it has 
been found that human ESCs express a broad range of integrins including α1, α2, α3, α5, 
α6, α7, α11, αV, αE, and β1, β2, β3, β5, β6 integrins, while human iPSCs were found 
expressing in majority α5, α6, αV, β1, and β5 integrins, with variations among different cell 
lines [266-268].  
The first step cells make to probe the ECM is mediated by the "inside-out" and 
"outside-in" bidirectional regulation of integrin-ligand binding [269-271].  Specifically, 
the binding of intracellular adaptor protein talin to the cytoplasmic domain of integrin 
induces conformational change of integrin's extracellular domain and endows high 
affinity to bind corresponding ECM ligands.  In return, the firm binding of integrin to 
ECM ligand activates the clustering of integrins through their intracellular domains and 
thus further recruitment of both adaptor and signaling proteins.  In the early stage of 
integrin-mediated cell-ECM adhesion (also known as "nascent adhesion"), the key 
components include adaptor proteins talin and paxillin and tyrosine kinases such as focal 
adhesion kinase (FAK) and Src family kinases [272, 273].  
Although intracellular force has been shown to be dispensable for the formation 
of nascent adhesions [274], as long as there remains intact binding between talin head 
domain and integrin, the early formation of cell-ECM adhesions has been found sensitive 
to the spacing of external ECM ligands.  As the size of the head of an integrin 
heterodimer consisting of an α subunit and a β subunit is approximately 20 nm in 
diameter [213], a nanometer scale variation in substrate topography could potentially 
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result in a significant change in the clustering of integrins and adaptor proteins which in 
turn initiates signal transduction controlling stem cell fates (Figure 5-11).  Results 
reported by multiple groups confirmed that successful integrin clustering requires a 
spacing between individual ECM ligands smaller than a threshold value of 50-70 nm, and 
too sparse distribution of individual ligands inhibited lateral crosslinking between 
integrins [275-278].  Interestingly, by simply clustering individual ECM ligands into 
oligomer nanopatterns, it could promote the cell-ECM adhesions and cell spreading 
without changing the overall ligand density, suggesting a critical role of nanoscale 
organization of integrins in the control of cell behaviors [279].  Given such sensitivity of 
integrin clustering to the spacing and local organization of ECM ligands, the myriad of 
cellular behaviors found responsive to the nanotopography might result from the 
sensitivity of FAs to nanoscale surface features that apply spatial restrictions on integrin 
clustering. In particular, as the nanoscale islands in many nanotopographical biomaterials 
are usually of a dimension of tens or hundreds of nanometers, they might limit the 
clustering of integrin and recruitment of FA proteins for morphological maturation 
(Figure 5-11).  Although originally found in somatic cell lines, such regulation 
mechanism has been confirmed in dictating stem cell adhesions and phenotypes as well. 
For examples, results from different independent studies [135, 214, 218, 230, 280, 281] 
all suggested a threshold size around 50-70 nm for surface nanotopographical features 
that allowed clustering of integrins into the nearly closest packing and resulting in 
optimal integrin activation and FA maturation in stem cells.  
During the maturation of nascent adhesions to focal adhesions (FAs), the 
recruitment of critical force-bearing adaptor proteins such as vinculin, α-actinin and 
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zyxin provides the indispensable connection to actomyosin contractile fibrils and the 
transmission of intracellular forces onto the adhesion complex through a positive-
feedback loop (Figure 5-11) [272, 282-291].  The force-dependent FA maturation has 
long been thought to be responsive to extracellular nanotopography along with other 
physical cues such as substrate rigidity [225, 285, 286].  Recently, a few interesting 
studies revealed several mechanisms by which nanoscale cues regulate different aspects 
of FA maturation.  In a recent study from the Sutherland group, it was found that 
nanoscale fibronectin islands of diameter 100-800 nm and inter-island distance about 
300-500 nm in average strictly confined the FAs onto individual islands, which prevented 
FAs from further enhancement of recruitment and thus morphological maturation [292]. 
Interestingly, by using vitronectin nanopatterns instead, they found unhindered FA 
morphological maturation mediated by the “bridging” between individual nanoislands, 
which was found to be facilitated by adaptor proteins such as vinculins and zyxins but not 
integrins.  Although such bridging effect has been also implicated in earlier study by 
Coyer et al. [293], the abovementioned results for the first time suggested a differential 
role of ECM ligands in the determination of FA morphological maturation in response to 
nanoscale surface features. Interestingly, a very recent study also from the Sutherland 
group found that unlike the morphological maturation, the recruitment of adaptors 
proteins (e.g., vinculin, α-actinin, and myosin IIa) per se, which was commonly 
associated with mature FAs and named the “biochemical maturation” of FAs, was not 
inhibited by nanoscale confinements of corresponding ECM ligands on 100-300 nm 
fibronectin nanopatterns [294].  This result clearly distinguished the nano-confined FAs 
from nascent adhesions in terms of their core biochemical compositions, even though 
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they share a similar nanometer length scale. Importantly, this study revealed it was the 
morphological maturation, instead of the biochemical maturation, that played a critical 
role in dictating the epidermal stem cell differentiation [294].  It implicated that the 
stability of FAs accompanying with the morphological maturation might hold the key to 
the nanotopography-driven stem cell fate regulation. This proposition was in line with 
earlier study by Kulangara et al., wherein the downregulation of zyxin – the force-
dependent adaptor protein sustaining FA stability – was observed on 350 nm 
nanogratings [295].  Nonetheless, how both FA morphological and biochemical 
maturations might play roles in general nanotopography-sensing and fate control of 
different types of stem cells is worth of further investigations, which should also take the 
FA-related mechanotransduction signaling pathways into consideration, as we will 
discuss in following. 
As an important mechanosensor, integrin-mediated cell-ECM adhesions relay the 
topographical cues from ECM to intracellular signaling networks since its early stage.  A 
very important signaling axis serving as cytoplasmic transducers of extracellular 
mechanical signals at downstream of cell-ECM adhesions is the FAK-Src signaling 
pathway [272, 296, 297].  Activated by integrin ligation, FAK is recruited to cell-ECM 
adhesion. Binding of FAK to integrin activates FAK through autophosphorylation on 
Y397. Further phosphorylation on FAK is completed by the binding to Src family 
proteins to integrin and FAK. Together, FAK and Src relay the signals from integrins to 
control Rho GTPase activities through, for instance, FAK/p190RhoGEF/RhoA, 
FAK/p190RhoGAP/RhoA and Grb2/SOS/Rac pathways [296].  It also controls the 
MAPK signaling pathways that govern cell proliferation, apoptosis and differentiation, 
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through FAK/Ras/Raf/MEK/ERK, Fyn/Shc/Grb2/SOS/Ras, and p38 MAPK pathways 
[298-301].  Although it has been found that nanotopographical substrates promoted FAK 
phosphorylation[302], given the dual, opposite effects of FAK on RhoA activation [296, 
303, 304] (e.g., activation through p190RhoGEF [305, 306] and inactivation via 
p190RhoGAP [307, 308], respectively), it remains an open question that whether the high 
FAK phosphorylation induced by nanotopographical substrate would result in high or 
low Rho activity.  Given their roles identified in previous studies, other signaling 
downstream of integrin and FAK activation, such as the PI3K/Akt pathway [309] and 
TGFβ/SMAD [310] pathway might also have potential roles in nanotopography-sensitive 
mechanotransduction and stem cell mechanobiology through regulation of cell 
proliferation, self-renewal and differentiation [259, 311, 312].  Further studies are needed 
to verify whether these signaling axes were actively regulated during the 
nanotopography-sensing by early cell-ECM adhesions and how. 
The maturation of FAs, along with the activation of its adaptor proteins as well as 
the cell tension, relays the extracellular mechanical signals further into another signaling 
axis intersecting with cell-ECM adhesions – the RhoA-ROCK pathway originating from 
G-protein coupled receptor (GPCR) signaling [313-316].  As a prominent 
mechanotransduction pathway, RhoA-ROCK signaling axis not only relays signals from 
integrin-mediated cell-ECM adhesions, but also forms a feedback loop in control of 
several mechanosensors.  As induced partly by the integrin/FAK activation, the activity 
of Rho family proteins, such as RhoA, could further activates two critical effectors - 
ROCK and mDia - that regulate the structural quality of filamentous actin cytoskeleton 
and the contractile activity of non-muscle myosin II motor proteins.  Specifically, ROCK 
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serves a dual function on enhancing both actin polymerization and cell tension 
generation, through LIM kinase-driven inhibition of cofilin (an actin severing protein) 
and myosin light chain kinase (MLCK)-driven non-muscle myosin II activity, 
respectively. In the meantime, mDia performs its role mainly in promoting actin 
polymerization by enhancing the activity of profilin (an actin polymerizing protein) 
[313].  These downstream effects could then feedback to the maturation of cell-ECM 
adhesions and further enhance their roles in Rho activation.  As a hallmark of activated 
RhoA-ROCK signaling, the non-muscle myosin II-driven cell tension has been found 
compromised on nanotopographical substrates in one of our recent studies [136]. 
However, it is still unclear that if such nanotopography-sensitive cell tension was 
regulated through repressed RhoA-ROCK signaling, which calls for further studies. 
In addition to the integrin-mediated cell-ECM adhesions, another group of plasma 
membrane-associated mechanosensors is the cell-cell contact mediated by cadherins in a 
calcium-dependent manner [266].  Well-known cadherins include E-cadherin, N-cadherin 
and VE-cadherin, which are commonly seen in epithelial, neural and vascular endothelial 
tissues, respectively [317].  Here, we will briefly discuss in focus the E-cadherin given its 
prevalence and importance in pluripotent stem cells, as well as the recent evidence 
demonstrating its sensitivity to nanotopography [135, 266].  
Unlike integrin, E-cadherin per se is not known for its force-dependent activation 
and clustering. Instead, E-cadherins recruit intracellular β-catenin upon Ca-mediated 
homophilic ligation within cell-cell contacts.  β-catenin subsequently recruit both p120-
catenin and α-catenin and then connect to actin cytoskeleton [318, 319].  However, the 
direct E-cadherin/β-catenin/α-catenin/actin linkage was demonstrated very unstable, if 
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ever possible, and no complex containing all four components has been isolated from 
cells [318, 319].  Interestingly, a recent study found that mechanical force is required for 
robust and stable connection from E-cadherin to actin cytoskeleton via the force-driven 
recruitment of vinculin by α-catenin [320].  As a direct force-sensor, α-catenin unfolded 
under intracellular force possibly transmitted through its transient connection with 
actomyosin contractile fibrils, exposing a cryptic domain for vinculin binding. As an 
important force-sensitive adaptor protein, the recruitment of vinculin substantiated the 
stability of E-cadherin-mediated adhesions under force through further lateral recruitment 
and mechanical linkage to actin cytoskeleton [321].  The positive-feedback loop 
suggested by recent studies between mechanical force and E-cadherin-mediated cell-cell 
contact [322-324] is reminiscent of that in FA maturation, supporting the identity of cell-
cell contacts as an important plasma-membrane associated mechanosensor. In the light of 
these discoveries, α-catenin in cell-cell contact shares a similar role as talin in cell-ECM 
adhesions, initiating force-dependent development and maturation of adhesion complex 
[291].  In fact, more and more crosstalk between cell-cell contacts and cell-ECM 
adhesions through either physical interconnection or intracellular signaling has been 
found in recent years [325-332].  
Such similarity and connection between cell-cell contacts and cell-ECM 
adhesions raise an interesting question: whether extracellular nanotopography could 
impose its regulations beyond the cell-ECM boundary to control the cell-cell interactions. 
Interestingly, as discussed above, we found that nanotopographical substrates with 
random roughness of characteristic sizes about 100 nm disrupted E-cadherin-mediated 
cell-cell contacts while promoting spontaneous differentiation of human ESCs [135].  
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Along with this observation and the notion of crosstalk between cell-cell and cell-ECM 
adhesions, it was not surprising to observe and understand that flat substrates 
preferentially induced prominent, stable cell-ECM adhesions, while small and instable 
FAs were mainly found on nanorough surfaces that rendered less accessible surfaces for 
cell adhesion and spreading [136].  Similar effect of nanotopography on FA morphology 
was also reported recently by the Dalby group [333].  Taken together, it implicated that 
the regulation by extracellular nanotopography might reach far deep into the cell through 
mechanosensing and mechanotransduction axes involving cell-ECM adhesions, cell-cell 
contacts and their interactions.  
5.4.2 Cytoskeletal Integrators  
As a cellular architecture physically anchored to both cell-ECM and cell-cell 
adhesions, and also an effector directly downstream of RhoA-ROCK signaling axis, the 
integrity of actin cytoskeleton, especially the formation of contractile actin stress fibers, 
serves as a critical integrator of a multitude of extracellular mechanical signals [334]. 
Given recent reports that disorganized F-actin cytoskeleton as well as compromised 
contractility was observed in cells cultured on nanorough substrates [135], we are 
particularly intrigued by the possibility that F-actin might serve as a cytoskeletal 
integrator of nanotopography-driven signaling in cell mechanotransduction.  Herein we 
will briefly discuss the current understanding of the role of F-actin in cell 
mechanotransduction, which might help lay down the foundation for future exploration of 
the mechanisms of cellular responses to nanotopography. 
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Recently, Hippo/YAP pathway, which was originally discovered in studies on 
regulations of cell growth and organ size, has been found as a downstream effector of the 
quality, dynamics as well as the intrinsic contractility of F-actin cytoskeleton, which has 
been thought as a potent regulator of stem cell mechanotransduction by integrating 
various upstream mechanical inputs and leading them to a convergent downstream 
signaling hub [335-340].  Interestingly, experimental evidence accumulated in past years 
started to implicate an emerging pattern in the mechanical regulation of Hippo/YAP 
pathway: extracellular mechanical cues (e.g., rigid substrate, external stretch, large cell 
size) promoting stable cell adhesions were all found enhancing the formation of 
prominent F-actin cytoskeleton and resulting in high nuclear YAP activity, while those 
cues (e.g., soft substrate and small cell size) demonstrated destabilizing cell adhesions 
were found compromising the integrity and robustness of F-actin and resulting in low 
YAP activity and dominant cytoplasmic YAP retention due to the association with 14-3-3 
proteins [335, 336].  Such a role of F-actin cytoskeleton as potent mechanical signal 
integrator has been supported by recent studies in both 2D and 3D contexts on a myriad 
of cellular behaviors and functions [336].  Further, the convergent signaling through F-
actin to suppress YAP activity has also been shown important in regulating motor 
neuronal differentiation of human ESCs on soft substrates in our recent study [223].  
In addition to the Hippo/YAP pathway, the integrity and polymerization of actin 
cytoskeleton has also been implicated in the regulation of SRF (serum response factor) 
signaling [341, 342].  In particular, the enhanced polymerization of cytoplasmic actin 
monomers (G-actin) has been found to release MAL, a transcription co-factor, from its 
association with G-actin and thus to initiate the nuclear translocation of MAL, resulting 
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in elevated SRF signaling.  For example, large cell size that elevated the cytoplasmic G-
actin level has been found to inhibit SRF signaling as well as the differentiation of 
epidermal stem cells [341]. 
Combining these observations with my recent observation of disorganized, 
compromised F-actin cytoskeleton in human ESCs cultured on nanotopographical 
substrates [135], we speculate that nanotopography might either activate F-actin damage-
dependent Hippo pathway and suppress nuclear YAP activity, or inhibit the nuclear 
translocation of MAL and the subsequent SRF signaling (Fig. 8).  Yet, how Hippo/YAP 
and/or MAL/SRF signaling might play roles in stem cell fate determination in response to 
nanotopography has not been addressed so far, to which the answer likely depends on 
stem cell sources and species as well.  This question calls careful future studies.  
5.4.3 Nuclear Mechanosensors and Transcriptional Actuators 
Although deeply embedded within a cell, the nucleus is an emerging, active 
mechanosensor as suggested by recent researches [343, 344].  As the most important 
mechanical components of the nucleus, the nuclear lamina that is mainly composed of 
intermediate filament proteins lamin A and C endows significant mechanical stiffness to 
the nucleus, and lamin A/C has been demonstrated critical for cell mechanotransduction 
and transcription regulation through signaling molecules such as MAL, emerin and F-/G-
actin [212, 343, 345-347].  In contrast, nuclei of embryonic stem cells that lack lamin 
A/C have been shown to be extremely soft and the emergence of lamin A/C has been 
proposed as an embryonic stem cell differentiation marker [348].  Counterintuitively, 
nucleus is also not just an isolated DNA factory.  Through its connection to cellular 
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cytoskeleton via KASH and SUN domain proteins (together also known as the LINC – 
linker of nucleoskeleton and cytoskeleton – complex) across the nuclear envelope as well 
as perinuclear adaptor proteins like nesprin and plectin, the nuclear lamina right 
underneath the inner membrane of nuclear envelope is structurally integrated into the 
cellular mechanical signaling network of actin filaments, microtubules and intermediate 
filaments [343, 349, 350].  Along with the abovementioned candidate 
mechanotransduction mechanisms potentially functioning in cellular responses to 
nanotopography, we are particular interested in the question that if the cell nucleus could 
serve an unexpected role in mechano-responsive stem cell fate regulation.  Herein, we 
will review recent reports revealing several nuclear structures as distinct mechanosensors, 
and discuss a few possible transcriptional actuators that might lead the nanotopography-
driven mechanotransduction to its culmination. 
 Using a cysteine shot gun technique in combination with in vitro shear force 
application [351], the Discher group has identified a group of proteins, including nuclear 
lamin A, that change their conformations and expose cryptic hydrophobic domains under 
unfolding forces [352].  Although such direct force-sensitive conformational change was 
not seen in nuclear lamin under physiological conditions, they did observed a clear 
scaling relation between nuclear lamin expression and in vivo ECM rigidity, suggesting a 
potential link between rigidity-sensitive cytoskeletal contractility and force-dependent 
nuclear lamin A functions [352].  This work also implicated that nuclear mechanical 
stiffness, as mainly endowed by lamin A/C, might scale with extracellular matrix rigidity, 
and this was recently confirmed by nanoindentation study conducted by Liu and 
colleagues [353].  Recently, Poh et al. have found that an intact linkage between 
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cytoskeleton and nucleoskeleton could transmit integrin-mediated twisting forces from 
cytoplasm membrane to Cajal bodies in the nucleus and thus directly dissociate the coilin 
and SMN protein complexes [354].  Furthermore, transmission of cytoskeletal stress 
within the actin stress fibers and microtubules has also been found critical for mediating 
the long-distance force-sensing, which potentially involves the nucleus [350, 355].  In 
addition, cell shape has also been used as an external regulator of nuclear mechanics to 
probe the mechanisms of nuclear mechanosensing.  By confining cells to high-aspect 
ratio morphology, the nuclear shape changed according at a loss of volume.  At high 
nucleus aspect ratio, the significant distortion of nucleus has been observed to result in 
prominent chromatin condensation, indicating that the mechanical deformation of nucleus 
might be a direct mechanosensor that controls the chromatin structures and apoptosis 
[356].  
In a very recent study, direct experimental evidence has been provided that an 
inner membrane-located protein, emerin, was a force-sensor and underwent force-driven 
phosphorylation [357].  Using isolated nuclei, this study demonstrated nuclear stiffening 
in response to external cyclic pulling forces, mimicking the cytoskeletal tension exerted 
upon nucleoskeleton.  They found it was driven by the recruitment of lamin A/C by Src-
mediated tyrosine-phosphorylated emerins under tension. Similar tension-dependent 
emerin phosphorylation has also been found sensitive to the rigidity of the cell-culture 
substrate and the mechanical force applied through integrin ligation, respectively. 
Although we are still at the beginning of understanding the mechanosensing in nucleus, 
all these discoveries above strongly suggested cell nucleus as a potent mechanosensor 
through multifaceted mechanisms such as direct force transmission, nucleus shape 
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distortion, nuclear lamina protein expression and phosphorylation.  We envision the study 
on nuclear mechanosensing and mechanobiology will initiate a new, active research field 
in addition to the ones established on cytoplasmic mechanosensing mechanisms.  
To the best of our knowledge, the study of nuclear mechanics in the context of 
stem cells sensing extracellular nanotopography has been rare.  Although it was found 
that nanotopography could induce nuclei deformation [358, 359], quantification of the 
mechanical forces on the nucleus in intact cells has not yet been demonstrated. Recently, 
the Dalby group has also reported mechanosensitive chromosomal repositioning in 
response to disordered nanopit arrays, wherein extracellular nanotopography posed 
chromosome 1 closer to the nuclear membrane during human MSC osteogenesis, and 
increased the mean inter-territory distance of chromosome 1 in the meantime [360].  
They have also found that the position of gene regulation along the chromosome was 
sensitive to substrate nanotopography [361], and subsequently identified that the 
nanotopography-enhanced gene regulation concentrated towards the telomeric end of the 
chromosome, where osteogenesis-regulated genes also clustered [360].  Yet, the direct 
connection between the nanotopography and chromosomal repositioning as well as gene 
regulation remains elusive.  Taken together, it raises an intriguing question that whether 
the topography-sensitive nuclear deformation and nuclear mechanical forces could 
initiate corresponding changes in nucleus stiffness and nuclear structure rearrangement, 
and how it might relate to stem cell fate determination. It calls for further studies. 
Recently, a few mechanosensitive nuclear actuators that relay extracellular 
mechanical signals to control the transcriptional activity and gene expression in the 
nucleus have been revealed. As a nuclear transcription co-factor, YAP could bind to 
136 
 
transcription factors TEAD and also co-translocate SMAD 2/3 (regulatory SMAD, R-
SMAD) to the nucleus, thus relaying the cytoplasmic mechanotransductive signals to 
transcriptional control machineries [223, 362-364].  As regulator of pro-survival and pro-
proliferation effectors, YAP activity has always been found correlated with pro-survival 
and pro-proliferation extracellular mechanical cues [365].  However, stem cell 
differentiation seems requiring either Hippo-dependent or -independent suppression of 
YAP activity, and it is still unclear what might fill in the transcriptional control position 
previously occupied by YAP [363, 366].  In principle, we reckoned that extracellular 
mechanical cues that induced the suppression of YAP might either stimulate or inactivate 
other transcriptional actuators in the same time, which eventually could determine the 
fate of stem cells.  In the light of the altered F-actin cytoskeleton observed on 
nanotopographical substrates, and the newly emergent role of cytoskeleton-
nucleoskeleton interaction and nuclear forces in regulating nucleoskeletal structures, 
chromatin structures and nuclear lamina protein expression and phosphorylation, we 
speculate that future studies on nuclear mechanotransduction might help us find the end 
link on the signaling axis through which substrate nanotopography controls stem cell fate. 
In fact, the expression of emerin in nucleus and the requirement of lamin A/C for its 
correct localization to nuclear membrane has recently been found playing an important 
role in MAL/SRF signaling [347, 367].  In particular, emerin promoted nuclear actin 
polymerization that in turn inactivated MAL nuclear export and thus promoted the 
transcriptional activity of MAL.  In addition, high level of emerin phosphorylation has 
also been found correlated with cells cultured on rigid substrate and high level of nuclear 
YAP localization and activity [357].  Mechanical tension through nesprin-1 onto isolated 
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nuclei was also found to induce RhoA activation in nucleus, although its exact  role in 
transcriptional control remains unclear [357].  To date, how these mechanisms might be 
involved in cellular responsiveness to substrate nanotopography is elusive.  In the near 
future, studies on the nanotopography-sensitivity of nuclear deformation, nuclear 
envelope mechanics, lamin A/C expression, nuclear lamina protein expression and 
phosphorylation, and nuclear transcription activation might help to validate our 
hypothesis regarding this end game of the mechanotransduction in stem cells (Figure 
5-11).  
5.5 Conclusion 
Stem cells are promising cell sources for the future tissue engineering and 
regenerative therapies.  The current challenge faced by stem cell engineering mainly has 
to do with the large-scale, long-term maintenance and high-specificity, high-yield, 
directed differentiation towards clinically relevant lineages.  Advances in nanotechnology 
and materials science could help leverage the regulation of stem cell fates and function 
via microenvironmental physical factors such as the nanotopographical cues to enhance 
the performance of synthetic biomaterials in future stem cell engineering. 
 In this chapter, a state of the art nanofabrication method was discussed for 
generating nanotopographical biomaterials for regulating stem cell fates and function.  
The proposed synthetic nanotopographical biomaterial has been successfully applied to 
control various phenotypes of hESCs, such as adhesion, migration, morphology and 
proliferation, and eventually in determining transcriptional activities and fates. By 
designing nanotopographical features mimicking in vivo stem cell niches, a diverse 
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toolbox of nanotopographical biomaterials have enabled either long-term maintenance or 
directed lineage commitment of different types of stem cells including hESCs, producing 
promising solutions for clinical regenerative treatments.  Although successful as it is as 
proof of concept, the stationary nanotopographical biomaterials alone might not be 
sufficiently satisfactory for meeting all the criteria set by the demanding clinical 
applications.  Soluble and insoluble biochemical cues, dynamic control of topographical 
features, as well as the in vitro co-culture of cells that share a common stem cell niche in 
vivo, have also been demonstrated to play in synergy with physical cues in regulating 
stem cell fates [211, 212, 368-372].  In future, the design and fabrication of 
nanotopographical biomaterials might need to be integrated with multifunctional 
biochemical modifications and even spatiotemporal patterning for simultaneously 
controlling multiple aspects of in vitro stem cell microenvrionment and fine tuning the 
specific terminal lineage commitment of stem cells at a large scale, eventually delivering 
the promise of stem cells to the regenerative medicine. 
 In order to shed light on our knowledge of stem cell biology and development, as 
well as to further improve the performance of nanotopography-driven stem cell fate 
regulation and fully realize the virtually unlimited potential of stem cells, it is also 
important to understand better the mechanosensing and mechanotransduction 
mechanisms underlying the cellular responses to extracellular nanotopography.  In this 
chapter, I summarized a few key mechanosensing and mechanotransduction mechanisms 
that have been implicated, although not completely proven, to play important roles in the 
regulation of stem cell fates via nanotopographical biomaterials.  Based on the current 
understanding of stem cell mechanobiology, I also proposed a few speculations regarding 
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how different mechanosensitive signaling events might eventually be integrated and 
converge onto several core mechanotransduction axes, which constitute the "chain of 
commands" from extracellular nanotopography to nuclear gene expression.  Future 
studies on the nanotopography-responsive mechanotransduction might have to involve 
molecular mechanosensors, transducers, integrators and actuators residing in different 
cellular compartments and organelles.  Elucidating the interconnections between each 
links in cell mechanotransduction remains another major challenge that needs to be 
addressed in the near future.  
Looking into the future, the ultimate success of stem cell engineering will be the 
in vivo demonstrations of functional engraftment and tissue regeneration. A 
multidisciplinary approach merging stem cell biology, materials science, biomedical 
engineering and nanotechnology will be the most promising route towards the eventual 
realization of clinical stem cell therapies. 
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Chapter 6 
Conclusions and Future Work 
 
6.1 Summary 
Taking advantage of state-of-art nanotechnologies and fabricating fascinating 
functional biomaterials, we can address numerous important problems in fundamental 
biology as well as clinical applications in disease diagnosis and treatment.  My doctoral 
research, therefore, has focused upon developing microengineered functional 
biomaterials and integrated microfluidics for biomedical applications in systems 
immunology, cancer biology and stem cell-based regenerative medicine.   
6.1.1 Integreted Microfluidics for Functional Immunophenotyping  
Developments of reliable, multiplexed biosensing techniques permitting 
simultaneous characterization of functional status of different subpopulations of immune 
cells is an exciting emerging concept that holds great promise not only for unraveling the 
pathogenesis of different immune diseases but also for translating the newly available 
therapeutic options into optimal personalized treatments.  To address this need, my 
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doctoral dissertation has centered on developing integrated microfluidic 
immunophenotyping device that could achieve rapid and efficient isolation, enrichment, 
stimulation and functional immunophenotyping of subpopulations of immune cells 
directly from blood specimens.  This intgergated MIPA device enabled us to achieve 
rapid and sensitive on-chip immunophenotyping assays for subpopulations of immune 
cells isolated directly from minute quantities of blood samples [8].  The MIPA device 
could achieve high capture yield (> 90%) and excellent capture purity (> 97%) for 
subpopulations of immune cells from blood samples.  For quantitative immunosensing, 
the MIPA device utilizes a commercially available homogenous chemiluminescence 
technique, the "AlphaLISA", which does not require any washing or blocking step, 
greatly shortening the total assay time and enhancing the dynamic range for analyte 
detection.  Owing to the miniaturized on-chip microfluidic environment, the MIPA 
device can achieve highly sensitive cellular immunophenotyping with 20-fold fewer cells 
as compared to standard whole-blood stimulation assay to assess functional status of 
patient immune system.  The total assay time of the MIPA device, including immune cell 
isolation and enrichment, stimulation and in situ detection of cytokines secreted by 
immune cells only need 4 hours, which is 6 times faster than that of whole-blood 
stimulation assay using conventional ELISA.  The MIPA device can provide a very high 
sensitivity for cytokine measurement, about 75 pg mL-1, which is comparable to ELISA.  
As a proof-of-concept of the importance of the new platform, we have applied this newly 
developed microfluidic technologies to address the critical need for an accurate 
measurement of the immune status in patients.  We have applied this innovative 
microfluidics-based immunomonitoring technology to identify the incidence of 
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immunoparalysis and determine its predictive power for post-operative infections in 
pediatric patients undergoing cardiac surgery with cardiopulmonary bypass.  Such an 
innovative tool will allow comprehensive and systems-level immunomonitoring to define 
and characterize the “immune status” of healthy individuals and patients, critical for 
clinical interventions and managements of patients with immune system disorders.   
6.1.2 Nanoroughened Surfaces for Capture of Circulating Tumor Cells 
Nanotechnologies including advanced nanofabrication and functional 
nanomaterials have provided new opportunities for many biological and medical 
applications.  My doctoral study has leveraged novel nanofabrication techniques to 
develop synthetic nanotopographical biomaterial to address specifically these broad 
challenges in understanding the CTC biology.  We introduced a simple yet effective 
microfabrication strategy for precise control and patterning of the local nanoroughness on 
glass surfaces using photolithography and RIE which are well-established processes used 
in semiconductor microfabrication.  Incorporating this nanotopographic surface into a 
microfluidic platform, we have proven a new approach that can efficiently isolate, enrich, 
and rapidly perform informative molecular and cellular analysis of live CTCs at the 
single-cell level.  Our method uniquely utilized the differential adhesion preference of 
cancer cells to nanorough surfaces when compared to normal blood cells and thus did not 
depend on their physical size or surface protein expression, a significant advantage as 
compared to other existing CTC capture techniques.  Our CTC capture chip, which 
includes the nanotopographical glass substrate and a microfluidic mixing chamber, can 
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provide a superior performance for efficient and non-invasive capture of rare and viable 
CTCs from blood.   
It is well known that EMT process of tumor cells, a process by which epithelial 
cells lose their cell polarity and cell-cell adhesion, and gain migratory and invasive 
properties to become mesenchymal cells, is essential for the initiation of metastasis for 
cancer progression.  However, most current EpCAM-antibody based CTC isolation 
methods can only isolate cancer cells with high expression of EpCAM (epithelial-like 
cells) and may loss the mesenchymal-like CTCs, hence precluding the capabilities for 
studying the crucial EMT process.  Because our CTC capture chip captures CTCs not 
based on cancer surface makers, it had been proven to be able to capture both epithelial-
like and mesenchymal-like cancer cells, particularly suitable for study the role of CTCs in 
EMT and metastasis.   
Furthermore, we have unitized the new CTC detection technology to monitor and 
study the CTCs in mouse xenograft as well as allograft models in vivo, hence provide the 
foundation for studies of molecular regulation of CTCs in cancer and CTCs as biomarker 
for therapeutic efficacy.  So far, studies of CTCs in metastasis have been limited by the 
inability to repetitively monitor CTCs in cancer patients.  Previous studies of CTCs in 
endogenous mouse models though have provided insightful understandings of metastasis, 
there is still a big gap between findings from endogenous mouse models and clinical 
interpretation in human.  In order to fill this technical gap, developing our own human 
cancer cell based murine xenograft models specific for CTCs becomes particularly 
important.  Adapting existing technology used to serially assay CTCs in human for 
studies in mice would allow for direct translation to clinical investigations and permit 
144 
 
early development of ‘‘companion’’ diagnostic assays for targeted therapies in mouse 
models of cancer.  Theirfor, we have performed serial analysis of temporal changes in 
CTCs in mouse xenograft as well as allograft models of breast and lung cancer during 
tumor progression and response to therapy in living mice.  We have demonstrated strong 
correlations in CTC quantity, the tumor volume and the cancer metastatic capability, 
hence revealed the pathophysiological role of CTCs in cancer metastasis.  Togethor, this 
new CTC capture technology for isolation of CTCs will allow informative analysis of 
live CTCs for accurate diagnosis and prognosis of cancer and help understand the crucial 
early metastatic process of cancer and hopefully discover new targets or phenotypes in 
the CTCs that can aid in the design of more effective molecular treatments. 
6.1.3 Biophysical Phenotyping of Inflammatory Breast Cancer Stem 
Cells 
Cancer stem cells have been proven to initiate tumorigenesis and are the primary 
population of cells responsible for cancer metastasis in numerous cancer types [32, 157-
162].  Within IBC, the ALDH+ population has been shown to represent the tumorigenic 
and metastatic subpopulation [32], but detailed studies characterizing the IBC CSC’s 
mechanical properties were lacking.  ALDH expression is also negatively correlated with 
survival outcome [32], thus we postulated that the ALDH+ CSCs of IBC would exhibit 
distinct biomechanical properties that would help explain their extremely aggressive 
metastatic behavior.  In order to more specifically ascertain and potentially explain the 
mechanical basis for the aggressive behavior of IBC CSC’s, we undertook novel 
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experiments and engineered devices targeted at quantitatively defining cells’ mechanical 
properties. 
This biophysical characterization of ALDH+ IBC CSCs revealed distinct 
biophysical properties that might mechanistically explain the functional differences seen 
between the IBC CSCs and non-CSC population.  These biophysical properties included 
a greater cell deformability, weaker adhesion strength, and less cellular traction force.  
This unique profile of biophysical characteristics associated with ALDH+ IBC CSCs 
could help explain how CSCs are better adapted than non-CSCs to successfully navigate 
through their dynamic microenvironment in the metastatic process.   
In the first step of the metastatic cascade, decreased adhesion of IBC CSCs, as 
demonstrated by their lower measured adhesion strength, might indicate why these cells 
are able to migrate away from the primary tumor.  The strongly adherent ALDH- cells 
might not be able to overcome their attachment, which is further supported by ALDH- 
cells’ reduced migration capacity in our in vitro studies.  Additionally, IBC CSCs, a 
highly metastatic cell population, showed significantly lower traction forces compared to 
their non-CSC counterparts, suggesting inherent differences in cell force generation 
correlated with aggressiveness.  In the next steps of the metastatic cascade, migrating 
cancer cells must invade through the basement membrane and squeeze through 
endothelial cell tight junctions during intravasation and extravasation.  As measured in 
our assays, the greater capacity for deformation of ALDH+ cells suggests significant 
plasticity towards cytoskeletal changes or reorganization and underlying mechanical 
differences in IBC CSCs.  This may account in part for their invasive capability to more 
successfully transit through a confining biophysical microenvironment.  Cell 
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deformability may thus be used as a label-free biophysical marker for identification and 
understanding of other CSCs in future studies.  Together, the biophysical profiling of IBC 
CSCs has provided comprehensively delineation of the live cell phenotypic 
characteristics of the model of the most metastatic breast cancer subtype, and yields a 
new understanding of IBC’s metastatic properties and how they might develop and be 
targeted for therapeutic interventions. 
6.1.4 Nanotopography-mediated Mechanoseing of Human Embryonic 
Stem Cells 
Stem cells are critical players during development, tissue regeneration, and 
healthy homeostatic cell turnover, and they are an important driving force for the 
developing fields of functional tissue engineering and regenerative medicine owing to 
their self-renewal capacity and pluripotency.  In vivo, local tissue structure defines stem 
cell environment and therefore regulate stem cell functions.  Stem cells interact with and 
interrogate their surroundings at the nanometer length scale.  Therefore novel 
biomaterials that can encode specific nanoscale biological cues (e.g., mechanical signals, 
and/or adhesive and soluble factor gradients) offer unique opportunities for engineering 
stem cell functions.  My doctoral research, therefore, is oriented toward developing 
synthetic nanoscale ex vivo stem cell microenvironment to direct hESC behaviors, and 
further employing them to identify the unique mechano-sensitive and -responsive 
properties of stem cells and the effect of the physical aspects of the local cellular 
microenvironment on regulating stem cell behaviors.  On this purpose, we have 
developed synthetic nanotopographical materials to direct stem cell behaviors, and 
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further employing them to identify the extrinsic nanotopographical cue and their 
downstream signaling pathways that regulate stem cell functions [135].  My study 
demonstrated that hESCs were intrinsically sensitive to the nanoscale topological cues on 
the substrate and the nanotopography cue could provide a potent regulatory signal over 
different hESC behaviors, including cell morphology, adhesion, proliferation, clonal 
expansion, self-renewal and fate.  In this work, we have futher investigate if and how the 
intrinsic mechanosensitive properties of hESCs to nanotopography could be leveraged to 
improve derivation of functional spinal MNs.  Combining dual Smad inhibition with 
nanotopographic cue, we have achieved accelerated high-yield and -purity generation of 
NEs and spinal MNs from hESCs.  Nanorough glass substrats are fully defined substrates 
that can be easily mass-produced for large-scale hESC culture.  Our results further 
showed that just like many other human adult stem cells [254, 260, 261], hESCs are 
intrinsic mechanosensitive, and surface topography can serve as an in vitro extracellular 
switch to direct the NE vs. NC lineage decisions.  The mechanism study indicated that 
topological sensing of hESCs might include feedback regulation involving 
mechanosensory integrin-mediated cell-matrix adhesion, cell cytoskalten reorganization 
and cell-cell interactions.  Together, our stem cell studies have highlighted the important 
role of nanotopographic cue in stem cell microenvironment to direct hESC behaviors that 
are desirable for functional tissue engineering and regenerative medicine.  
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6.2 Future Work 
6.2.1 Integreted Microfluidic Immunophenotyping Device for 
Multiplexed Detection 
In my doctoral research, a microfluidics-based immunophenotyping device has 
been developed for functional cellular immunophenotyping of the immune status of 
patients with immue disorders. Yet, the proposed MIPA device currently only permits 
measurement of one cytokine from one type of immue cell subpopulation. Continued 
progress in many fields ranging from fundamental biological to patient care critically 
hinges on the availability of specific, reliable assay systems capable of multiplex 
detection from a single sample (multiplexed cell-secreted cytokine detection from 
multiple immue cell subpopulations).  Therefore, to address this critical technical need, 
contining research could be performed to establish a highly integrated, automated 
microfluidic immunomonitoring technology to achieve rapid, accurate and multiplexed 
detection of multiple cytokines secreted from different types of immune cell 
subpopulations from blood specimens.   
For example, based on our first-generation MIPA device, we can develop a fully 
integrated and automatic second-generation MIPA device that can achieve isolation 3 
subpopulations of immune cells (CD14+ monocytes, CD4+ and CD8+ T-cells) from 
human blood specimen and parallel stimulation and detection of multiple cytokines 
(TNF-α, IL-6, IL-10, and IFN-) secreted from these subpopulations of immune cells 
(Figure 6-1).  I select CD14+ monocytes, CD4+ and CD8+ T-cells as the immune 
effector cells as they are reported as major subpopulations involved in the response of the  
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Figure 6-1  Concept of new microfluidic device for multiplexed cellular  immunophenotyping. (A) 2nd 
generation MIPA device for parallel detection of multiple cytokines secreted from immune cells.  (B) 
Sequential operation steps for immunosensing.  
immune system to inflammatory stimuli, such as CPB [373-375].  The selected panel of 
these four inflammatory cytokines has also been reported to yield positive, predictive 
values indicating the development of organ damage [376] and bacterial infections [377]. 
The new device will integrate an array of 3 independent first-generation MIPA 
units for isolation of different tpes of subpopulations of immune cells (Figure 6-1A).  
Each cell isolation unit includes a PDMS microfiltration membrane (PMM) for cell 
isolation.  The new integrated MIPA device, when combined with different-sized 
antibody-conjugated microbeads targeting different surface proteins, could provide an 
effective solution for isolation and enrichment of multiple subpopulations of immune 
cells (CD14+ monocytes, CD4+ and CD8+ T-cells) simultaneously from blood 
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specimens.   To achieve quantitative parallel detections of multiple cytokines secreted 
from each isolated subpopulation of immune cells with AlphaLISA, each MIPA unit will 
have a microfluidic interconnect channel that fluidically connecting an array of 4 
cytokine conjugation and detection chambers to the main cell filtration chamber (Figure 
6-1A).  Each array of the cytokine conjugation and detection chambers will be used for 
multi-detection of the 4 types of cytokines.  After LPS (for monocytes) or PMA (for T-
cells) stimulation and incubation, cytokines secreted by the isolated cells will be 
delivered along each of the interconnect channels using microfluidic pumps integrated in 
the MIPA device.  The reagent loading (i.e., AlphaLISA detection beads), mixing, and 
conjugation will be accomplished sequentially by modulating the on/off states of 
integrated microfluidic valves (Figure 6-1B). The new integrated device is automatically 
controlled by microfluidic valves that are actuated using an external air pneumatic 
actuation controller connected to a LabView software-installed personal computer.     
The sophisticated device structure incorporating a large number of microfluidic 
pumps and valves warrants a careful design and validation to achieve efficient analyte 
transport and reagent mixing.  We should carefully design these microfluidic components 
and their arrangement using the commercial finite-element method (FEM) software 
(COMSOL 4.2a Multiphysics) and experimentally validate their performance.  After 
developing new deivce, we will then repeat our assays (similar to Chapter 2) to carefully 
examine the capture efficiency and purity for immune cell subpopulations as a function 
of the PMM through-hole size, porosity, flow rate and total sample volume, and to 
establish the standard curve for detection of all proposed cytokines by AlphaLISA and 
correlate the concentration values between AlphaLISA and ELISA measurements.   
151 
 
The new parallel functional immunophenotyping assay device are expected to 
simultaneously measure cell secretion of 4 cytokines, while reducing the entire assay 
time down to about 2 hrs, a nearly 10-fold reduction in time compared to the standard 
whole blood assay using ELISA.  Based on our preliminary results charactering the limit 
of detection (LOD) in Chapter 2, we expect the sensitivity of our assays to be sufficiently 
high and in the range of tens of pg/mL, comparable to that of ELISA.  
In Chapter 2, we have performed preliminary study using the MIPA device to 
measure TNF-α secretion from monocytes to identify immunoparalyzed children 
following CPB. However, a potential limitation is the possibility that monocytes may not 
be the key/only predictor of immunoparalysis.  The incomplete understanding of the 
pathophysiology of immunoparalysis leaves the possibility that even though monocyte 
deactivation is extensively characterized in immunoparalysis, functional testing of other 
subpopulations of leukocytes may better predict immunoparalysis.  In this case, I believe 
the development of the new multiplexed device has a distinct advantage as it allows us to 
immunophenotype different subpopulations of immune cells simultaneously and to 
design subsequent studies to determine the contribution of immune cell subpopulations in 
the event that CD14+ monocytes do not most accurately identify immunoparalyzed 
patients.   
With new multiplexed device, we may futher perform real-time 
immunophenotyping of pediatric patients following CPB using the MIPA device to 
identify immunoparalyzed patients and determine its predictive power for post-operative 
infections.  Immunoparalysis in children following CPB has a highly predictable 
incidence (~20%) and increases the likelihood of developing a post-operative infection 
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[114, 378].  These studies argue for a real-time platform that provides clinicians this 
patient-specific information across a variety of cohorts.   
The incidence and time course of immunoparalysis as well as data on 
development of infections from any patient along with the functional status of the 
subpopulations of immune cells (CD14+ monocytes, CD4+ and CD8+ T-cells) will be 
collected and analyzed in relationship to the individual patient’s immunophenotype 
(dichotomized as immunoparalyzed or non-immunoparalyzed).  To immunophenotype 
the enrolled patients, patient blood will be collected right before the CPB, on the post-
operative days 1, 3, 5, 7, and then every 7 days until patient discharge from the ICU.   
Concentrations of TNF-α, IL-6, IL-10, and IFN- measured using the new device for the 
subpopulations will be compared and correlated with the results generated using the 
standard whole blood assay.  Based on previous studies using whole blood assay [11], 
immunoparalysis is defined as TNF-α production of less than 200 pg/mL.  Patients will 
be first dichotomized as immunoparalyzed or non-immunoparalyzed using this value 
from the standard whole blood assay.  Receiver operator curves (ROC) will then be 
generated to determine the cutoff values of these multiple cytokines for identifying 
patients as immunoparalyzed using the new MIPA device for the subpopulations of 
immune cells.  Next, more samples from patients enrolled in the study will be used to 
validate the cutoff values established from the first cohort of 40 patients.  Test 
characteristics including sensitivity, specificity, positive and negative predictive values 
will be determined on this validation cohort and further be compared between the two 
immune monitoring methods (i.e., the new multiplexed microfludic device for leukocyte 
subpopulations and the standard whole blood assay).  Additional clinical data, including 
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development of an infection from any source, length of stay in the ICU, length of stay in 
hospital, and mortality will be collected and correlated with the immunophenotype 
determined by both methods discussed above. 
In addition to the immunophenotyping of pediatric patients following CPB, the 
new technology can be applied as general tool for many different immune diseases.  For 
example, we may use the new immunophenotyping technology to define post-operative 
infections in the same manner as the SPECS Study: as culture positive infections, 
knowing that patients can develop infections and sepsis without positive cultures.  To 
address this concern, patients will also be followed daily to determine if the care team 
starts or alters antibiotics. Once there is a change in antibiotic administration, the care 
team will be contacted to determine the rational for starting/altering antibiotics. Factors 
leading to the decision to starting/altering antibiotics will be recorded, and patients will 
also be classified as presumed infection. Using this approach, while the primary analysis 
will be conducted with the primary outcome as culture positive infections, a secondary 
analysis could be performed with presumed infections. 
6.2.2 Biophysical and Molulular Characteristical Study of CTCs  
Dissemination of cancer cells from primary tumor in the form of metastasis in 
distant organs is responsible for 90% of cancer-related deaths, representing over 500,000 
people dying every year in the United States alone.  Consequently, metastases are among 
the most important biological problems to address in cancer research.  Although a cellular 
link between the primary malignant tumor and the peripheral metastases has been 
established in the form of CTCs in peripheral blood, a major challenge remains in 
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deciphering the biology of this very unique cellular population, and ultimately, improving 
our systems level understanding of "how cancer spreads and kills".  Despite the clinical 
and pathophysiological importance of CTCs, the current molecular and cellular 
understanding of CTCs is extremely poor, largely owing to the fact that current 
techniques to isolate and characterize these rare cells are limited by low yield and purity, 
complex techniques, and expensive proprietary equipments, compounded by yielding 
little phenotypic and molecular information about the CTCs themselves.  As such, there 
is still little knowledge about characteristics of CTCs such as timing of CTC release from 
primary tumors, their heterogeneity and molecular and cellular properties, and the degree 
to which they are representative of either primary or metastatic tumor deposits.  During 
my doctoral study, I have successfully developed a nanotopographical-material-based 
microfluidic platform for efficient and non-invasive capture of rare and viable CTCs from 
blood [29].  This pioneer work fulfills the critical need for isolation of rare CTCs and 
made informative analysis of live CTCs possible.  In my future research, I will leverage 
the novel CTC isolation technique and develop new functional biomaterials and 
engineering platforms for comprehensive study of cancer metastases and 
characterizations of CTCs, to provide new knowledge for cancer pathophysiology and 
more effective techniques for personalized therapy. 
First, I plan to perform comprehensive study of the biomechanical properties of 
CTCs.  Recent studies have shown that malignant phenotype, metastatic potential, and 
tissue tropism of cancer cells are correlated with their mechanical properties (such as 
deformability) [379, 380].  Thus, biomechanical properties of CTCs might serve as a 
specific diagnostic marker for cancer.  To approach this window of opportunity, I will 
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develop a microfabricated Cell-Mechanical-Phenotyping (CMP) chip for efficient 
trapping and high-throughput, highly-sensitive, and label-free quantification of cell size, 
deformability and expression levels of surface receptors of live single CTCs.  In this 
research, I will quantify and compare the deformation responses of CTCs with normal 
cancer cells and healthy human epithelial cells under various pressures in an array of V-
shaped trapping channels, in order to determine the specific mechanical characteristics of 
CTCs, including the cell shape, size distribution and stiffness.  The internal walls of the 
trapping channels can be functionalized with different antibodies against specific surface 
receptors of cancer cells.  As such, the expression levels of target surface receptors can be 
measured based on the immunoaffinities of the trapped cancer cells to channel wall.  I 
hypothesize that my experimental results will potentially reveal distinct mechanical 
properties (ex. higher mechanical deformability) of CTCs from the normal cancer cells 
and healthy human epithelial cells.  In addition, functional and phenotypic variation 
among individual single cells, or single-cell functional heterogeneity, is a common 
feature for tumor cells.  Thus, quantitative functional analysis of cancer cells down to a 
single-cell resolution is required for a precise characterization of CTCs.  Comprehensive 
study of the biomechanical properties and expression levels of different surface receptors 
of live single CTCs using this novel CMP-chip will for the first time provide us a 
complete pattern of the mechanical and biochemical phenotypes of CTCs at single cell 
level, hence pinpoint specific diagnostic markers for cancer.  This microfluidics-based 
platform can serve as a comprehensive and standardized monitoring platform to define 
and characterize the “mechanophenotype” of healthy individuals and cancer patients 
before, during, and after targeted therapies thus provides new knowledge of cancer 
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pathophysiology, critical for developing better, more effective interventions for 
personalized therapy. 
In addition to the study on biomechanical properties of CTCs, I will explore the 
potential correlations in CTC quantity in patient blood, the tumor volume and the time 
course of the anti-cancer treatments, hence reveal the pathophysiological role of CTCs in 
cancer metastasis.  I will utilize our recent developed nanomaterial-based CTC-capture 
chip to monitor serial changes in CTC quantity, and the tumor size in cancer (ex. breast 
or lung cancer) patients using computed tomograms (CT scans).  Additional clinical data, 
including development of a secondary tumor, length and type of anti-cancer treatment 
and overall survival will be collected and correlated with the temporal change of CTC 
quantity determined by my CTC-capture chip discussed above.  I envision that 
monitoring the correlations in CTC quantity and the anti-cancer treatment response using 
the new engineering platform may ultimately be a powerful tool enabling accurate, early 
clinical decision-making.   
Further, I will work closely with cancer specialist to perform fundamental study 
on molecular signaling in metastasis. I will perform RNA sequencing of isolated CTCs 
and identify possible candidate genes which are enriched in CTCs and important for 
metastasis.  For example, I may pursue Wnt2 and Fn1, two known candidate genes 
important in oncogenesis [381], as potential prototypes of CTC-enriched transcripts and 
accordingly may identify candidate therapeutic targets to prevent the distal spread of 
cancer.  Thus, through a combined using of both engineering tools and biological 
methods, we may generate an unbiased RNA sequencing profile for CTC-specific 
expression patterns.  This CTC-specific RNA sequencing profile, which is in a urgent 
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need but currently unavailable, may provide opportunities to find extraordinary 
subpopulations of cancer cells such as metastasis-initiating cells (MICs) and cancer stem 
cells (CSCs) among CTCs.  Overall, the comprehensive mechanical and molecular 
profiling of CTCs can help for broad screening of important cancer cell surface markers 
to search the crucial effective factors in metastasis and could be a paradigm of how 
advances in engineering tools boost development in medicine. 
6.2.3 Blood-on-a-Chip for Point-of-Care Diagnosis  
Blood is a treasure of information about the functional status of the whole body 
[105].  Every second of every day, blood is circulated around the body and takes the 
reasonability for a lot of critical living functions for human lives.  Blood is a complex 
mixture of many different components including red blood cells, white blood cells, 
platelets and plasma, and each component play an important role in many live functions 
[105].  For example, red blood cells deliver oxygen from the lung to all parts of the body 
then pick up carbon dioxide and remove it from tissues and organs.  White blood cells 
fight infection and play a major role in our immune system.  Platelets help the blood 
clotting process by gathering at the site of an injury and prevent a blood leaking.  Plasma 
is the liquid portion of the blood, a mixture of water, sugar, fat, protein, and salts.  The 
main job of the plasma is to transport blood cells throughout body along with nutrients, 
waste products, clotting factors, hormones and proteins that help maintain the body a 
proper working function.  In a circumstance of disease such as cancer, we may find 
abnormal components like rare CTCs in the blood which is indicator of a possible 
formation of tumor in the body [10, 12, 120].  As a result, blood harbors a massive 
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amount of information about the functioning of all tissues and organs in the body.  Blood 
cells constantly die and replaced by new ones, and the plasma components such as 
hormones and proteins are continuously refreshed when blood circulated throughout the 
body.  Whenever occurred an abnormal or dysfunction of any tissues and organs in the 
body, there will be an instant reflection in the change of the blood component.  As such, 
by analysis of blood we can gain not only the massive amount of but also the freshest 
information about the status a disease.  In addition to its massive information blood can 
provide, drawing blood is one of the most convenient diagnosis approaches in current 
clinical practice, hence it enables broad potential biomedical applications for numerous 
disease diagnosis.  As such, blood sample processing and analysis are of great importance 
for both medical and science applications, and hold a central role in the diagnosis of 
many physiologic and pathologic conditions, such as immune system dysfunction and 
cancer.  However, tapping into this wealth of information, for clinical and scientific 
applications, requires not only the understanding of the biology involved but also 
adequate technologies.  Yet, current available sample preparation procedures for blood 
analysis involve handling multiple steps prone to introducing artifacts, whereas analysis 
methods commonly require skilled technicians and well-equipped, expensive 
laboratories.  
Recent advances in microfluidics and microfabrication have made possible 
miniaturization and integration of biosample preparative and analytical techniques on a 
single chip to enable rapid, sensitive, and multiplexed high-throughput on-chip cell-based 
assays.  Some of these microfluidic tools have been demonstrated as promising 
technologies with integrated cell trapping and analysis functionalities and a minimum 
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sample requirement to achieve rapid functional phenotyping analysis of immune cells 
[67, 70] or CTCs [117, 123, 124] directly isolated from blood within one lab-on-a-chip-
type device.  Therefore my future research will focus on developing promising 
microfluidic technologies with integrated cell trapping and analysis functionalities and a 
minimum sample requirement to achieve rapid functional phenotyping analysis of 
immune cells, red blood cells, platelets or CTCs directly isolated from blood within one 
lab-on-a-chip-type device. These types of “blood-on-a-chip” devices are extremely 
attractive for blood analysis and disease diagnosis. 
 One good example is new microfluidic chip for point-of-care diagnosis of human 
immunodeficiency virus (HIV) infection / acquired immumunodeficiency syndrome 
(AIDS).  HIV/AIDS is a severe human immune disease caused by human 
immunodeficiency virus [382, 383].  It is one of the most destructive pandemics in the 
world, causing more than 1.8 million deaths per year [383].  Currently, the major HIV 
diagnosis method is called the antibody test.  In this test, HIV antigens are used to capture 
HIV antibodies in the person’s serum.  However, most HIV patients will not develop a 
detectable antibody level until 30 days after infection.  Another simpler yet less accurate 
diagnosis method is WBC count test, especially CD4+ T-cell number counting [33].  
CD4+ T-cell is the major leukocyte attacked by HIV, the cell number typically drops 
below 200 cells/μL when the HIV infection occurs.  As a result, the absolute counts of 
CD4+ T cells and the ratio of CD4+ / CD8+ T cells are commonly used as indicators of 
the onset of the AIDS and as benchmarks for the initiation of antiviral therapy to treat 
AIDS.  Currently, most of the above well-established diagnosis methods require 
sophisticate expensive instruments and specifically trained technicians to perform the 
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tests.  However, most patients who suffer from HIV usually live in the developing 
countries with limited medical resources.  Therefore, to make HIV diagnosis more 
accessible and efficient, I will develop a portable microfluidic platform to measure 
CD4+/CD8+ T-cell numbers in human blood.  
We can utilize our PDMS surface micromachining technique to generate PDMS-
based HIV-test device consists of two cell isolation units and each contains a PDMS 
microfiltration membrane (PMM) with array of through holes for isolation and 
enumeration of CD4+ and CD8+ T-cells.  Similar to our MIPA platform, for isolation 
and purification of CD4+ and CD8+ T-cells from blood specimens, I will employ a 
combined use of the PMMs in the device and antibody-conjugated polystyrene 
microbeads.  Using the biotin-streptavidin conjugation chemistry, polystyrene 
microbeads can be coated with antibodies against cell surface antigens that are specific to 
the desired subpopulation of immune cells (CD4+ or CD8+ T-cells).  When mixed with a 
blood specimen for 15-30 min, the microbeads could selectively capture desired CD4+ or 
CD8+ T-cells by recognizing and binding covalently to the CD4 or CD8 surface proteins 
of the cells.  Owing to their significant physical size increase after captured by 
microbeads (diameter of 15µm), when the blood sample is passing through the PMM, the 
desired subpopulation of immune cells could be easily isolated and regularly retained on 
the PMM in the through holes, while the other blood cells including undesired immune 
cells and erythrocytes (red blood cells) would be eluded through the PMM.  For a point-
of-care test, the numbers of CD4+ or CD8+ T-cells can be easily counted under an 
optical microscope due to transparency of PDMS-based device.  Hence, this point-of-care 
HIV-test device does not require sophisticate instruments and specifically trained 
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technicians to perform the tests, particularly suitable for HIV diagnosis in developing 
countries.  Because of the simplicity and miniaturization of the chip, I expect to provide a 
simple, economic and fast (entire assay time < 20 min) solution for diagnosis of 
HIV/AIDS using minutes of blood sample (down to 5 µL/test). 
Another blood-on-a-chip prototype we may pursue is high-throughput RBC-
Deformability chip for diagnosis of malaria.  Malaria is the most deadly parasitic disease 
threatening 200 million people worldwide and causing nearly one million annual deaths 
[384].  Researches have demonstrated that red blood cell (RBC) deformability plays a 
major role in the pathogenesis of malaria [385].  Healthy human RBCs have exceptional 
deformability enabling them to pass capillaries that are smaller than the diameter of 
RBCs, which is of crucial importance to both macro and microcirculation.   The most 
severe human malaria parasite, Plasmodium falciparum, invades and develops within 
RBCs, and transitions through morphologically distinct ring, trophozoite and schizont 
stages during the 48 hour maturation period within the RBC.  While ring stage parasite-
infected RBCs are less deformable than uninfected RBCs by only several-fold, late 
(trophozoite and schizont) stage parasite-infected RBCs are stiffer by a factor of up to 50 
or more.  Therefore, measurement of the RBC deformability is one of the most efficient 
ways of diagnosis of malaria.  To address this critical need, we can develop a “RBC-
Deformability chip” for high-throughput, highly-sensitive, and label-free characterization 
of RBC deformability at single cell level.  Specifically, RBC deformability measurement 
is made when single RBCs flow through a V-shaped constriction channel that is 
marginally smaller than RBCs’ diameters.  Under a fixed pressure, the RBC 
deformability is simply determined by the penetrating length of the RBC into the 
162 
 
constriction channel.  For high-throughput measurement, the RBC-Deformability chip 
includes an array of constriction channels (up to 104) that permits measurement of 
thousands of RBCs simultaneously.  A computer-assisted scanning system will be 
developed to record the positions of the trapped cells and convert them into the final cell 
deformability profile.  Together, this microfluidics-based RBC-Deformability chip will 
offer for new solution for diagnosis of malaria and clearly is a prototype of blood-on-a-
chip for blood analysis and disease diagnosis. 
6.3 Conclusions 
Numerous exciting topics exist at the interface between biology and 
micro/nanotechnology. Taking advantage of state-of-art micro/nanotechnologies and 
fabricating fascinating functional biomaterials, my doctoral research have addressed 
numerous important problems in fundamental biology as well as clinical applications in 
disease diagnosis and treatment.  Examples include new micro/nanoengineered functional 
biomaterials and integreted biosystems for biomedical applications in systems 
immunology, cancer biology and stem cell-based regenerative medicine.  I envision that 
these interdisciplinary researchs can potentially provid new and better solotions for wide 
range investigation of the interactions of biological entities (from nanoscale biomolecules 
to micron-sized mammalian cells) with the micro/nanoscale microenvironment and high 
throughput quantitative micro/nanoscale analysis of molecular and cellular 
functions.  Finally, I expect that these novel micro/nanoengineered functional 
biomaterials and biosystems will not only permit advances in engineering but also greatly 
contribute to improving human health.  
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Appendix A 
Fabrication of MIPA Device  
A.1 Silicon Wafer Cleaning 
1. Piranha clean (H2SO4: H2O2 = 1: 1) for 10 min and BHF dip for 1 min. 
2. DI water rinse for 10 min and air dry the wafer. 
3. Dehydration bake on hotplate for 120°C, 5 min 
A.2 Microfluidic Channel Mold Fabrication 
1. Photoresist Patterning 
a) Spin coat 3 μm SPR220 photoresist and softbake at 110°C for 3min, manually or 
using ACS 200 cluster tool.  
b) Expose the photoresist using MA/BA-6 Mask Aligner (Exposure intensity ~20J/s) 
for 10s. 
c) Develop the exposed photoresist using AZ 300 Developer for 30s, manually or 
using ACS 200 cluster tool. 
2. Plasma Etching 
Etch silicon using deep reactive ion-etching (DRIE; Deep Silicon Etcher, STS; 
Recipe-LNF Pegasus Recipe 1; Etch rate ~ 5µm/min).  
3. Silicon Surface Silanization 
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a) O2 Plasma activate the Silicon mold surface for 2 min (Plasma Cleaner PDC-001, 
Harrick Plasma: O2, 80W, 250 mT, 5min), right before silanization. 
b) Silanize the Silicon mold using 100µl of Silane (tridecafluoro- 1, 1, 2, 2,-
tetrahydrooctyl)-1-trichlorosilane (United Chemical Technologies) for 1 hr under 
vacuum in a desiccator. 
A.3 PDMS Microfiltration Membrane Fabrication 
1. Silicon Surface Silanization 
c) O2 Plasma activate the Silicon wafer surface for 2 min (Plasma Cleaner PDC-001, 
Harrick Plasma: O2, 80W, 250 mT, 5min), right before silanization. 
d) Silanize the Silicon wafer using 100µl of Silane (tridecafluoro- 1, 1, 2, 2,-
tetrahydrooctyl)-1-trichlorosilane (United Chemical Technologies) for 1 hr under 
vacuum in a desiccator. 
2. PDMS Precursor Preparation 
a) Mix the Sylgard 184 base and curing agent in ratio of 10: 1.  
b) Degas in vacuum desiccator for ~30 min. 
c) Spin Coating of the PDMS Membrane 
d) Spin coat PDMS precursor at 500 rpm for 10 s (spread) followed by 7200 rpm for 
30 s (spin) for a 10 µm membrane.  
e) Bake the wafer overnight at 60°C before further processing. 
4. Photoresist Patterning 
a) O2 Plasma activate the PDMS membrane surface for 5-10 min (Plasma Cleaner 
PDC-001, Harrick Plasma: O2, 80W, 250 mT, 5min), right before photoresisit 
spin-coating to allow a uniform photoresist coating. 
b) Spin coat AZ 9260 photoresist at 500 rpm for 10 s (spread) followed by 2400 rpm 
for 30 s (spin; 10 µm). 
c) Soft bake the wafer with photoresist in an oven at 80°C for 10 min and cool down 
to room temperature slowly (~20 min). 
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d) Expose the photoresist to the pattern using a MA/BA-6 Mask Aligner/Bond 
(Exposure intensity ~20J/s) for 50s. 
e) Develop the exposed wafer using AZ 400K developer (Ratio of Developer: Water 
= 1:4) for ~2 min. Visually inspect the developed wafer very carefully. 
5. Plasma Etching of PDMS 
a) The patterned wafer is then processed with reactive ion etching (RIE; LAM 9400) 
using SF6 and O2 gas mixtures to transfer patterns from patterned photoresist to 
the underlying PDMS layer.  Recipe: gas (SF6 (90 sccm) and O2 (6 sccm)), 
chamber pressure (0.67 Pa), bias voltage (100 V), RF power (500 W), PDMS 
etching rate 1 μm/min and photoresist etching rate 0.5 μm/min. 
b) Remove the photoresist in PR2000 solution for 5 min, rinse and wash the sample 
with water and dry the sample with N2 gun.  
c) Bake the sample overnight in a oven at 60°C to let the PDMS recover. 
A.4 Device Assembly 
1. PDMS Precursor Preparation 
a) Mix the Sylgard 184 base and curing agent in ratio of 10: 1.  
b) Degas in vacuum desiccator for ~30 min. 
2. PDMS Soft Lithography 
a) Place the silanized silicon mold in a Petri dish. 
b) Pour PDMS precursor over mold, ~1 mm thick (bottom chamber); ~4 mm thick 
(top chamber). 
c) Degas in vacuum desiccator for ~30 min. 
d) Bake PDMS in a furnace overnight at 60°C before further processing.  
e) Cut and peel the PDMS chambers from silicon mold. 
3. Inlet Fabrication 
a) Dice and separate the individual PDMS devices. 
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b) Punch the inlet hole (diameter 1 mm) through the top chamber PDMS using a 
Biopsy Punch. 
4. Bonding of the Membrane with PDMS Top chamber 
a) O2 plasma activate the PDMS membrane and PDMS chamber (top) with 
microchannel facing upwards in a plasma cleaner (Plasma Cleaner PDC-001, 
Harrick Plasma: O2, 80W, 250 mT) for 2 min. 
b) Align and bond the top chamber (microchannels facing down) to the membrane. 
c) Bake the bonded device in an oven at 90ºC for 5min.  
d) Cut the membrane boundaries using a scalpel and gently peel off bonded 
membrane from the silicon wafer. 
5. Outlet Fabrication 
In a symmetrically opposite end of the inlet, punch an outlet hole (diameter 1 mm) 
through the PDMS top chamber and the membrane using a Biopsy Punch.  
6. Bonding of the PDMS Bottom Chamber with Cover Glass Substrate 
a) O2 plasma activate a cover glass substrate (No. 1, 18 x 18mm, thickness 150µm 
and the PDMS bottom chamber, with microchannel facing downwards, in a 
Plasma Cleaner for 2 min. 
b) Bond the bottom chamber (microchannels facing up) to the cover glass substrate. 
c) Bake the bonded part in an oven at 90ºC for 5min. 
7. Bonding of the PDMS Top Chamber with Membrane to Bottom Chamber 
a) O2 plasma activate the top chamber with the membrane and PDMS bottom 
chamber on cover glass substrate, with membrane and bottom chamber 
microchannel facing upwards, in a Plasma Cleaner for 2 min. 
b) Align and bond the top chamber with membrane to the bottom chamber. 
c) Bake the bonded device in an oven at 90ºC for 5min. 
d) Seal the device on the sides to prevent potential flow leakage with PDMS 
precursor and cure the PDMS in an oven at 90ºC for 1 hr. 
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Appendix B 
Capture of Subpopulations of Immune Cells Using 
Surface Functionalized Microbeads 
B.1  Surface Functionalization of Microbeads with 
Biotinylated Antibody 
1. Vortex the streptavidin-coated microbead suspension (Bangs Lab; diameter 15 
µm, supplied at 1% solids) for 20s before use. 
2. Wash microbeads 2-3 times. To do the washing, dilute an aliquot of Microbeads 
with DI water at a 1:10 v/v ratio.  Centrifuge the diluted microbead suspension at 
3000 rpm for 10 min.  After washing the microbeads, resuspend the final pellet in 
10X PBS (0.1 M PBS, pH 7.4) to a concentration of 0.05% solids (0.5 mg/mL). 
3. To this solution, add biotinylated antibody to the washed microbeads suspension. 
The protein concentration will have to be optimized based on the binding capacity 
of the microbeads. For example, 200 µL streptavidin-coated microbead 
suspension (Bangs Lab; diameter 15 µm, supplied at 1% solids) should be diluted 
in 4 mL 10X PBS (final concentration 300,000 bead/mL) after washing. Then 160 
µL biotinylated anti-CD14 anitbody (Invitrogen) should be mixed with the 4 mL 
diluted microbead suspension. 
4. Incubate and mix the solution with a roller mixer (Invitrogen) at 15 rpm at room 
temperature for 30-40 min. 
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5. Wash the functionalized microbeads 3 times.  To do the washing, dilute the 
surface functionalized microbead suspension with DI water at a 1:10 v/v ratio.  
Centrifuge the diluted microbead suspension at 3000 rpm for 10 min.  After 
washing the microbeads, resuspend the final pellet to a required concentration in 
cell culture medium for the following cell isolation. For storage, resuspend the 
antibody-coated beads in10X PBS to desired storage concentration (often 0.5 
mg/mL). 
B.2 Capture of Subpopulations of Immune Cells Using 
Surface Functionalized MicroBeads   
1. Mix the surface functionalized microbeads with lysed blood at a optimized bead :  
cell ratio. For commercial available s-pluriBead (pluriSelect GmbH, Leipzig, 
Gemany; diameter 32 µm), use 40 µl bead suspension per 1ml lysed blood (106 
target cells) in 2mL tube (bead: target cell = 1: 3). For the above prepared 
microbeads (Bangs Lab; diameter 15 µm), bead : target cell = 1 : 2. 
2. Incubate and mix the solution with a roller mixer (Invitrogen) at 15 rpm at room 
temperature for 30-60 min to capture targeted cells. 
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Appendix C 
Human Blood Specimen Collection and Processing 
C.1  Human Blood Specimen Collection 
Human blood specimens were obtained from healthy donors and collected into the 
vacutainer containing ethylenediaminetetraacetic acid (EDTA) according to the 
standard protocol.  Human blood specimens were processed and assayed within 6 hrs 
after blood collection. 
C.2 Lysis of Red Blood Cell from Blood 
1. Add Lysis Buffer (eBioscience, San Diego, CA) to whole blood at a 10:1 v/v ratio.  
2. Incubate for 10 minutes at room temperature (no more than 15 minutes). 
3. Add 20-30 mL PBS to stop lysis. 
4. Spin the cells at 300xg at for 10min, then resuspend the PBMCs in cell culture 
media to the original volume. 
5. Quantify the white blood cell concentration by hemocytometer or flow cytometry. 
Note: In general a small number of residual red cells do not interfere with the 
following assays. However, if required, a second round of lysis can be performed. 
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Appendix D 
AlphaLISA Protocol  
D.1 Standard Curve Calibration  
1. Analyte Standard Dilution 
a) Preparation of 1X AlphaLISA Immunoassay Buffer: Add 2 mL of 10X 
AlphaLISA Immunoassay Buffer to 18 mL DI H2O. 
b) Preparation of analyte (e.x. human TNF-α) standard dilutions: Reconstitute 
lyophilized human TNF (0.1 μg) in 100 μL DI H2O (1 μg/mL) and then the 
analyte is series diluted1X AlphaLISA Immunoassay Buffer to 10,000 - 1 pg/mL.  
2. AlphaLISA Beads Preparation (Prepare just before use) 
a) Prepare 10X Acceptor beads + Biotinylated Antibody MIX (250 μg/mL /25 nM): 
Add 2.5 μL of 5 mg/mL Acceptor beads and 2.5 μL of 500 nM biotinylated 
antibody to 47.5 μL of 1X AlphaLISA Immunoassay Buffer.  
b) Prepare 10X Streptavidin-Donor beads (800 μg/mL): Keep the beads under 
subdued laboratory lighting.  Add 8 μL of 5 mg/mL SA-Donor beads to 42 μL of 
1X AlphaLISA Immunoassay Buffer.   
3. Assay Loading Procedure in 384-well Microplate:  
a) Add 20 μL analyte with various concentrations into a well of a 384-well microplate. 
b) Add 2.5 uL 10X Acceptor beads + Biotinylated Antibody MIX (250 μg/mL /25 
nM) to each well to achieve a final concentration of 40 ug/mL for Accept beads 
and 4 nM for Biotinylated Antibody. 
171 
 
c) Incubate 60 min at at 37°C and 5% CO2. 
d) Add 2.5 uL 800 μg/mL Strepatividin-Donor Beads (80 μg/mL final) 
e) Incubate 30 min at 37°C and 5% CO2. 
c) Read using PHERAstar MicroPlate Reader (BMG) 
D.2 MIPA Device Measurement 
1. MIPA Device Preparation 
a) Apply O2 Plasma to activate the top surface of the MIPA device for 2 min to make 
the top PDMS surface hydrophilic. 
b) Add 50uL Pluronics or RPMI cell culture media on the inlet and outlet of MIPA 
device and put it in the vacuum pump to degas.  Slightly reduce the pressure and 
reintroduce the gas for two times.  The device should fill with RPMI without 
bubble inside.  
2. Preparation of Cell Stimuli (Prepare just before use) 
a) Preparation of LPS for monocytes: Add 1mg LPS powder into 1mL RPMI media 
(1000 ug/mL). Dilute the LPS solution into 1000, 500, 100 ng/mL. Keep 1000 
ug/mL LPS solution into -20C for future use.  
b) Preparation of PMA/Ionomycin for T-cells: First, dilute 2 µl of PMA stock (5 
mg/ml) in 200 µl of RPMI culture media to make a stock of 50 µg/ml (diluted 
PMA).  Next, mix 2 µl of diluted PMA (final 50 ng /ml) and 2.7 µl of ionomycin 
(final 10 µg/ml) in 2 mL of culture media  
3. AlphaLISA Beads Preparation: (Prepare just before use) 
a) Prepare 10X Acceptor beads + Biotinylated Antibody MIX (250 μg/mL /25 nM): 
Add 2.5 μL of 5 mg/mL Acceptor beads and 2.5 μL of 500 nM biotinylated 
antibody to 47.5 μL of 1X AlphaLISA Immunoassay Buffer.  
b) Prepare 10X Streptavidin-Donor beads (800 μg/mL): Keep the beads under 
subdued laboratory lighting.  Add 8 μL of 5 mg/mL SA-Donor beads to 42 μL of 
1X AlphaLISA Immunoassay Buffer.   
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4. Assay Loading Procedure in MIPA Device:  
a) Inject required volume of cell sample (PBMCs or microbead captured 
subpopulation of immune cells such as monocytes, T-cells) through inlet using 
pipette to capture required number of target cells in MIPA device. 
b) Inject 50 μL LPS (for monocytes or PBMCs) or PMA/Ionomycin (for T-cells or 
PBMCs) solution from the inlet using pipette 2-3 times to wash away unwanted 
cells (red blood cells, immune cells other than target subset) and file the MIPA 
device with stimulus.  After stimulus loading, insert pipette tips into the inlet and 
outlet of the device to prevent evaporation and provide a shear stress free 
microenvironment for cell stimulation.   
c) Incubate the MIPA device at 37°C and 5% CO2 for 2 hr to stimulate the cells.   
d) Then, remove the pipette tips inserted into the inlet and outlet of MIPA device. 
Add 2.5 uL 10X Acceptor beads + Biotinylated Antibody MIX (250 μg/mL /25 
nM) using pipette from outlet to each device to achieve a final concentration of 40 
ug/mL for Accept beads and 4 nM for Biotinylated Antibody in the device.  After 
the loading, leave the pipette tip in outlet and insert another pipette tip in inlet to 
prevent evaporation. Fully mix the Acceptor beads and Biotinylated Antibody in 
the device by pipette from inlet and outlet a few times. 
e)  Incubate 60 min at 37°C and 5% CO2. 
f) Add 2.5 µL 10X Streptavidin Donor beads into device using the same method as 
described in 4d).   
g) Incubate with the cells at 37°C and 5% CO2 for 30 min.  
h) Read AlphaLISA signal using customized optical setup. 
D.3 Optical Setup for Detection of AlphaLISA Signal 
In this setup, a 500 mW 680 nm laser diode (S-67-500C-100-H, Coherent, Clara, CA) 
was used as an excitation light to induce singlet oxygen from AlphaLISA donor beads.  
An electronic shutter (SmartShutter, Lambda SC, Shutter Instrument, Novato, CA) 
was placed in front of the laser to control the timing of laser pulse for excitation.  The 
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laser light was guided into the inverted fluorescent microscope (Nikon Eclipse Ti-S, 
Nikon) and passed through the excitation filter (680/13nm BrightLine, Semrock, 
Rochester, New York) and dichroic mirror (ZT660dcspxr, Chroma, Bellows Falls, 
VT). The 2X objective (CFI Plan Achromat, N.A. = 0.06, Nikon) was used to focus 
the excitation light onto the device.  After the excitation, the 615nm AlphaLISA 
emission signal, which passed through the dichroic mirror and the 660 nm shortpass 
filter (ET660SP, Chroma, Bellows Falls, VT), was then detected by an electron 
multiplying charge-coupled device (EMCCD) camera (Photometrics, Tucson, AZ).  
The microscopic analysis software (NIS-Element BR, Nikon) was used to 
synchronize the timing of shutter in front of laser and the opening time of the 
EMCCD.  The software simultaneously counted the AlphaLISA emission signal 
intensity from the EMCCD during the measurement.  
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Appendix E 
ELISA Protocol 
E.1  Plate and Sample Preparation: 
1. Primary Antibody Immobilization   
To prepare the ELISA plate, 100µL capture antibody is first prepared and 
immediately coated on the 96-well microplate.  Then seal the plate and incubate it 
overnight at 4°C.   
2. Sample Pre-treatment  
For LPS-stimulated cell sample solution, 500µL THP-1 cell solution of 2 x 105 
cells/mL is first dispenseed into a 48-well microplate.  Then, the THP-1 cells are 
stimulated with 50µL LPS (10-100ng/mL) solution and incubate for 4 hours at 37°C.   
3. Antibody Blocking  
During the cell incubation, bring the 96-well microplate to room temperature for 30 
min, then aspirate capture antibody solution and wash with wash buffer (0.05% 
Tween 20 in DPBS, pH 7.4) three times.  Complete removal of liquid at each step is 
essential for good performance.  For last wash, sit the wash buffer in wells for 1 
minute.  After the last wash, remove any remaining wash buffer by aspirating or by 
inverting the plate and blotting it against clean paper towels.  After that, block plate 
by adding 300µL reagent diluent (1% BSA in PBS) to each well and incubate at room 
temperature on shaker for 1 hour.  After the blocking step, repeat the aspiration/wash 
175 
 
steps for three times and incubate for 5 minutes for last wash.  The plate is now ready 
for assay loading. 
E.2  Assay Loading Protocol 
1. Sample Loading  
Add 100µL LPS-stimulated THP-1 cell solution or standard TNF-α analyte (1-
10000pg/mL, as a calibration curve) into the antibody-coated 96-well microplate.  
Then, cover the plate with an adhesive strip and incubate 2 hours at room temperature 
on shaker, following by aspiration/wash steps for three times.   
2. Detection Antibody Loading  
Add 100µL detection antibody to each well incubating 2 hours at room temperature 
on shaker, following by aspiration/wash steps for three times.   
3. HRP/Substrate/Stop Solution Loading 
Add 100µL streptavidin-HRP to each well for 20 minutes incubation at room 
temperature.  Then, empty wells and wash five times with 200µL wash buffer.  Then 
add 100µL substrate solution to each well and incubate for 20 minutes at room 
temperature.  The reaction takes 8-10 minutes at room temperature.  After that, add 
50µL stop solution (sulfuric or phosphoric acid) to each well and gently tap the plate 
to ensure thorough mixing.  Because the substrate and stop solution are both light 
sensitive, the plate should avoid directly placing under the light.   
4. ELISA Signal Reading   
Finally, use a microplate reader (SpectraMax M2e, Molecular Device) to determine 
the optical density (OD) of each sample well.  The reading wavelength range is set at 
450-570 nm.  The final OD is the subtracted readings at 540 nm or 570 nm from the 
readings at 450 nm.  This subtraction will correct optical imperfections of the 96-well 
microplate.  
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Appendix F 
Fabrication and Characterization of Nanorough Glass 
Samples 
F.1  Fabrication of Nanorough Glass Samples 
1. Photoresist Patterning 
a) Photoresist (SPR220, 3 μm ) is first spin-coated on glass wafers (Borofloat 33, 
Plan Optik, Elsoff, Germany and softbake at 110°C for 3min, manually or using 
ACS 200 cluster tool.  
b) Expose the photoresist using MA/BA-6 Mask Aligner (Exposure intensity ~20J/s) 
for 10s. 
c) Develop the exposed photoresist using AZ 300 Developer for 30s, manually or 
using ACS 200 cluster tool. 
Note: The Photoresist Patterning step can be skipped if no patterning required and 
unifroem roughness will be generated on the glass surface. 
2. Plasma Etching 
a) The patterned glass wafer was then processed with RIE (LAM 9400, Lam 
Research, Fremont, CA) for different periods of time to generate different levels 
of the nanoscale surface roughness (Rq = 1 - 150 nm) on the exposed regions of 
the glass wafer, where the photoresist had previously been developed and 
dissolved.  The RIE processing condition used in this work was: SF6 (8 sccm), 
C4F8 (50 sccm), He (50 sccm), Ar (50 sccm), chamber pressure (1.33 Pa), bias 
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voltage (100 V), and radio frequency power (500 W).  The resulting RIE glass 
etch rate was about 50 nm/min.  For un-patterned nanorough glass samples, bare 
glass wafers were directly processed with RIE using the same RIE condition as 
described above. 
b) After the RIE process, photoresist is striped using solvents (SPR2000), and the 
glass wafer was rinsed using distilled water and air dried.   
c) The glass wafers were cut into small pieces (e.x. 2 cm × 2 cm) using dicing saw 
(ADT7100; Advanced Dicing Technologies Ltd., Yokneam, Israel).  
F.2 Surface Characterization Using Atomic Force Microscopy  
Nanoroughness of the glass or PDMS surfaces was measured at room temperature 
with atomic force microscopy (Veeco NanoMan Atomic Force Microscope; Digital 
Instruments Inc., Santa Barbara, CA) using a non-contact, tapping mode and standard Si 
tapping mode AFM tips.  The AFM scan size was set as 10 µm × 10 µm with a scan rate 
of 1 Hz.  The resulting map of the local surface height was represented using AFM 
topographs.  The nanoroughness of each sample was characterized using the root mean 
square (RMS) roughness Rq of the local surface height over the whole sample area 
scanned by AFM.  The initial surface roughness Rq of unprocessed bare glass wafer and 
PDMS surface characterized by AFM was about 1 nm and 0.5 nm, respectively. 
F.3 Anti-EpCAM Antibody Coating  
Glass Surfaces are functionalized with anti-EpCAM antibodies using avidin-biotin 
chemistry.   
1. O2 plasma treatment for the glass substrates for 1-2min. 
2. The glass substrates are modified with 4% (v/v) 3-mercaptopropyl 
trimethoxysilane (Sigma-Aldrich) in ethanol at room temperature for 30-45 min. 
3. Rinse and wash with ethanol. 
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4. The glass surfaces are then treated with N-ymaleimidobutyryloxy succinimide 
ester (GMBS, 1 mM or 0.28%; Thermo Fisher Scientific, Rockford, IL) in ethanol 
for 15 min.  
5. Rinse with PBS. 
6. The glass surfaces are treated with 10 µg/ml Neutravidin (Thermo Fisher 
Scientific) in PBS at room temperature for 30 min, leading to immobilization of 
Neutravidin onto GMBS. 
7. The glass surfaces were rinsed with PBS to remove excess free avidin. 
8. Add biotinylated anti-EpCAM antibody (R&D Systems, Minneapolis, MN) at a 
concentration of 10 µg/ml in PBS with 1% (w/v) bovine serum albumin (BSA; 
Equitech-Bio Inc, Kerrville, TX) and 0.09% (w/v) sodium azide (Sigma-Aldrich) 
to the glass surfaces and allow to react for 15–30 min 
9. The glass substrates are washed with PBS, air dried and stored at ambient 
temperature for up to three weeks till later use. 
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Appendix G 
Cell Adhesion Strength Measurement Protocol 
G.1 Fabrication of PDMS Microfluidic Channels for Cell 
Adhesion Strength Measurements 
G.1.1 Fabrication of Silicon Mold for the Microfluidic Channels 
1. Photoresist Patterning 
a) Spin coat 3 μm SPR220 photoresist and softbake at 110°C for 3min, manually or 
using ACS 200 cluster tool.  
b) Expose the photoresist using MA/BA-6 Mask Aligner (intensity ~20J/s) for 10s. 
c) Develop the exposed photoresist using AZ 300 Developer for 30s, manually or 
using ACS 200 cluster tool. 
2. Plasma Etching 
Etch silicon using DRIE (Deep Silicon Etcher, STS; Etch rate ~ 5µm/min).  
3. Silicon Surface Silanization 
a) O2 Plasma activate the Silicon mold surface for 2 min (Plasma Cleaner PDC-001, 
Harrick Plasma: O2, 80W, 250 mT, 5min), right before silanization. 
b) Silanize the Silicon mold using 100µl of Silane (tridecafluoro- 1, 1, 2, 2,-
tetrahydrooctyl)-1-trichlorosilane (United Chemical Technologies) for 1 hr under 
vacuum to facilitate subsequent release of the PDMS from the mold. 
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G.1.2 Fabrication of the Microfluidic Channels 
1. PDMS Precursor Preparation 
a) Mix the Sylgard 184 base and curing agent in ratio of 10: 1.  
b) Degas in vacuum desiccator for ~30 min. 
2. PDMS Soft Lithography 
a) Place the silanized silicon mold in a Petri dish. 
b) Pour PDMS precursor over mold about 3-5 mm thick. 
c) Degas in vacuum desiccator for ~30 min. 
d) Bake PDMS in a furnace overnight at 60°C before further processing.  
e) Cut and peel off the fully cured PDMS microfluidic channels from silicon mold. 
3. Inlet and Outlet Fabrication 
a) Dice and separate the individual PDMS devices. 
b) Punch the inlet and outlet hole (diameter 0.75 mm) through the PDMS using a 
Biopsy Punch. 
4. Bonding of the PDMS Microfluidic Channels with Glass Substrates 
a) O2 plasma activate glass substrates and the PDMS microfluidic channels with 
microchannel facing upwards in a plasma cleaner (Plasma Cleaner PDC-001, 
Harrick Plasma: O2, 80W, 250 mT) for 2 min. 
b) Align and bond the microfluidic channels facing to the glass substrates. 
c) Bake the bonded device in an oven at 90ºC for 5 min.  
Note: For nanorough glass substrates, a device holder composed of two pieces of 
polyacrylate plates was home-machined to sandwich the PDMS channel and the 
nanorough glass substrate using screws at the four corners of the polyacrylate plates.  
Two through-holes were drilled on the top polyacrylate plate to align with the inlet and 
outlet holes of the PDMS microfluidic channel, thus allowing a convenience connection 
of tubings to the microfluidic channel.  The complete assembly using polyacrylate plates 
to hold the PDMS microfluidic channel could endure a back pressure of about 50 psi 
without leaking. 
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G.2 Cell Adhesion Strength Measurements 
1. Cancer cells (MCF-7, MBA-MB-231, PC3 cells or SUM149) in growth media are 
first injected into the microfluidic channel by pipette and the cells are allowed to 
adhere to the bottom glass substrate in an incubator for 12 hrs.  An optimized cell 
loading density (1 × 106 cells mL-1) should be used to ensure a uniform seeding of 
single cells on the substrate.   
2. The microfluidic channel is then connected to a syringe pump. 
3.  To remove floating cells before cell adhesion strength measurements, PBS is 
flowed into the channel with a very low flow rate (10 µL min-1 for 1 min, then 30 
µL min-1 for 1 min).   
4. Then increase the flow rate to a designated value (50-1500 µL min-1) and 
maintained constant for 5 min to exert a constant directional fluid shear stress on 
cells.  During the assay, detachment of cells is monitored with the Carl Zeiss Axio 
Observer Z1 microscope using a 10× objective (0.3 NA; EC Plan NEOFLUAR®; 
Carl Zeiss MicroImaging).  Phase-contract images are recorded at 10 sec intervals 
for a total period of 5 min.   
5. The numbers of adherent cells on glass substrates before and after their treatments 
with this sustained 5-min directional fluid shear are then quantified from the 
recorded microscope images using ImageJ (National Institutes of Health, 
Bethesda, MD).   
6. The fluidic shear stress (τ0) exerted on cells is calculated using the equation τ0 = 
(6µQ) / (WH2), where µ is the viscosity of culture media (~10-3 Pa s), Q is the 
flow rate, and W and H are the microfluidic channel width and height, 
respectively.  Adhesion strength of cells is defined as the fluidic shear stress at 
which 50% of cells initially attached on glass surfaces would detach after exposed 
to fluid shear for 5 min.   
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Appendix H 
PDMS Micropost Array for Cellular Traction Force 
Measurement 
H.1 Fabrication of PDMS Micropost Array 
H.1.1 Fabrication of Silicon Mold for the PDMS Micropost Array 
1. Photoresist Patterning 
a) Spin coat 3 μm SPR220 photoresist and softbake at 110°C for 3min, manually or 
using ACS 200 cluster tool.  
b) Expose the photoresist using GCA AS200 AutoStep Aligner. 
c) Develop the exposed photoresist using AZ 300 Developer for 30s, manually or 
using ACS 200 cluster tool. 
2. Plasma Etching 
Etch silicon using DRIE (Deep Silicon Etcher, STS; Etch rate ~ 5µm/min).  
3. Silicon Surface Silanization 
a) O2 Plasma activate the Silicon mold surface for 2 min (Plasma Cleaner PDC-001, 
Harrick Plasma: O2, 80W, 250 mT, 5min), right before silanization. 
b) Silanize the Silicon mold using 100µl of Silane (tridecafluoro- 1, 1, 2, 2,-
tetrahydrooctyl)-1-trichlorosilane (United Chemical Technologies) for 4 hr under 
vacuum to facilitate subsequent release of the negative PDMS mold. 
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H.1.2 Fabrication of Negative PDMS Mold 
1. PDMS Precursor Preparation 
a) Mix the PDMS precursor with base and curing agent in ratio of 10: 1.  
b) Degas in vacuum desiccator for ~30 min. 
2. PDMS Soft Lithography 
a) Place the silanized silicon mold in a Petri dish. 
b) Pour PDMS precursor over mold about 3 mm thick. 
c) Degas in vacuum desiccator for ~30 min. 
d) Fully cure the PDMS in a furnace at 110ºC for 30 min.  
e) Peel off the fully cured negative PDMS mold from the silicon mold, and the 
excessive PDMS is trimmed using a razor blade. 
3. Silanization of Negative PDMS Mold 
a) O2 Plasma activate the negative PDMS mold for 2 min (Plasma Cleaner PDC-001, 
Harrick Plasma: O2, 80W, 250 mT, 5min), right before silanization. 
b) Silanize the Silicon mold using 100µl of Silane (tridecafluoro- 1, 1, 2, 2,-
tetrahydrooctyl)-1-trichlorosilane (United Chemical Technologies) for 24 hr 
under vacuum to facilitate subsequent release of the PDMS micropost array from 
the negative PDMS mold. 
c) Dice and separate the individual negative PDMS molds. 
H.1.3 Fabrication of PDMS Micropost Array 
1. PDMS Precursor Preparation 
a) Mix the PDMS precursor with base and curing agent in ratio of 10: 1.  
b) Degas in vacuum desiccator for ~30 min. 
2. PDMS Soft Lithography 
a) Pour PDMS precursor over the negative PDMS mold. 
b) Degas in vacuum desiccator for ~10 min. 
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c) A 25 cm × 25 cm cover glass, which served as the substrate for the PDMS 
micropost array, is then placed on top of the negative PDMS mold. 
d) Fully cure the PDMS in a furnace at 110ºC for 40 hr.  
e) Peel off the fully cured PDMS micropost array from the negative PDMS mold, 
and the excessive PDMS is trimmed using a razor blade. 
f) Sonicate the PDMS microposts in 100% ethanol for 30 s to regenerated 
freestanding PDMS microposts which may be collapsed in the peeling process.  
g) Dry-release the PDMS micropost array with liquid CO2 using the critical point 
dryer.   
H.2 Surface Functionalization of PDMS Micropost Array 
H.2.1 Fabrication of PDMS Stamps for Microcontact Printing 
1. Mix the PDMS precursor with base and curing agent in ratio of 30: 1.  
2. Pour PDMS precursor in a Petri dish about 3 mm thick. 
3. Degas in vacuum desiccator for ~30 min. 
4. Fully cure the PDMS in a furnace at 110ºC for 30 min.  
5. Dice and PDMS into individual PDMS stamps (5mm × 5 mm) with flat surface. 
H.2.2 Microcontact Printing 
1. Ink the flat 30:1 PDMS stamp with fibronectin (BD Biosciences, San Jose, CA) 
at a saturating concentration of 50 mg mL-1 in distilled water for 1 hr at room 
temperature.   
2. The PDMS stamp is then thoroughly rinsed with distilled water and blown dry 
with nitrogen gas.   
3. In parallel, the PDMS micropost array is treated with ultraviolet (UV) ozone 
(UV-ozone cleaner; Jelight, Irvine, CA) for 7 min to ionize the PDMS surface 
and thus facilitate transfer of ECM molecules from the stamp to the PDMS 
micropost tops.   
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4. The fibronectin-coated PDMS stamp is then gently placed in conformal contact 
with the PDMS micropost array for 10s to complete the protein transfer process.  
5. To utilize the PDMS micropost array for live-cell traction force measurements, 
the PDMS microposts are stained by rinsing in a 5 µg/mL 1,1′-dioleyl-3,3,3′,3′-
tetramethylindocarbocyanine methanesulfonate (Δ9-DiI; Invitrogen) solution.   
6. Rinse wash with distilled water. 
7. Pluronics F127 NF dissolved in PBS (0.2%, w/v; BASF, Ludwigshafen, 
Germany) is then adsorbed to the PDMS surface for 1 hr at room temperature to 
prevent protein adsorption to nonfunctionalized portions of the PDMS micropost 
array. 
8. Rinse wash with distilled water. 
H.3 Quantification of Cellular Traction Force 
Cell traction forces are quantified as described as follows. In brief, phase-contrast 
images of live cells and fluorescence images of Δ9-DiI stained PDMS microposts 
underlying the cells are taken at the focal plane passing through the top surface of the 
posts with a 40× objective on the Zeiss Observer Z1 microscope attached with the 
AxioCam camera.  The microscope is enclosed in the Carl Zeiss XL S1 
environmental chamber to maintain the experimental environment at 37°C and 5% 
CO2.  Images are then analyzed with a custom-developed MATLAB program to 
calculate the deflection δ of the post centroid from its ideal position determined by 
the free and undeflected posts, which is then converted to the horizontal traction force 
f using the expression f = Kδ, where K is the nominal spring constant of the PDMS 
micropost calculated from the Euler-Bernoulli beam theory. 
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Appendix I 
General Cell Related Assays 
I.1 Cell Culture and Reagents 
THP-1 cells (ATCC, Manassas, VA) are cultured in the cell growth medium (RPMI-
1640, ATCC, Manassas, VA) supplemented with 0.05 mM 2-mercaptoethanol 
(Invitrogen, Carlsbad, CA) and 10% (v/v) heat-inactivated fetal bovine serum (FBS; 
Atlanta Biological, Atlanta, GA).  Cells are maintained at 37oC with 5% CO2 and 100% 
humidity and passaged every two days. 
NIH/3T3 mouse embryonic fibroblasts (ATCC, Manassas, VA) are maintained in a 
growth medium consisting of high-glucose Dulbecco’s modified Eagle’s medium 
(DMEM; Invitrogen, Carlsbad, CA) supplemented with 10% bovine serum (Atlanta 
Biological, Atlanta, GA), 100 μg mL-1 L-glutamine, 100 units mL-1 penicillin, and 100 μg 
mL-1 streptomycin.  Fresh 0.25% trypsin-EDTA in phosphate buffered saline (PBS) is 
used to re-suspend NIH/3T3 cells.  NIH/3T3 cells are seeded at a low density (3,000 
cells/cm2) in the growth medium onto the glass or PDMS surfaces. 
hESCs (H9; WiCell, Madison, WI) are cultured on a feeder-free synthetic polymer 
coating (PMEDSAH) [386, 387] with the Human-Cell-Conditioned Medium (hCCM, 
GlobalStem, Rockville, MD) at 37ºC in 5% CO2.  hESC colonies are observed every 24 
hr using a Leica stereomicroscope (Leica Microsystems Inc, Buffalo Grove, IL).  
Differentiated cells are removed mechanically using a sterile pulled-glass pipette.  The 
culture medium is replaced every 24 hr.  Cultures are passaged every 4-7 days.  
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Hela and MCF-7 cells (ATCC, Manassas, VA) are maintained in growth media 
consisting of high-glucose Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen, 
Carlsbad, CA) supplemented with 10% fetal bovine serum (Atlanta Biological, Atlanta, 
GA), 0.5 μg mL-1 Fungizone (Invitrogen), 5 μg mL-1 Gentamicin (Invitrogen), 100 units 
mL-1 penicillin, and 100 μg mL-1 streptomycin.  PC-3 and MDA-MB-231 cells are 
cultured in growth media (RPMI-1640, ATCC) supplemented with 10% fetal bovine 
serum (Atlanta Biological), 0.5 μg mL-1 Fungizone (Invitrogen), 5 μg mL-1 Gentamicin 
(Invitrogen), 100 units mL-1 penicillin, and 100 μg mL-1 streptomycin.  SUM149 cells are 
cultured in growth media (Ham’s F-12 w/L-glutamine, Fisher Scientific, Hanover Park, 
IL) supplemented with 5% fetal bovine serum (Atlanta Biological), 0.5 μg mL-1 
Fungizone (Invitrogen), 5 μg mL-1 Gentamicin (Invitrogen), 5 μg mL-1 Insulin (Sigma-
Aldrich, St. Louis, MO), 1 μg mL-1 Hydrocortisone (Sigma-Aldrich), 50 units mL-1 
penicillin, and 50 μg mL-1 streptomycin.  Cells are maintained at 37ºC with 5% CO2 and 
100% humidity. Fresh 0.25% trypsin-EDTA in phosphate buffered saline (PBS) is used 
to re-suspend cells.   
I.2 SEM Specimen Preparation 
Cells are washed three times with 50 mM Na-cacodylate buffer (pH 7.3; Sigma-
Aldrich, St. Louis, MO), fixed for 1 hr with 2% glutaraldehyde (Electron Microscopy 
Sciences, Hatfield, PA) in 50 mM Na-cacodylate buffer, and dehydrated in a graded 
series of ethanol concentrations through 100% over a period of 1.5 hr.  Dehydration in 
100% ethanol is performed three times.  Dehydrated samples are then dried with liquid 
CO2 using a super critical point dryer (Samdri®-PVT-3D, Tousimis, Rockville, MD).  
Samples are mounted on stubs, sputtered with gold palladium, observed and 
photographed under SEM (Hitachi SU8000 Ultra-High Resolution SEM; Hitachi High 
Technologies America, Inc., Pleasanton, CA). 
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I.3 EdU Cell Proliferation Assay 
For the EdU cell proliferation assay, cells are first starved at confluence in the growth 
medium supplemented with 0.5% bovine serum (Invitrogen) for 48 hr to synchronize cell 
cycle before trypsinization.  Synchronized cells are re-plated on the glass substrates and 
recovered in the complete growth medium for 12 to 24 hr, and are then exposed to 4 µM 
5-ethynyl-2′-deoxyuridine (EdU; Invitrogen) in the growth medium for 8 hr.  Cells are 
then fixed with 3.7% formaldehyde (Electron Microscopy Science) in PBS, 
permeabilized with 0.3% Triton X-100 (Roche Applied Science, Indianapolis, IN) in PBS, 
blocked with 10% goat serum, and stained with Alexa Fluor 488 conjugated azide 
targeting the alkyne groups in EdU that is incorporated in newly synthesized DNA.  Cells 
are co-stained with Hoechst 33342 (Invitrogen) to visualize cell nucleus. 
I.4 Immunofluorescence Staining 
In brief, cells were incubated in an ice-cold cytoskeleton buffer (50 mM NaCl, 150 
mM sucrose, 3 mM MgCl2, 1 μg ml-1 aprotinin, 1 μg ml-1 leupeptin, and 1 μg ml-1 
pepstatin) for 1 min, and then permeabilized for 1 min in the cytoskeleton buffer 
supplemented with 0.5% Triton X-100.  Detergent-extracted cells were fixed with 4% 
paraformaldehyde in PBS for 30 min, washed with PBS, incubated with 10% goat serum 
(Invitrogen) for 1 hr, incubated with a primary antibody to vinculin produced in mouse 
(Sigma-Aldrich) for 1 hr, and stained with Alexa Fluor 488 conjugated goat anti-mouse 
IgG secondary antibody (Invitrogen) for 1 hr.  Alexa Fluor 555 conjugated phalloidin 
(Invitrogen) and DAPI were used to visualize F-actin and nucleus, respectively. 
In brief, cells are incubated in an ice-cold cytoskeleton buffer (50 mM NaCl, 150 mM 
sucrose, 3 mM MgCl2, 1 μg mL-1 aprotinin, 1 μg mL-1 leupeptin, and 1 μg mL-1 pepstatin) 
for 1 min and then permeabilized with 0.5% Triton X-100 (Roche Applied Science, 
Indianapolis, IN) in the cytoskeleton buffer for 1 min.  Detergent-extracted cells are fixed 
with 4 % paraformaldehyde (Electron Microscopy Sciences) in PBS for 30 min and 
washed three times with PBS.  The fixed cells are then incubated with 10% goat serum 
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(Invitrogen) for 1 hr and then primary antibodies for 1 hr and Alexa Fluor 488, 555 or 
647 conjugated IgG secondary antibodies for 1 hr.  Alexa Fluor 555 conjugated 
phalloidin (Invitrogen) and 4',6-diamidino-2-phenylindole (DAPI; Invitrogen) are add 
with secondary antibodies for visualization of actin microfilaments and nucleus, 
respectively. After each incubation steps, cells are washed with PBS 2-3 times. 
I.5 Quantitative Analysis of Cell Spread Area and Focal 
Adhesion 
In brief, immunofluorescence images of actin CSK and vinculin are obtained using 
epi-fluorescence microscopy (Carl Zeiss Axio Observer Z1 Carl Zeiss MicroImaging, 
Thornwood, NY) equipped with a thermoelectrically-cooled monochrome CCD camera 
(AxioCam camera; Carl Zeiss MicroImaging) and a 40× objective (0.75 NA; EC Plan 
NEOFLUAR®; Carl Zeiss MicroImaging).  Images are captured using the Axiovision 
Software (Carl Zeiss MicroImaging) and processed using custom-developed MATLAB 
programs (Mathworks, Natick, MA).  To determine the cell spread area, the Canny edge 
detection method is used to binarize the actin fibers and FAs in the images, and then 
image dilation, erosion, and fill operations were used to fill in the gaps between the white 
pixels in the images.  The resultant white pixels are summed to quantify cell spread area.  
To quantify FA number and area, the grayscale vinculin image is thresholded to produce 
a black and white FA image from which the white pixels, representing FAs, are counted 
and summed.  
I.6 Quantitative Analysis of Cell Migration 
Timelapse microscopy experiments are performed for cell migration assays.  
Individual cells are chosen at random, and their phase-contract images are recorded with 
5-min intervals for a total period of 20 hr with the Carl Zeiss Axio Observer Z1 
microscope using a 10× objective (0.3 NA; EC Plan NEOFLUAR®; Carl Zeiss 
MicroImaging).  The microscope is enclosed in an enviromental chamber (XL S1 
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chamber; Carl Zeiss MicroImaging) to maintain the experimental environment at 37°C 
and 5% CO2.  Cell migration trajectories and speeds are determined from the recorded 
microscope images using ImageJ (National Institutes of Health, Bethesda, MD) and the 
manual object tracking plug-in MTrackJ (developed by Dr. E. Meijering, Biomedical 
Imaging Group of Rotterdam, University Medical Center of Rotterdam, Netherlands). 
I.7 Cell Motility Assay 
The Cellomics Cell Motility kit (Thermo Scientific, Waltham, MA) was used to 
determine cell motility.  According to the manufacturer’s protocol, single cell 
suspensions were plated in three wells of a 96-well plate that had previously been coated 
with blue fluorescent microbeads.  After 24 hr of incubation, the area a cell migrated was 
represented by the negative space in the microbead carpet that was pushed away or 
phagocytosed by the cell.  Cells were then fixed, and the migration tracks were imaged 
using fluorescence microscopy with an Olympus DP26 single chip color CCD camera 
and an Olympus IX-51 inverted microscope (Olympus, Center Valley, PA).  To quantify 
cell motility, the whole sample surface area was imaged and the image processing 
software ImageJ (National Institutes of Health, Bethesda, MD) was then used to 
determine the migration track area of each cell.   
I.8 ALDEFLUOR Assay  
The ALDEFLUOR assay was performed using the ALDEFLOUR Kit (Stemcell 
Technologies, Vancouver, Canada) according to the manufacturer’s instructions[189]. 
Briefly, ALDEFLUOR treated cells quenched with ALDH inhibitor 
diethylaminobenzaldehyde (DEAB) were used to set the ALDEFLUOR-positive FACS 
gate, which we defined as a gate containing less than 0.1% of DEAB-treated cells.  Cells 
treated with ALDEFLUOR alone were then sorted by FACS and used for downstream 
experiments.  SUM149 cells above this fluorescence threshold were sorted as ALDH+ 
and the bottom matching percentage was sorted as ALDH-. 
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I.9 Cancer Cell Invasion Assay 
In vitro invasion was assayed using the Biocoat Matrigel invasion chamber (BD 
Biosciences, San Jose, CA).  Cells were plated in triplicate in the top portion of the 
invasion chamber in serum-free medium with 5% serum growth medium in the bottom 
chamber to induce invasion through the Matrigel membrane.  After 24 hr of incubation, 
non-invading cells were removed from the top chamber with a cotton swab, and invading 
cells were fixed with formaldehyde and stained with 1% crystal violet.  Matrigel 
membranes were then removed and de-stained in 10% acetic acid, and an VersaMax 
optical density reading (Molecular Devices, Sunnyvale, CA) of the acetic acid was taken 
at 590 nm.  In some experiments, Matrigel membranes stained with crystal violet were 
imaged with invaded cells manually counted. 
I.10 Cell Proliferation Assay 
Cell proliferation rates were quantified using an MTT Cell Proliferation Assay Kit 
(Life technologies, Grand Island, NY).  Cells were sorted by FACS and plated in 
triplicate onto 96-well plates.  MTT staining and a subsequent optical density reading 
(Molecular Devices VersaMax) at 590 nm were carried out at 24 hr, 36 hr, 72 hr, and 96 
hr post sorting. 
I.11 Cell Deformability Measurement 
The cell deformability was measured using a PDMS-based microfluidic deformability 
microcytometer developed in our lab (fabrication process is similar to Appendix G1).  
The deformability microcytometer contains an array of funnel-shaped long confining 
microchannels that trap individual live cancer cells in each channel for single cell 
deformability measurement.  Each channel has a length of 300 µm, a height of 30 µm, a 
width at the wide end (entry) of 30 µm and a width at the narrow end of 4 µm.  The 
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channel wall is pre-coated with Pluronic-127 (Sigma) for 30 min such that friction 
between the cell and the channel wall can be neglected.  Single cancer cells in suspension 
are first loaded into the channel using a pressure pump (ELVESYS, Paris, French) under 
low pressure (0.1-0.5 kPa).  The differential pressure acting on cancer cells will gradually 
push the cells down the funnel, and ultimately the motion of cancer cells will stop due to 
the confining channel and the cells will be trapped in place.  After the cell trapping, the 
loading pressure is gradually increased in steps (0.5 kPa for each step) to push the cell 
further into the channel.  The trapped cells will have different deformation under different 
pressure.  For inert microfluidic channels where cell trapping is dictated by steric 
interactions of cancer cells with the confining channel, the penetration length (L) of 
individual cancer cells into the confining channel will be purely determined by cell size 
and deformability.  Thereby, the single cell deformability can be calculated based on 
model equation Deformability = 16.9×d× (A×ΔP)-1, where ΔP is the change of the flow 
pressure, d is the penetrating length under the pressure change, and A is the projective 
area of the cell.  Cell volume V is calculated as V = (4×A×π-1)-1/2.  During the assay, 
deformed cells were monitored with the Carl Zeiss Axio Observer Z1 microscope using a 
10× objective (0.3 NA; EC Plan NEOFLUAR®; Carl Zeiss MicroImaging).  Phase-
contrast images were recorded.  The penetration length (L) and the longitudinal and 
lateral diameters (Dlong and Dlat ) of each cell for each pressure were quantified from the 
recorded microscope images using ImageJ (National Institutes of Health, Bethesda, MD) 
to calculate the projective area of the cell A ≈ 0.25π×Dlong×Dlat. 
I.12 Western Blot Analysis 
Whole cell lysates are prepared from cells, separated on 7.5% SDS-polyacrylamide gel 
and transferred to PVDF membranes.  The membranes are incubated with 5% milk in 
PBS for 1 hr and then incubated with primary antibodies overnight at 4ºC.  Primary 
antibodies used in this thesis are as follows: mouse anti-NMMIIA (1:1000; Abcam, 
Cambridge, MA), mouse anti-E-cadherin (1:1000; Invitrogen, Carsbad, CA), mouse anti-
vinculin (1:1000; Sigma-Aldrich, St. Louis, MO), mouse anti-FAK (1:500; BD 
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Biosciences, San Diego, CA), rabbit anti-Oct4 (1:2000; Santa Cruz, Santa Cruz, CA), and 
rabbit anti-β-actin (1:1000; Cell Signaling, Danvers, MA).  Blots are incubated with 
peroxidase-coupled secondary antibodies (Promega, Madison, WI) for 1 hr, and protein 
expression is detected with SuperSignal West Pico Chemiluminescent Substrate (Thermo 
Scientific, Rockford, IL).  
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